| Period End | Type | Status | Affected | % Workforce | Announced | Expected Completion | Geography | Segment / Function | Charge | Source | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | restructuring | in_progress | 2027-01-31 | Global | All three segments (unallocated) | USD 15 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in Q3 FY2026 (exact date not disclosed); workforce reduction to optimize management structure. $15M expense recorded in both the three and nine months ended July 31, 2026; $9M liability remaining at quarter-end. Expected annual cost savings of $30M-$35M. Number of employees affected not disclosed. | |||
| 2026-07-31 | restructuring | in_progress | 2026-10-31 | Global | All three segments (unallocated) | USD 28 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in Q2 FY2025 (exact date not disclosed); $28M expense recorded in the nine months ended July 31, 2026 (approximately zero in the three months ended). $4M liability remaining at quarter-end; $109M total expense since inception. Expected annual cost savings of $90M-$95M. Number of employees affected not disclosed. | |||
| 2026-07-31 | acquisition_addition | completed | 2026-06-24 | 2026-06-24 | Global | Life Sciences and Diagnostics Markets | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of BC Midco I, Inc. for $950M net consideration; results consolidated from acquisition date. Headcount added not disclosed; MD&A attributes the increase in total headcount primarily to this acquisition. | |||
| 2026-07-31 | restructuring | in_progress | 2026-07-01 | 2027-01-31 | Global | All segments | USD 15 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY26 Plan implemented in Q3 FY26 to optimize management structure. Expected to reduce annual costs by $30-35 million. Completion expected by Q1 FY27. | ||
| 2026-07-31 | restructuring | in_progress | 2025-04-01 | 2026-10-31 | Global | All segments | USD 28 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25. $28 million expense recorded in nine months ended July 31, 2026. Expected completion by end of FY26. | ||
| 2026-07-31 | acquisition_addition | completed | 2026-06-24 | 2026-06-24 | Global | Life Sciences and Diagnostics Markets | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquired 100% of Biocare for $950 million. Headcount increase attributed to this acquisition in MD&A. | |||
| 2026-07-31 | restructuring | in_progress | Employee Severance [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-07-31 | restructuring | in_progress | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2026-07-31 | restructuring | in_progress | Employee Severance [Member] / FY26 Restructuring Plan [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-07-31 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-07-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-04-30 | restructuring | in_progress | 2025-01-31 | 2026-10-31 | Global | All three business segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets) | USD 28 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced during fiscal Q2 2025 (quarter ended 2025-01-31); exact announcement date not disclosed. Workforce reduction via severance; no employee count disclosed. Charge is six months ended 2026-04-30 ($8M in Q2 alone); $5M liability remains at quarter end; total expense since inception $109M. Expected to substantially complete by end of fiscal 2026. | ||
| 2026-04-30 | acquisition_addition | announced | 2026-03-06 | 2026-10-31 | Not disclosed | Life Sciences and Diagnostics Markets | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement to acquire 100% of BC Midco I, Inc. (Biocare) for ~$950M cash; no headcount added disclosed. Closing may occur in fiscal Q3 2026 or no later than fiscal year-end 2026. | |||
| 2026-04-30 | restructuring | in_progress | 2025-04-30 | 2026-10-31 | Global | All segments | USD 28 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25. $28M expense recorded in six months ended April 30, 2026. Expected to substantially complete by end of fiscal year 2026. Employee count not disclosed for current period activity. | ||
| 2026-04-30 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-04-30 | restructuring | in_progress | Cost of Sales [Member] | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-04-30 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-04-30 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-04-30 | restructuring | in_progress | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2026-04-30 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-01-31 | restructuring | in_progress | 2026-10-31 | Global | All three reportable segments | USD 20 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Workforce reduction plan announced in fiscal year 2025 second quarter to optimize management structure; no employee count disclosed. Q1 FY2026 charge of $20M ($5M cost of products and services, $15M SG&A); liability of $16M at quarter-end; total expense since inception $101M; expected annual cost savings of $90M-$95M. Announcement date not specified beyond 'second quarter of fiscal year 2025'. | |||
| 2026-01-31 | restructuring | in_progress | 2025-04-01 | 2026-10-31 | Global | All segments | USD 20 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25. $20M expense recorded in Q2 FY26. Expected to substantially complete by end of fiscal year 2026. Employee count not disclosed for this period. | ||
| 2026-01-31 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 20,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-01-31 | restructuring | in_progress | Cost of Sales [Member] | USD 5,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-01-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-01-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2026-01-31 | restructuring | in_progress | USD 20,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2026-01-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 20,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | 2026-04-30 | Global | All three operating segments; management structure optimization | USD 81 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY25 Plan announced in Q2 fiscal 2025 (February–April 2025; exact date not disclosed) to optimize the management structure. Headcount affected not disclosed. FY2025 expense of $81M comprises severance, other personnel costs and $18M non-cash accelerated share-based compensation; $46M cash paid, $18M liability remaining at 2025-10-31. Expected annualized savings of $75–80M. Completion date derived from filer's statement of substantial completion by Q2 fiscal 2026 (quarter ending April 30, 2026). | |||
| 2025-10-31 | restructuring | completed | 500 | 3% | Global | All three operating segments; company-wide workforce reduction | USD 1 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY24 Plan initiated in Q3 fiscal 2024 (May–July 2024; exact date not disclosed), comprising a reduction of approximately 500 regular employees (~3% of global workforce). All workforce management actions and payments were completed during fiscal 2025; FY2025 expense was $1M (cumulative program cost since inception $73M). Headcount reduction originally executed in fiscal 2024 per prior filings; captured here at plan completion as disclosed in the current 10-K. | ||
| 2025-10-31 | restructuring | in_progress | 2025-05-31 | 2026-04-30 | Global | All three operating segments; management structure optimization | USD 81 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Announced in the second quarter of fiscal year 2025; date shown is quarter-end approximation as no exact date given. Expected to substantially complete by Q2 FY2026 (approximate completion date shown is quarter-end). Employees affected not disclosed. Expected annual cost savings of approximately $75-80 million. $18 million liability remained at 2025-10-31. Prior FY24 and FY23 plans (500 and 400 employees respectively) had all workforce actions completed before FY2025; only residual expenses of $1 million (FY24 Plan) were recorded in FY2025 and are not extracted as separate actions. | ||
| 2025-10-31 | restructuring | in_progress | 2025-01-01 | 2026-06-30 | Global | All Segments | USD 81 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Total expense of $81 million recorded in FY25. | ||
| 2025-10-31 | restructuring | completed | 500 | 3% | 2024-07-01 | Global | All Segments | USD 73 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY24 Plan initiated in Q3 FY24. Reduction of approximately 500 regular employees (3% of global workforce). All workforce management actions and payments completed. | |
| 2025-10-31 | restructuring | completed | 400 | 2% | 2023-07-01 | Global | All Segments | USD 50 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY23 Plan initiated in Q4 FY23. Reduction of approximately 400 regular employees (2% of global workforce). All workforce management actions and payments completed. | |
| 2025-10-31 | restructuring | in_progress | 2025-04-01 | 2026-04-01 | Global | All segments | USD 81 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Charge includes severance and personnel costs. Employee count not explicitly disclosed for this specific plan in the text, though total headcount reduced by ~200 net from prior plans. | ||
| 2025-10-31 | restructuring | completed | 2024-07-01 | Global | All segments | USD 1 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | FY24 Plan initiated in Q3 FY24. Reduced headcount by approx 500 employees (3% of global workforce). Plan completed in FY25 with $1M additional expense recorded. | |||
| 2025-10-31 | restructuring | completed | 2023-10-01 | Global | All segments | USD 4 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23. Reduced headcount by approx 400 employees (2% of global workforce). Plan completed in FY25 with $4M expense recorded in FY24. | |||
| 2025-10-31 | restructuring | in_progress | Employee Severance [Member] | USD 82,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Facility Closing [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | USD 82,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2025-10-31 | restructuring | in_progress | Cost of Sales [Member] | USD 21,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 5,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 56,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 81,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | USD 82,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-10-31 | restructuring | in_progress | 500 | FY24 Restructuring Plan [Member] | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | 2025-02-01 | 2026-04-30 | All three business segments | USD 73 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY25 Plan announced in Q2 fiscal 2025 to optimize management structure; workforce reduction expense includes severance and personnel-related costs; $17 million recorded in Q3 and $73 million since inception; expected to substantially complete by Q2 fiscal 2026; estimated $75-80 million annual cost reduction; liability of $23 million at July 31, 2025 | |||
| 2025-07-31 | restructuring | completed | 2024-08-01 | 2025-07-31 | All three business segments | USD 73 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY24 Plan announced in Q3 fiscal 2024 to reduce costs in response to macroeconomic conditions; all workforce management actions and payments completed as of July 31, 2025; $1 million change-in-estimate expense recorded in the nine months ended July 31, 2025; expected ~$100 million annual cost reduction | |||
| 2025-07-31 | restructuring | in_progress | 2026-04-30 | All three business segments | USD 73 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in second quarter of fiscal 2025 (exact date not disclosed); workforce reduction to optimize management structure. Expense of $73M recorded in nine months ended July 31, 2025 ($17M in Q3); expected annual cost savings of $75M-$80M. Number of employees affected not disclosed. | ||||
| 2025-07-31 | restructuring | completed | All three business segments | USD 73 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in third quarter of fiscal 2024 (exact date not disclosed); all workforce management actions and payments completed as of July 31, 2025. Total expense since inception $73M, of which $1M recorded in nine months ended July 31, 2025 due to changes in estimates. Expected annual cost savings of approximately $100M. Number of employees affected not disclosed. | |||||
| 2025-07-31 | restructuring | in_progress | 2025-04-01 | 2026-04-30 | Global | All segments | USD 17 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25 to optimize management structure. $17M expense recorded in Q3 FY25. Expected completion by Q2 FY26. | ||
| 2025-07-31 | restructuring | completed | 2024-07-01 | Global | All segments | USD 1 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY24 Plan announced in Q3 FY24. Completed all workforce actions as of July 31, 2025. $1M expense recorded in YTD FY25 due to changes in estimates. | |||
| 2025-07-31 | restructuring | in_progress | Employee Severance [Member] | USD 17,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | Cost of Sales [Member] | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 10,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | USD 17,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-07-31 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 17,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-07-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 17,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | 2025-02-01 | 2026-04-30 | All three business segments | USD 56 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY25 Plan announced in Q2 fiscal 2025 to optimize management structure; workforce reduction charge includes severance and personnel-related costs; expected to substantially complete by Q2 fiscal 2026; estimated $75-$80 million in annual cost savings when completed; liability of $51 million at April 30, 2025 | |||
| 2025-04-30 | restructuring | in_progress | 2024-08-01 | 2025-10-31 | All three business segments | USD 1 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY24 Plan announced in Q3 fiscal 2024 to reduce costs in response to macroeconomic conditions; workforce actions substantially complete as of April 30, 2025 with remaining payments expected by end of fiscal 2025; $1 million change-in-estimate charge in the six months ended April 30, 2025; expected ~$100 million annual cost savings | |||
| 2025-04-30 | restructuring | completed | 2023-11-01 | All three business segments | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY23 Plan substantially complete; cash payments of $1 million and $2 million settled in the three and six months ended April 30, 2025, respectively | |||||
| 2025-04-30 | restructuring | in_progress | 2026-07-31 | All three reportable segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets) | USD 56 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in the second quarter of fiscal 2025 (exact date not disclosed); workforce reduction to optimize management structure. Charge of $56M recorded in both the three and six months ended April 30, 2025. Expected to substantially complete by Q2 FY2026; estimated annual cost savings of $75-80 million. Number of employees affected not disclosed. Liability balance of $52M at April 30, 2025 (includes $1M FY24 Plan balance). | ||||
| 2025-04-30 | restructuring | completed | 2025-10-31 | All three reportable segments | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in the third quarter of fiscal 2024 (exact date not disclosed). Workforce management actions substantially complete as of April 30, 2025; remaining payments expected to settle by end of fiscal 2025. $1M charge recorded in the six months ended April 30, 2025 due to changes in estimates; total expense since inception $73M. Employees affected not disclosed. | ||||
| 2025-04-30 | restructuring | completed | All three reportable segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | All workforce management actions and payments substantially completed; $2M of cash payments settled in the six months ended April 30, 2025. Total expense since inception $50M. Employees affected not disclosed. | ||||||
| 2025-04-30 | restructuring | in_progress | 2025-02-01 | 2026-04-30 | Global | All segments | USD 56 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY25 Plan announced in Q2 FY25 to optimize management structure. Expected to substantially complete by Q2 FY26. Includes severance and personnel-related costs. | ||
| 2025-04-30 | restructuring | completed | 2024-08-01 | 2025-10-31 | Global | All segments | USD 1 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY24 Plan announced in Q3 FY24. Substantially completed workforce actions; remaining payments expected by end of FY25. Charge reflects changes in estimates. | ||
| 2025-04-30 | restructuring | completed | 2023-11-01 | Global | All segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY23 Plan. Substantially completed all workforce management actions and payments. Settled cash payments of $1M in Q2 FY25. | ||||
| 2025-04-30 | restructuring | in_progress | Employee Severance [Member] | USD 56,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | Cost of Sales [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | Research and Development Expense [Member] | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 38,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | USD 56,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-04-30 | restructuring | in_progress | Employee Severance [Member] / FY25 Restructuring Plan [Member] | USD 56,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-04-30 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 56,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | 2024-08-01 | 2025-04-30 | All three business segments | USD 73 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | Workforce reduction announced Q3 FY2024; majority completed by end of FY2024, remaining activities expected substantially complete by Q2 FY2025. Approximately $1 million in changes of estimate recorded in Q1 FY2025. Expected to reduce annual cost of sales and operating expenses by approximately $100 million. Liability of $4 million at January 31, 2025. | |||
| 2025-01-31 | restructuring | completed | 2023-01-01 | All three business segments | USD 50 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | Workforce management actions substantially completed; $1 million cash settled in Q1 FY2025, remaining $1 million accrual to be settled in Q2 FY2025. | ||||
| 2025-01-31 | restructuring | in_progress | 2024 | 2025-04-30 | Global | All three business segments (workforce reduction) | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in Q3 FY2024; $1M charge in Q1 FY2025 reflects changes in estimate; $5M accrual balance at quarter end; expected annual cost savings of approximately $100M; number of employees affected not disclosed | ||
| 2025-01-31 | restructuring | completed | 2023 | 2025-04-30 | Global | All three business segments (workforce reduction) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Workforce actions substantially completed; $1M accrual remaining to be settled in Q2 FY2025; no restructuring expense recorded in Q1 FY2025; number of employees affected not disclosed | |||
| 2025-01-31 | restructuring | in_progress | 2024-07-01 | 2025-04-30 | Global | All segments | USD 1 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Fiscal Year 2024 Plan. Majority of workforce reduction completed by end of FY2024. Remaining activities expected to substantially complete by Q2 FY2025. $1M expense recorded in Q1 FY2025 due to changes in estimate. | ||
| 2025-01-31 | restructuring | completed | 2023-07-01 | 2025-04-30 | Global | All segments | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Fiscal Year 2023 Plan. Substantially completed all workforce management actions. $1M cash payments settled in Q1 FY2025. Remaining accrual of $1M to be settled in Q2 FY2025. | ||
| 2025-01-31 | restructuring | in_progress | Employee Severance [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | Cost of Sales [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2025-01-31 | restructuring | in_progress | FY24 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2025-01-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | 500 | 3% | 2024-07 | 2025-04-30 | All three business segments (charges not allocated to segment results) | USD 72 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY24 Plan initiated in fiscal Q3 2024 (May–July 2024); announcement_date reflects the quarter-end month since the exact date is not disclosed. Involves reduction of approximately 500 regular employees, about 3 percent of the global workforce; majority of the reduction completed in FY2024 with remaining activities expected substantially complete by end of fiscal Q2 2025 (April 30, 2025). FY2024 charge covers severance, accelerated share-based compensation and other personnel costs; program expected to remove roughly $100 million of annual costs when complete. Implied workforce base (~500/3%) is consistent with the ~17,900 disclosed total. | |
| 2024-10-31 | restructuring | in_progress | 400 | 2% | 2023-10 | 2025-01-31 | All three business segments (charges not allocated to segment results) | USD 50 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY23 Plan initiated in fiscal Q4 2023 (August–October 2023, i.e., the prior fiscal year); announcement_date reflects the quarter-end month. Figures are plan-level/cumulative since inception: approximately 400 regular employees (~2 percent of global workforce) plus consolidation of excess facilities including some site closures. FY2024 restructuring expense was $4 million ($46 million recorded in FY2023; $50 million cumulative since inception). Majority of the workforce reduction completed in FY2024; remaining activities expected substantially complete by end of fiscal Q1 2025 (January 31, 2025). Expected to remove roughly $80 million of annual costs when complete. Not double-counted with prior-year 10-K reporting; captured here as the plan-level figures re-disclosed in this filing. | |
| 2024-10-31 | acquisition_addition | completed | 2024-09-20 | 2024-09-20 | Diagnostics and Genomics (expands contract development and manufacturing organization; goodwill allocated to the diagnostics and genomics reporting unit) | USD 915 (millions) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired 100 percent of BIOVECTRA stock for $915 million in cash on September 20, 2024; the $915 million is total purchase consideration, not a workforce charge. Employee headcount added through the acquisition is not disclosed. BIOVECTRA became a wholly-owned subsidiary, expanding Agilent's contract development and manufacturing organization; results consolidated from the acquisition date. Assumed interest-free government loans (Strategic Innovation Fund; Atlantic Canada Opportunities Agency) recorded in short- and long-term debt. | |||
| 2024-10-31 | other | announced | 2024-11 | 2025-01-31 | Company-wide segment re-organization: diagnostics and genomics combined with liquid chromatography and mass spectrometry platforms into a new 'life sciences and diagnostics markets' segment; chemistries and supplies, laboratory automation and robotics, and software and informatics moved to Agilent CrossLab; remaining divisions (gas chromatography, GC/MS, remarketed instruments, spectroscopy, vacuum) form a new 'applied markets' segment | subsequent_events f5-10k / GLM-5.3-flash-HTML | Organizational structure change announced November 2024, creating three new reportable segments effective with first-quarter fiscal 2025 reporting (expected_completion_date reflects the end of fiscal Q1 2025, January 31, 2025). No workforce reduction or headcount impact disclosed; captured as an organizational workforce action since employees move between the redefined segments. | ||||
| 2024-10-31 | restructuring | in_progress | 500 | 3% | 2024-05-01 | 2025-04-30 | Global | All three business segments | USD 72 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Initiated in Q3 FY2024; reduction of approximately 500 regular employees (~3% of global workforce). Expected annual cost savings of ~$100M when complete. Substantially complete by end of Q2 FY2025. |
| 2024-10-31 | restructuring | in_progress | 400 | 2% | 2023-08-01 | 2025-01-31 | Global | All three business segments; includes facility consolidation and site closures | USD 4 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY23 Plan initiated in Q4 FY2023; $4M charged in FY2024 (cumulative $50M since inception). Headcount reduction of ~400 (~2% of workforce) plus excess facility consolidation. Expected annual cost savings of ~$80M when complete. |
| 2024-10-31 | acquisition_addition | completed | 2024-09-20 | 2024-09-20 | Canada | Diagnostics and Genomics — advanced manufacturing partnerships (CDMO) | USD 915 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of BIOVECTRA for $915M cash; headcount added not disclosed. Represents 3% of total assets at year-end. | ||
| 2024-10-31 | divestiture_reduction | completed | 2023-10-01 | 2023-10-31 | United States | Diagnostics and Genomics — Resolution Bioscience | USD 43 (millions) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Divested in Q4 FY2023 for $50M with $43M gain; headcount removed not disclosed. Prior-year action referenced for context; no FY2024 headcount impact quantified. | ||
| 2024-10-31 | restructuring | in_progress | 500 | 3% | 2024-07-01 | 2025-07-31 | Global | All segments | USD 72 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY24 Plan initiated in Q3 FY24. Reduction of 500 regular employees (3% of global workforce). Majority completed in FY24; remaining activities expected by end of Q2 FY25. |
| 2024-10-31 | restructuring | in_progress | 400 | 2% | 2023-07-01 | 2025-01-31 | Global | All segments | USD 4 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY23 Plan initiated in Q4 FY23. Reduction of 400 regular employees (2% of global workforce) and consolidation of excess facilities. $4 million expense recorded in FY24. Majority completed in FY24; remaining activities expected by end of Q1 FY25. |
| 2024-10-31 | restructuring | in_progress | 500 | 3% | 2024-07-01 | 2025-07-31 | Global | All segments | USD 72 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | FY24 Plan initiated in Q3 FY24. Reduction of ~500 regular employees (~3% of global workforce). Expected to substantially complete by end of Q2 FY25. |
| 2024-10-31 | restructuring | in_progress | 400 | 2% | 2024-01-01 | 2025-04-30 | Global | All segments | USD 4 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23. Reduction of ~400 regular employees (~2% of global workforce) and consolidation of excess facilities. $4M expense recorded in FY24. Expected to substantially complete by end of Q1 FY25. |
| 2024-10-31 | restructuring | in_progress | Employee Severance [Member] | USD 75,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Facility Closing [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | USD 76,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2024-10-31 | restructuring | in_progress | Cost of Sales [Member] | USD 13,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 21,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 42,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 72,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | FY23 Restructuring Plan [Member] | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Employee Severance [Member] / FY23 Restructuring Plan [Member] | USD 3,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Facility Closing [Member] / FY23 Restructuring Plan [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | USD 76,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-10-31 | restructuring | in_progress | 500 | FY24 Restructuring Plan [Member] | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | 500 | 3% | 2024-05-01 | 2025-04-30 | Global | All three business segments | USD 67 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY24 Plan announced in Q3 FY2024; workforce reduction of approximately 500 regular employees (~3% of global workforce). Majority of reduction to be completed by end of FY2024, remaining activities substantially complete by Q2 FY2025. Expected to yield ~$100 million in annual cost reductions. Includes $6 million non-cash accelerated share-based compensation; liability of $42 million at July 31, 2024. |
| 2024-07-31 | restructuring | in_progress | 400 | 2% | 2023-08-01 | 2024-10-31 | Global | All three business segments | USD 50 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY23 Plan initiated in Q4 FY2023; ~400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. Majority of workforce reduction completed in Q1 FY2024; remaining activities substantially complete by end of FY2024. Expected to yield ~$80 million in annual cost reductions. Total expense since inception $50 million; liability of $4 million at July 31, 2024. |
| 2024-07-31 | restructuring | in_progress | 500 | 3% | 2025-04-30 | Global | All three business segments (life sciences and applied markets, diagnostics and genomics, Agilent CrossLab) | USD 67 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced in Q3 FY2024; exact announcement date not disclosed. Reduction of approximately 500 regular employees (~3% of global workforce); $67M charge recorded in both the three and nine months ended July 31, 2024; $42M liability remaining at quarter-end. Expected to deliver roughly $100M in annual cost savings when complete. | |
| 2024-07-31 | restructuring | in_progress | 400 | 2% | 2024-10-31 | Global | All three business segments; includes consolidation of excess facilities and site closures | USD 4 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan initiated in Q4 FY2023 (prior to this quarter); exact announcement date not disclosed. Charge shown is the nine-month FY2024 amount (approximately zero in the three months ended July 31, 2024); total expense since inception is $50M. Remaining activities expected to be substantially complete by end of FY2024; $4M liability remaining at quarter-end. | |
| 2024-07-31 | acquisition_addition | announced | 2024-07-21 | 2024-12-31 | Global | Contract development and manufacturing organization (BIOVECTRA) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement signed July 21, 2024 to acquire BIOVECTRA for $925 million in cash, subject to customary closing conditions including regulatory approvals; close expected before calendar year 2025. Headcount added through the acquisition is not disclosed. | |||
| 2024-07-31 | restructuring | in_progress | 500 | 3% | 2024-07-31 | 2025-04-30 | Global | All segments | USD 67 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY24 Plan announced in Q3 FY24. Reduction of ~500 regular employees (~3% of global workforce). Majority of workforce reduction to be completed by end of FY24; remaining activities by Q2 FY25. |
| 2024-07-31 | restructuring | in_progress | 400 | 2% | 2023-10-31 | 2024-10-31 | Global | All segments | USD 4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23. Reduction of ~400 regular employees (~2% of global workforce) and consolidation of excess facilities. Majority of workforce reduction completed in Q1 FY24; remaining activities expected to be substantially complete by end of FY24. |
| 2024-07-31 | restructuring | in_progress | Employee Severance [Member] | USD 67,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | Facility Closing [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | USD 67,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2024-07-31 | restructuring | in_progress | Cost of Sales [Member] | USD 12,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 18,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 37,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | 500 | FY24 Restructuring Plan [Member] | USD 67,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||
| 2024-07-31 | restructuring | in_progress | Employee Severance [Member] / FY24 Restructuring Plan [Member] | USD 67,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | FY23 Restructuring Plan [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-07-31 | restructuring | in_progress | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | USD 67,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | 400 | 2% | 2023-11-01 | 2024-10-31 | All three business segments | USD 50 (millions) | restructuring_footnote f5-10q / GLM-5.3-flash-fp4-HTML | FY23 Plan initiated Q4 FY2023; ~400 regular employees (~2% of workforce) plus excess facility consolidation including site closures. $50 million cumulative since inception; $1 million in Q2 and $4 million in six months ended April 30, 2024. Majority of workforce reduction completed in Q1 FY2024; remaining activities expected substantially complete by end of FY2024. Expected to reduce annual cost of sales and operating expenses by $80 million. | |
| 2024-04-30 | restructuring | announced | 500 | 3% | 2024-05-29 | 2024-10-31 | USD 55 (millions) | subsequent_events f5-10q / GLM-5.3-flash-fp4-HTML | FY24 Plan announced May 29, 2024; reduction of approximately 500 regular employees (~3% of global workforce). Costs include severance and other personnel costs, estimated at approximately $55 million. Expected to reduce annual cost of sales and operating expenses by approximately $100 million; most activities to be completed by end of fiscal year 2024. | ||
| 2024-04-30 | restructuring | in_progress | 400 | 2% | 2024-10-31 | Global | All three business segments | USD 50 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Initiated in Q4 FY2023 (exact announcement date not disclosed in this filing); reduction of approximately 400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. $50M recorded since inception, of which $4M in the six months and $1M in the three months ended April 30, 2024; $6M accrual remaining at April 30, 2024. Implied total (400 / 2%) is broadly consistent with disclosed headcount of ~17,600. | |
| 2024-04-30 | restructuring | announced | 500 | 3% | 2024-05-29 | 2024-10-31 | Global | All business segments | USD 55 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced May 29, 2024, after the April 30, 2024 quarter close; reduction of approximately 500 regular employees (~3% of global workforce), estimated cost approximately $55M, mostly to be completed by end of fiscal year 2024. Implied total (500 / 3%) is broadly consistent with disclosed headcount of ~17,600. |
| 2024-04-30 | restructuring | in_progress | 400 | 2% | 2023-10-31 | 2024-10-31 | Global | All segments | USD 50 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23. Includes headcount reduction and facility consolidation. Total costs since inception $50 million. Majority of workforce reduction completed in Q1 FY24. |
| 2024-04-30 | restructuring | announced | 500 | 3% | 2024-05-29 | 2024-10-31 | Global | All segments | USD 55 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | FY24 Plan announced May 29, 2024. Includes headcount reduction of approx 500 regular employees. Estimated costs $55 million. |
| 2024-04-30 | restructuring | in_progress | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2024-04-30 | restructuring | in_progress | Employee Severance [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | Facility Closing [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | Cost of Sales [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-04-30 | restructuring | in_progress | Segment Reconciling Items [Member] | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | 400 | 2% | 2024-10-31 | Global | All three business segments (costs not allocated to segments) | USD 49 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY23 Plan initiated in Q4 FY2023 (exact announcement date not disclosed); covers ~400 regular employees (~2% of global workforce) plus consolidation of excess facilities including site closures. $3M charged in Q1 FY2024; $49M cumulative since inception; $11M accrual at 2024-01-31. Majority of workforce reduction completed in Q1 FY2024; expected annual cost savings of $80M. | |
| 2024-01-31 | restructuring | in_progress | 400 | 2% | 2023-10-31 | 2024-10-31 | Global | All segments | USD 49 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23 to reduce headcount by approx. 400 regular employees (approx. 2% of global workforce) and consolidate excess facilities. Total costs recorded since inception are $49 million. Majority of workforce reduction completed in Q1 FY24; remaining activities expected to substantially complete by end of FY24. |
| 2024-01-31 | restructuring | in_progress | 400 | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Employee Severance [Member] | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Facility Closing [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Cost of Sales [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2024-01-31 | restructuring | in_progress | Segment Reconciling Items [Member] | USD -3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | 400 | 2% | 2024-10-31 | All three business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, Agilent CrossLab | USD 46 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY23 Plan initiated in Q4 fiscal 2023 (August-October 2023); no specific announcement date disclosed. Reduction is approximately 400 regular employees (~2% of global workforce per filer; 400 of ~18,100 is roughly 2.2%, filer rounds down). FY2023 charges of ~$46 million comprise $33M workforce reduction expense and $13M excess-facilities consolidation (including $8M accelerated depreciation of right-of-use and machinery/equipment assets), partially offset by $1M accelerated share-based compensation credit; $36M accrual remained at October 31, 2023, recorded in other accrued liabilities, plus some site closures. Majority of workforce reduction expected complete in Q1 fiscal 2024; remaining activities substantially complete by end of fiscal 2024. Program expected to yield $80 million in annual cost-of-sales and operating-expense reductions once completed. Restructuring costs were not allocated to segment results. | ||
| 2023-10-31 | restructuring | in_progress | 400 | 2% | 2023-07-31 | 2023-10-31 | Global | All three business segments | USD 46 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Initiated in Q4 FY2023; reduction of approximately 400 regular employees (~2% of global workforce) plus consolidation of excess facilities and site closures. Majority of workforce reduction expected to complete in Q1 2024, with remaining activities substantially complete by end of FY2024; expected annual cost savings of $80 million. Announcement date approximated to start of Q4 FY2023 (Aug 1, 2023) as no exact date is given; expected_completion_date reflects the majority-reduction milestone. |
| 2023-10-31 | divestiture_reduction | completed | 2023-04-30 | 2023-10-31 | United States | Diagnostics and Genomics — Resolution Bioscience | USD 270 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Exit decision made in Q3 FY2023 with a $270 million long-lived asset impairment charge; business divested in Q4 FY2023 for $50 million with a $43 million gain. Headcount associated with the business not disclosed. Announcement date approximated to end of Q3 FY2023 (Jul 31, 2023). | ||
| 2023-10-31 | acquisition_addition | completed | Diagnostics and Genomics; Life Sciences and Applied Markets | USD 51 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Two businesses acquired during FY2023 for a total purchase price of $51 million; acquired headcount not disclosed. | |||||
| 2023-10-31 | restructuring | in_progress | 400 | 2% | 2023-10-01 | 2024-10-31 | Global | All segments | USD 46 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY23 Plan initiated in Q4 FY23. Includes workforce reduction of approx 400 regular employees (2% of global workforce) and consolidation of excess facilities. Total costs recorded in FY23 were $46 million. Majority of workforce reduction expected to complete in Q1 FY24; remaining activities by end of FY24. |
| 2023-10-31 | restructuring | in_progress | 400 | 2% | 2023-10-31 | 2024-10-31 | Global | All segments | USD 46 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | FY23 Plan initiated in Q4 FY23. Includes workforce reduction of approx 400 regular employees (2% of global workforce) and consolidation of excess facilities. Majority of workforce reduction expected to complete in Q1 FY24; remaining activities by end of FY24. |
| 2023-10-31 | restructuring | in_progress | 400 | USD 46,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Employee Severance [Member] | USD 33,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Facility Closing [Member] | USD 13,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Cost of Sales [Member] | USD 11,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 6,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 29,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-10-31 | restructuring | in_progress | Corporate, Non-Segment [Member] | USD 46,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2023-07-31 | restructuring | in_progress | Diagnostics and Genomics | USD 277 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision made during the quarter to shut down the Resolution Bioscience business; charge is a long-lived asset impairment written down to zero, not severance. Note 1 states a $270 million long-lived asset impairment while Note 9, the cash flow statement and the segment reconciliation show $277 million. No employee count, announcement date or completion date disclosed. | |||||
| 2023-07-31 | restructuring | completed | 2023-07-31 | Diagnostics and Genomics | USD 270 (millions) | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Shutdown of Resolution Bioscience business resulted in $270 million long-lived asset impairment charge. Employee count not disclosed. | ||||
| 2023-01-31 | acquisition_addition | completed | Diagnostics and Genomics | USD 30 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Avida Biomed completed during the quarter (cash outflow of $30 million); added $11 million goodwill and $23 million intangibles in the diagnostics and genomics segment. Headcount added through the acquisition was not disclosed. | |||||
| 2022-10-31 | other | completed | 2022-05-23 | 2022-05-23 | Russia | MD&A f5-10k / GLM-5.3-flash-HTML | Country exit: after suspending sanctioned sales and halting most product shipments to Russia in March 2022, the company ceased major operations within Russia effective May 23, 2022. The in-country workforce was wound down as part of the shutdown, but the affected headcount is not quantified. An immaterial shutdown-related expense was recorded for the three months ended April 30, 2022, and Russia-derived sales were an immaterial share of total revenue. | ||||
| 2022-04-30 | acquisition_addition | completed | 2022-02 | Diagnostics and Genomics (implied by intangible asset context) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of advanced AI technology completed in February 2022; $21M of intangibles recorded and contingent consideration added, but no headcount added was disclosed. | |||||
| 2022-04-30 | other | announced | 2022-05-23 | 2022-05-23 | Russia | All functions (Russia operations) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sanctions-related suspension of sales began early March 2022; total cessation of Russia operations effective May 23, 2022 (post-quarter). Immaterial shutdown expense recorded in Q2 FY2022; no affected-employee count disclosed. | |||
| 2021-10-31 | acquisition_addition | completed | 2021-04-15 | Diagnostics and Genomics | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired privately-held Resolution Bioscience, Inc. on April 15, 2021 for $561 million cash plus contingent payments of up to $145 million tied to revenue and technical milestones; adds NGS-based precision oncology capabilities. Employee headcount acquired was not disclosed. | |||||
| 2021-10-31 | restructuring | in_progress | USD 37 (millions) | other f5-10k / GLM-5.3-flash-HTML | Ongoing transformational initiatives program encompassing targeted cost-reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, and in-sourcing/outsourcing. $37 million charged in fiscal 2021; no affected-employee headcount or completion timeline disclosed. Risk factors separately reference ongoing reorganizations, workforce reductions and site closures, and the segment reconciliation shows $1 million of accelerated share-based compensation from workforce reductions. | ||||||
| 2021-10-31 | acquisition_addition | completed | 2021-04-15 | 2021-04-15 | United States | Diagnostics and genomics | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Resolution Bioscience completed 2021-04-15 for $561M cash plus up to $145M contingent; headcount added not disclosed | |||
| 2021-07-31 | acquisition_addition | completed | 2021-04-15 | 2021-04-15 | Diagnostics and Genomics | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Resolution Bioscience for $550 million cash plus up to $145 million contingent payments; headcount added not disclosed. Goodwill of $365 million recorded in the Diagnostics and Genomics segment. | ||||
| 2021-04-30 | acquisition_addition | completed | 2021-04-15 | 2021-04-15 | United States | Diagnostics and Genomics | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Resolution Bioscience completed April 15, 2021 for $550M cash plus up to $145M contingent payments; headcount added not disclosed. | |||
| 2021-01-31 | acquisition_addition | announced | 2021-03-01 | 2021-04-30 | United States | Diagnostics and Genomics | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement signed March 1, 2021 to acquire Resolution Bioscience for $550 million cash plus up to $145 million contingent payments; expected to close in Q2 FY2021. Headcount added not disclosed. | |||
| 2020-10-31 | restructuring | in_progress | USD 53 (millions) | other f5-10k / GLM-5.3-flash-HTML | Multi-year program of targeted cost-reduction activities (manufacturing transfers, site consolidations, business reorganizations, in-/outsourcing); only the FY2020 charge of $53M is captured — comparative prior-year charges excluded. No affected-employee count, announcement date, or completion date disclosed. | ||||||
| 2020-10-31 | reduction_in_force | completed | USD 2 (millions) | other f5-10k / GLM-5.3-flash-HTML | Disclosed only as accelerated share-based compensation expense related to a workforce reduction during FY2020; affected headcount and timing details not disclosed. | ||||||
| 2020-10-31 | restructuring | in_progress | Enterprise-wide | USD 2 (millions) | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2020 segment reconciliation includes a $2M line for accelerated share-based compensation related to a workforce reduction; no headcount, date, or geography disclosed. Separate transformational initiatives charges of $53M in FY2020 cover cost-reduction activities (manufacturing transfers, site consolidations, reorganizations) without stated employee counts. | |||||
| 2020-07-31 | restructuring | completed | Global | Diagnostics and Genomics — sequencer development program | USD 99 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Shut-down of the sequencer development program recorded during the nine months ended July 31, 2020; $90M in-process R&D impairment plus long-lived assets written down to zero ($98M carrying amount), $99M total asset impairment per cash flow statement. No employee count, severance amount, or announcement date disclosed. | ||||
| 2019-10-31 | acquisition_addition | completed | 2018-11-14 | Life Sciences and Applied Markets | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | ACEA Biosciences Inc., a developer of cell analysis tools, acquired for $250 million; November 14, 2018 shown is the completion date (falls in fiscal 2019 for this October year-end filer). No employee headcount added through the deal is disclosed. | |||||
| 2019-10-31 | acquisition_addition | completed | 2019-08-23 | United States (Vermont) | Life Sciences and Applied Markets | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Privately held Lionheart Technologies LLC (BioTek), a life science instrumentation maker, acquired for $1.17 billion, funded with $470 million cash and $700 million debt; date shown is the completion date. Filing cites intent to utilize the assembled workforce but discloses no headcount; Vermont organization per Exhibit 21.1. | ||||
| 2019-10-31 | acquisition_addition | completed | 2019-08-23 | 2019-08-23 | United States | Life Sciences and Applied Markets | USD 1,170 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Lionheart Technologies LLC (BioTek), funded with $470M cash and $700M debt; acquired headcount not disclosed. | ||
| 2019-10-31 | acquisition_addition | completed | 2018-11-14 | 2018-11-14 | United States | Life Sciences and Applied Markets | USD 250 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition completed early in fiscal 2019 (Nov 14, 2018); acquired headcount not disclosed. | ||
| 2019-10-31 | restructuring | completed | 2019-10-31 | Global | Corporate | USD 44 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Transformational initiatives include manufacturing transfers, site consolidations, and business reorganizations; employee-affected counts not disclosed. Prior year charge was $25 million. | |||
| 2019-10-31 | acquisition_addition | completed | 2019-08-23 | Global | Life Sciences and Applied Markets | USD 1,170 (millions) | Item 1. Business; Note 3. Acquisitions f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Completed acquisition of Lionheart Technologies LLC (BioTek) for $1.17 billion. Headcount not explicitly disclosed. | |||
| 2019-10-31 | acquisition_addition | completed | 2018-11-14 | Global | Life Sciences and Applied Markets | USD 250 (millions) | Item 1. Business; Note 3. Acquisitions f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquired 100% of ACEA Biosciences for $250 million. Headcount not explicitly disclosed. | |||
| 2019-07-31 | acquisition_addition | completed | 2018-11-14 | 2018-11-14 | Life Sciences and Applied Markets | USD 250 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Closed in Q1 of fiscal 2019 (prior quarter of the same fiscal year); purchase price disclosed, no employee count disclosed. Goodwill additions of $153 million in the nine months relate primarily to this acquisition. | |||
| 2019-07-31 | acquisition_addition | completed | 2019-08-23 | 2019-08-23 | USD 1,165 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter event; date shown is the completion date. Purchase price disclosed, no employee count disclosed. Funded in part by a $500 million short-term loan facility drawn in full; results included from the close in Q4 fiscal 2019. | ||||
| 2019-04-30 | acquisition_addition | completed | 2018-11-14 | Life Sciences and Applied Markets | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 100% stock acquisition of ACEA Biosciences for approximately $250 million cash; headcount added not disclosed | |||||
| 2019-01-31 | acquisition_addition | completed | 2018-11-14 | 2018-11-14 | United States | Life Sciences and Applied Markets | USD 250 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of ACEA Biosciences, a cell analysis tools developer, for approximately $250 million in cash; headcount added not disclosed. Purchase accounting substantially complete, to be finalized during 2019. | ||
| 2018-10-31 | restructuring | in_progress | USD 25 (millions) | other f5-10k / GLM-5.3-flash-HTML | Multi-year cost-reduction program covering manufacturing transfers, site consolidations, legal-entity/business reorganizations and in-/outsourcing. FY2018 charge was $25 million (vs $12 million in FY2017). No headcount, announcement date, or completion date disclosed; program status not explicitly stated. | ||||||
| 2018-10-31 | other | in_progress | Primarily the NMR business | USD 9 (millions) | other f5-10k / GLM-5.3-flash-HTML | Business exit and divestiture costs of $9 million recognized in FY2018, primarily related to the NMR business. No headcount, timeline, or program status disclosed; recorded as 'other' because the filing does not describe a sale, spin-off, or headcount reduction. | |||||
| 2018-10-31 | acquisition_addition | completed | USD 536 (millions) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Seven businesses acquired during FY2018 for combined purchase price of approximately $536 million; largest was Advanced Analytical Technologies, Inc. for approximately $268 million in cash. Headcount added was not disclosed; filer states the acquisitions were not material individually or in aggregate. Acquisitions spanned multiple segments (e.g., Lasergen and AATI in Diagnostics and Genomics; Ultra Scientific and ProZyme in Agilent CrossLab). | ||||||
| 2018-10-31 | acquisition_addition | completed | USD 250 (millions) | subsequent_events f5-10k / GLM-5.3-flash-HTML | 100 percent of ACEA Biosciences Inc., a developer of cell analysis tools, acquired on November 14, 2018 (after fiscal year-end) for approximately $250 million in cash; results included from the close date. Headcount not disclosed. | ||||||
| 2018-10-31 | acquisition_addition | completed | Global | Multiple (largest: Advanced Analytical Technologies, Inc.) | USD 536 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Seven businesses acquired during fiscal 2018 for a combined purchase price of approximately $536 million; largest was AATI at approximately $268 million in cash. No headcount added disclosed | ||||
| 2018-10-31 | acquisition_addition | completed | United States | Diagnostics and Genomics (genomics) | USD 107 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Exercise of option to acquire all remaining shares of Lasergen, Inc. during fiscal 2018 for approximately $107 million cash, on top of an $80 million preferred investment made in fiscal 2016; no headcount disclosed | ||||
| 2018-10-31 | acquisition_addition | completed | 2018-11-14 | 2018-11-14 | United States | Life Sciences and Applied Markets (cell analysis) | USD 250 (millions) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 100% of ACEA Biosciences Inc. closed after fiscal year-end; results included from close date; no headcount disclosed | ||
| 2018-10-31 | restructuring | in_progress | Global | Enterprise (transformational initiatives) | USD 25 (millions) | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Transformational initiatives charge of $25 million recorded in fiscal 2018 (versus $12 million in fiscal 2017); covers manufacturing transfers, site consolidations and business reorganizations. No employee counts or restructuring footnote disclosed | ||||
| 2018-10-31 | divestiture_reduction | in_progress | Global | NMR business | USD 9 (millions) | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Business exit and divestiture costs of $9 million in fiscal 2018, primarily related to the NMR business; no headcount impact disclosed | ||||
| 2018-10-31 | acquisition_addition | completed | 2018-11-14 | Global | Diagnostics and Genomics | USD 250 (millions) | subsequent_events f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences Inc. for approximately $250 million in cash. Headcount not disclosed. | |||
| 2018-10-31 | acquisition_addition | completed | 2018-10-31 | Global | Various | USD 536 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | In 2018, we acquired seven businesses, for a combined purchase price of approximately $536 million. The largest was Advanced Analytical Technologies, Inc. for approximately $268 million. Headcount not disclosed. | |||
| 2018-07-31 | acquisition_addition | completed | 2018-05-07 | 2018-05-07 | United States | Diagnostics and Genomics | USD 107 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired remaining shares of Lasergen for approximately $107 million cash; acquired headcount not disclosed. | ||
| 2018-07-31 | acquisition_addition | completed | 2018-05-14 | 2018-05-14 | Switzerland | Agilent CrossLab | USD 41 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of Genohm SA, a lab informatics company, for approximately $41 million cash; acquired headcount not disclosed. | ||
| 2018-07-31 | acquisition_addition | completed | 2018-05-31 | 2018-05-31 | United States | Diagnostics and Genomics | USD 269 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of Advanced Analytical Technologies for approximately $269 million cash; acquired headcount not disclosed. | ||
| 2018-07-31 | acquisition_addition | completed | 2018-07-16 | 2018-07-16 | United States | Agilent CrossLab | USD 32 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired substantially all assets and liabilities of Ultra Scientific for $32 million cash, plus a $3 million contingent payment treated as post-acquisition compensation; acquired headcount not disclosed. | ||
| 2018-07-31 | acquisition_addition | announced | 2018-08-01 | 2018-08-01 | United States | Agilent CrossLab | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter acquisition of ProZyme, a glycan analysis reagents provider; combined cash for this and the Young In Scientific acquisition was approximately $80 million; acquired headcount not disclosed. | |||
| 2018-07-31 | acquisition_addition | announced | 2018-08-17 | 2018-08-17 | South Korea | Agilent CrossLab | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter acquisition of certain assets from Young In Scientific, an analytical instrument distributor; acquired headcount not disclosed. | |||
| 2018-04-30 | acquisition_addition | completed | 2018-05-07 | USD 105 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Option exercised and merger agreement signed during the quarter to buy the remaining Lasergen, Inc. shares not already owned (48% initial stake); additional cash consideration $105 million. Acquisition completed 2018-05-07. No headcount added disclosed. | |||||
| 2018-04-30 | acquisition_addition | completed | 2018-03-07 | 2018-05-31 | United States | USD 250 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Merger agreement for Advanced Analytical Technologies, Inc. (Ankeny, Iowa), $250 million cash subject to purchase price adjustments; completed 2018-05-31. No headcount added disclosed. | |||
| 2018-04-30 | acquisition_addition | completed | 2018-05-14 | Switzerland | USD 40 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquired 100% of Genohm SA, a lab informatics company, for approximately $40 million cash; completed 2018-05-14 (post-quarter). No headcount added disclosed. | ||||
| 2018-04-30 | acquisition_addition | announced | 2018-05-23 | South Korea | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement signed to acquire certain assets of Young In Scientific Co. Ltd., a distributor of analytical instruments; closing expected during fiscal Q4 2018 (cash consideration part of approximately $60 million combined with Ultra Scientific). No headcount disclosed. | |||||
| 2018-04-30 | acquisition_addition | announced | 2018-05-25 | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement signed to acquire substantially all assets and liabilities of Ultra Scientific Incorporated; closing expected during fiscal Q3 2018 (cash consideration part of approximately $60 million combined with Young In Scientific). No headcount disclosed. | ||||||
| 2018-04-30 | restructuring | in_progress | Enterprise-wide | USD 9 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Transformational initiatives expense of $9 million for the six months ended April 30, 2018 ($5 million in the quarter); described as targeted cost reduction activities including manufacturing transfers, site consolidations and business reorganizations. No employee counts, severance detail or completion dates disclosed. | |||||
| 2018-01-31 | acquisition_addition | completed | Diagnostics and Genomics | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition closed during the quarter (goodwill addition of $5 million disclosed in Note 7); no headcount added disclosed. Related incremental R&D and SG&A spend noted in segment discussion. | ||||||
| 2018-01-31 | acquisition_addition | announced | 2018-02-23 | USD 105 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter event; completion contingent on merger agreement and closing conditions. No workforce impact disclosed; Agilent already held a 48 percent stake. | |||||
| 2017-10-31 | acquisition_addition | completed | 2017-01-20 | Belgium | Diagnostics and Genomics | MD&A f5-10k / GLM-5.3-flash-HTML | Completed acquisition of 100% of Multiplicom NV, a Belgian molecular diagnostics company, for approximately $72 million in cash; disclosed date is the acquisition completion date. Employee count added not disclosed. Note 9 shows fiscal 2017 goodwill additions of $52 million in Diagnostics and Genomics consistent with this deal. | ||||
| 2017-10-31 | acquisition_addition | completed | 2017-07-07 | United Kingdom | Life Sciences and Applied Markets | MD&A f5-10k / GLM-5.3-flash-HTML | Completed acquisition of Cobalt Light Systems, an Oxfordshire-based Raman spectroscopy provider, for approximately $53 million in cash; disclosed date is the acquisition completion date. Employee count added not disclosed. Note 9 shows fiscal 2017 goodwill additions of $26 million in Life Sciences and Applied Markets consistent with this deal. | ||||
| 2017-10-31 | acquisition_addition | completed | 2017-01-20 | 2017-01-20 | Belgium (Europe) | Diagnostics and Genomics | USD 72 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 100% of Multiplicom NV completed January 20, 2017 for approximately $72 million in cash; acquired headcount not disclosed. | ||
| 2017-10-31 | acquisition_addition | completed | 2017-07-07 | 2017-07-07 | United Kingdom | Life Sciences and Applied Markets | USD 53 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Cobalt Light Systems completed July 7, 2017 for approximately $53 million in cash; acquired headcount not disclosed. | ||
| 2017-07-31 | acquisition_addition | completed | 2017-01-20 | Belgium (Europe) | Diagnostics and Genomics | USD 72 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Purchase price approximately $72 million in cash; acquired headcount not disclosed in filing | |||
| 2017-07-31 | acquisition_addition | completed | 2017-07-07 | United Kingdom (Oxfordshire) | Life Sciences and Applied Markets | USD 53 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Purchase price approximately $53 million in cash; acquired headcount not disclosed in filing | |||
| 2017-04-30 | acquisition_addition | completed | 2017-01-20 | Europe (Belgium headquarters) | Diagnostics and Genomics | USD 72 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Purchase price approximately $72 million in cash; acquired headcount not disclosed in this filing | |||
| 2017-04-30 | acquisition_addition | completed | Agilent CrossLab | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | MD&A attributes R&D and SG&A expense increases partly to headcount growth from the iLab acquisition; acquisition date and added headcount not disclosed in this filing | ||||||
| 2017-01-31 | acquisition_addition | completed | 2017-01-20 | Belgium (Europe) | Diagnostics and Genomics | USD 72 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Multiplicom NV completed January 20, 2017 for approximately $72 million in cash; acquired headcount not disclosed. Purchase accounting preliminary. | |||
| 2016-10-31 | restructuring | completed | 2014 | 2016-10-31 | Life Sciences and Applied Markets (NMR product line) | other f5-10k / GLM-5.3-flash-HTML | Multi-year business exit: decision to cease the NMR product line made in Q4 FY2014; restructuring and related charges of roughly $68M (FY2014) and $6M (FY2015) recorded; exit completed during FY2016. Employee impact not disclosed. FY2016 segment reconciliation shows $11M of restructuring and business exit related costs in total. | ||||
| 2016-10-31 | acquisition_addition | completed | 2015-11 | 2015-11 | Cell metabolism / bioenergetics instruments and assay kits | USD 242 (millions) | MD&A f5-10k / GLM-5.3-flash-HTML | Acquisition of Seahorse Bioscience completed for $242M cash; results consolidated into Agilent from November 1, 2015 (start of FY2016). Headcount added through the acquisition not disclosed. | |||
| 2016-10-31 | acquisition_addition | completed | 2016-08-01 | 2016-08-01 | Cloud-based core laboratory management software | USD 26 (millions) | MD&A f5-10k / GLM-5.3-flash-HTML | Acquisition of substantially all assets of iLab Solutions LLC completed August 1, 2016 for $26M cash; results consolidated from that date. Headcount added not disclosed. | |||
| 2016-10-31 | acquisition_addition | announced | 2016-12-19 | 2017-01 | Belgium | Molecular diagnostics (genetic testing assays) | EUR 68 (millions) | subsequent_events f5-10k / GLM-5.3-flash-HTML | Agreement signed December 19, 2016 to acquire 100% of the stock of Multiplicom NV for approximately €68M cash; closing expected mid-January 2017 (fiscal Q1 2017), subject to local laws and customary conditions. Headcount not disclosed. | ||
| 2016-10-31 | restructuring | completed | 2014-10-31 | 2016-10-31 | Global | Life Sciences and Applied Markets (NMR product line) | USD 11 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Exit of the nuclear magnetic resonance business announced in Q4 FY2014 and completed during fiscal 2016; $11M is total restructuring and business exit related costs for FY2016, not NMR-specific. Employees affected not disclosed. | ||
| 2016-10-31 | acquisition_addition | completed | 2015-11-01 | 2015-11-01 | United States | Life Sciences and Applied Markets (cell metabolism / bioenergetics instruments) | USD 242 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Seahorse Bioscience acquired for $242M cash; results consolidated from November 1, 2015. Headcount added not disclosed; value shown is purchase price. | ||
| 2016-10-31 | acquisition_addition | completed | 2016-08-01 | 2016-08-01 | United States | Agilent CrossLab (cloud-based core lab management software) | USD 26 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Substantially all assets of iLab Solutions LLC acquired for $26M cash. Headcount added not disclosed; value shown is purchase price. | ||
| 2016-10-31 | acquisition_addition | announced | 2016-12-19 | 2017-01-15 | Belgium / Europe | Diagnostics and Genomics (molecular diagnostic assays) | EUR 68 (millions) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Agreement signed to acquire 100% of Multiplicom NV for approximately EUR 68 million in cash; expected close mid-January 2017. Headcount added not disclosed; value shown is purchase price. | ||
| 2016-10-31 | restructuring | completed | 2014-10-01 | 2016-10-31 | Global | Life Sciences and Applied Markets | USD 6 (millions) | Item 1. Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Exit of NMR business completed in fiscal 2016. $6 million in restructuring and other related costs recorded in 2015; $68 million recorded in 2014. Employee count not explicitly disclosed for this action. | ||
| 2016-10-31 | restructuring | completed | 2014-10-31 | 2016-10-31 | Global | Life Sciences and Applied Markets | USD 6 (millions) | Item 1. Business - Exit of Nuclear Magnetic Resonance Business f5-10k / Qwen3.6-27B-Q8_0 | Exit of NMR business completed in fiscal 2016. $6 million in restructuring and other related costs recorded in 2015; $68 million recorded in 2014. Employee count not specified. | ||
| 2016-10-31 | restructuring | completed | Global | Global | Item 1. Business - Research and Development f5-10k / Qwen3.6-27B-Q8_0 | Announced workforce reduction plan resulted in acceleration of share-based compensation. Incremental expense of $0 million in 2016. Employee count not specified. | |||||
| 2016-07-31 | acquisition_addition | completed | 2015-11-01 | 2015-11-01 | Life Sciences and Applied Markets | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Seahorse Bioscience for $242 million in cash, completed November 1, 2015; added $137 million of goodwill to the Life Sciences and Applied Markets segment. Headcount added not disclosed. | ||||
| 2016-07-31 | divestiture_reduction | in_progress | NMR business | USD 7 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Charge shown is the nine-month total ($1 million in the three months ended July 31, 2016). Filer attributes gross margin and revenue improvements to the NMR exit; no employee count, announcement date or completion date disclosed. | |||||
| 2016-07-31 | acquisition_addition | completed | 2016-08-01 | 2016-08-01 | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter acquisition of substantially all assets of iLab Solutions LLC for $26 million in cash; purchase price allocation not yet complete and results included from Q4 FY2016. Headcount added not disclosed. | |||||
| 2016-04-30 | acquisition_addition | completed | 2015-11-01 | Life Sciences and Applied Markets | USD 242 (millions) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Seahorse Bioscience completed November 1, 2015 for $242 million; no employee headcount added through the acquisition is disclosed in this filing. | ||||
| 2016-01-31 | acquisition_addition | completed | 2015-11-01 | Life Sciences and Applied Markets | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Seahorse Bioscience acquired for $242 million; no employee headcount disclosed. | |||||
| 2016-01-31 | divestiture_reduction | in_progress | Life Sciences and Applied Markets (NMR business) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Company exiting NMR business; no affected-employee count disclosed. | ||||||
| 2016-01-31 | restructuring | completed | 2016-04-30 | United States | Corporate / All Segments | USD -16 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Freeze of benefit accruals under U.S. Retirement Plan and Supplemental Benefits Retirement Plan effective April 30, 2016. Recorded $15 million curtailment gain and $1 million settlement gain. | |||
| 2016-01-31 | acquisition_addition | completed | 2015-11-01 | Life Sciences and Applied Markets | USD 242 (millions) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Seahorse Bioscience for $242 million. Headcount not explicitly disclosed. | ||||
| 2015-10-31 | restructuring | in_progress | 300 | 2014 | 2016 | Primarily United Kingdom and California, United States | Life Sciences and Applied Markets (NMR product line) | USD 6 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year program: decision taken in Q4 FY2014 (quarter ended October 31, 2014) to cease manufacture and sale of the nuclear magnetic resonance product line, entailing severance for roughly 300 employees plus intangible impairments, asset write-downs and inventory charges. After attrition and internal redeployment, approximately 30 employees remained pending termination as of October 31, 2015. FY2015 expense of $6 million followed $68 million recorded in FY2014; approximately $15 million paid to date under the program and an $8 million restructuring accrual (recorded in other accrued liabilities) remained at fiscal year-end. Filer expects completion by early fiscal 2016. | |
| 2015-10-31 | restructuring | in_progress | 300 | 2014-10 | 2016-01-31 | Primarily United Kingdom and California | Life Sciences and Applied Markets — NMR product line | USD 6 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Cumulative through fiscal year-end: ~300 employees affected since announcement in Q4 FY2014. FY2015 charge was $6M (FY2014 charge was $68M). Approximately 30 employees still pending termination as of 2015-10-31; expected completion early fiscal 2016. Approximately $15M paid to date under these restructuring activities. | |
| 2015-10-31 | divestiture_reduction | completed | 2013-09-19 | 2014-11-01 | Global | Electronic Measurement business (Keysight Technologies) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Spin-off of Keysight Technologies completed 2014-11-01 (first day of FY2015). Keysight headcount not disclosed in this filing. Keysight results reported as discontinued operations. | |||
| 2015-10-31 | acquisition_addition | completed | 2015-05-19 | 2015-05-19 | Europe | Diagnostics and Genomics — clinical genetics software | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Cartagenia for €60 million; headcount added not disclosed. | |||
| 2015-10-31 | divestiture_reduction | completed | 2015-04-30 | 2015-04-30 | Global | Life Sciences and Applied Markets — X-ray diffraction (XRD) business | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of XRD business to Rigaku; no material impact on results stated. Headcount removed not disclosed. | |||
| 2015-10-31 | acquisition_addition | completed | 2015-11-02 | 2015-11-02 | United States | Life Sciences and Applied Markets — cell metabolism and bioenergetics instruments | USD 242 (millions) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Seahorse Bioscience for $242M cash, completed 2015-11-02 (one day after fiscal year-end). Headcount added not disclosed. Results to be included from Q1 FY2016. | ||
| 2015-10-31 | restructuring | in_progress | 300 | 2014-10-31 | 2016-04-30 | United Kingdom and California | Life Sciences and Applied Markets (NMR Business) | USD 6 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Workforce reduction of approximately 300 employees primarily located in the UK and California. $6 million in restructuring and other related costs recorded in 2015. Approximately 30 employees pending termination as of Oct 31, 2015. Expected completion by early fiscal 2016. | |
| 2015-10-31 | acquisition_addition | completed | 2015-11-02 | 2015-11-02 | Global | Life Sciences and Applied Markets | USD 242 (millions) | subsequent_events f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Seahorse Bioscience completed Nov 2, 2015 for $242 million in cash. Headcount not explicitly disclosed. | ||
| 2015-10-31 | acquisition_addition | completed | 2015-05-19 | 2015-05-19 | Global | Diagnostics and Genomics | EUR 60 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Cartagenia completed May 19, 2015 for €60 million. Headcount not explicitly disclosed. | ||
| 2015-10-31 | restructuring | in_progress | 300 | 2014-10-31 | 2016-04-30 | United Kingdom and California | Life Sciences and Applied Markets | USD 6 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Exit of NMR business announced in Q4 FY2014. Workforce reduction of approx 300 employees. Approx 30 employees pending termination as of FY2015 year-end. Expected completion early FY2016. FY2015 charge of $6 million. | |
| 2015-10-31 | restructuring | in_progress | USD 6,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2015-10-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-10-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-10-31 | restructuring | in_progress | Asset impairment [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-10-31 | restructuring | in_progress | Other Restructuring [Member] | USD 8,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-10-31 | restructuring | in_progress | NMR [Member] | USD 6,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2015-07-31 | restructuring | in_progress | 300 | 2016-01-31 | United Kingdom and California (primarily) | Life Sciences and Applied Markets (NMR product line) | USD 9 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision to cease NMR manufacture and sale made in Q4 fiscal 2014; exact announcement date not disclosed. Approximately 300 employees in the workforce reduction; approximately 60 pending termination as of 2015-07-31. Charge figure is the restructuring/special accrual balance at 2015-07-31, equal to nine-month income statement expense. Expected completion by early fiscal 2016. | ||
| 2015-07-31 | acquisition_addition | completed | 2015-05-19 | 2015-05-19 | Diagnostics and Genomics | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Cartagenia (clinical genetics/molecular pathology software) completed for EUR 60 million; no headcount added disclosed. | ||||
| 2015-07-31 | restructuring | in_progress | 300 | 2014-10-31 | 2016-01-31 | United Kingdom and California | Life Sciences and Applied Markets (NMR Business) | USD 9 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Workforce reduction of approx. 300 employees announced in Q4 FY2014. Approx. 60 employees pending termination as of July 31, 2015. Expected completion early FY2016. Remaining accrual of $9 million. | |
| 2015-07-31 | restructuring | in_progress | 300 | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | ||||||
| 2015-04-30 | restructuring | in_progress | 300 | 2014 | 2016-10-31 | United Kingdom and California | Life sciences and applied markets (NMR product line) | USD 9 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Decision to cease NMR manufacture and sale made in fiscal Q4 2014; approximately 300 employees in the workforce reduction. Approximately 180 employees still pending termination at April 30, 2015; about $9 million paid to date; restructuring and other special accruals totaled $14 million at April 30, 2015. Charge shown is income-statement expense for the six months ended April 30, 2015. Announcement date known only to fiscal-quarter precision. | |
| 2015-04-30 | divestiture_reduction | completed | 2013-09-19 | 2014-11-01 | Global | Electronic measurement business (Keysight Technologies) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Spin-off of Keysight completed November 1, 2014 (fiscal 2015 first quarter); Keysight employees are no longer in Agilent's continuing-operations headcount. No employee count for the transferred workforce is disclosed in this filing. | |||
| 2015-04-30 | restructuring | in_progress | 300 | 2014-10-31 | 2016-10-31 | United Kingdom and California | Life Sciences and Applied Markets | USD 14 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Workforce reduction of approximately 300 employees primarily located in the United Kingdom and California. As of April 30, 2015, approximately 180 employees are pending termination. Total restructuring accrual balance was $14 million. | |
| 2015-04-30 | restructuring | in_progress | 300 | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2015-04-30 | restructuring | in_progress | Employee Severance [Member] | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-04-30 | restructuring | in_progress | Other Restructuring [Member] | USD 7,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-01-31 | restructuring | in_progress | 300 | 2016-10-31 | United Kingdom and California | Life Sciences and Applied Markets | USD 16 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program covers workforce reduction of approximately 300 employees on exit of the NMR product line; about 200 employees still pending termination at 2015-01-31. Charge shown is the accrual balance at 2015-01-31 ($12M workforce reduction plus $4M inventory/other special charges); $3M was expensed in the quarter. Decision made in Q4 fiscal 2014; no specific announcement date disclosed. | ||
| 2015-01-31 | divestiture_reduction | completed | 2013-09-19 | 2014-11-01 | Global | Electronic measurement business (Keysight Technologies) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Spin-off of Keysight completed 2014-11-01; Keysight assets, liabilities and results removed from continuing operations. No headcount transferred with the separation is disclosed in this filing. | |||
| 2015-01-31 | restructuring | in_progress | 300 | 2014-10-31 | 2016-10-31 | United Kingdom and California | Life Sciences and Applied Markets | USD 16 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Workforce reduction of approx. 300 employees due to exit of NMR product line. Approx. 200 employees pending termination as of Jan 31, 2015. Total accrual balance $16 million. | |
| 2015-01-31 | restructuring | in_progress | Employee Severance [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-01-31 | restructuring | in_progress | Other Restructuring [Member] | USD 2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2015-01-31 | restructuring | in_progress | 300 | USD 3,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-10-31 | restructuring | in_progress | 300 | 2014 | 2016-10-31 | Primarily the United Kingdom and California, United States | Life Sciences and Diagnostics segment — Nuclear Magnetic Resonance (NMR) product line | USD 68 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Announced in fiscal Q4 2014; company ceased taking new NMR system orders due to lack of growth and profitability. Charges comprise severance/personnel costs for roughly 300 employees plus non-cash intangible impairments and inventory write-downs; jobs to be eliminated mostly within about 12 months, with restructuring substantially complete by end of fiscal 2016. At October 31, 2014 substantially all affected employees were pending termination, ~$2 million paid, and a $17 million accrual remained. Exit expected to improve fiscal 2015 operating profit by roughly $10 million. | |
| 2014-10-31 | restructuring | in_progress | 400 | 2% | 2013 | 2015-01-31 | United States (substantially complete) and international locations | All three reportable segments (life sciences and diagnostics, chemical analysis, electronic measurement) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year program accrued in fiscal Q2 2013 for about 450 regular employees, described as roughly 2 percent of the global workforce at announcement; about 50 redeployed within the company, reducing the plan to about 400. Figures are cumulative program totals. Fiscal 2014 included a $4 million charge reversal for redeployed employees and $17 million of cash payments; cumulative payments of about $46 million with roughly 70 employees (including Keysight employees) pending termination as of October 31, 2014, under the combined restructuring and manufacturing-streamlining actions. Expected to reduce annual cost of sales and operating expenses by roughly $50 million. | |
| 2014-10-31 | restructuring | in_progress | 250 | 2013 | 2015-01-31 | Not specified | Manufacturing operations — aimed at reducing annual cost of sales | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Streamlining of manufacturing operations, described as previously announced (specific quarter not stated), with an anticipated reduction of approximately 250 positions. Together with the targeted restructuring program, total headcount reductions of approximately 650 positions. Combined actions substantially complete in the U.S., with about 70 employees pending termination and ~$46 million paid as of October 31, 2014; international completion expected by end of fiscal Q1 2015. | ||
| 2014-10-31 | divestiture_reduction | completed | 8,300 | 2013-09-19 | 2014-11-01 | Global | Electronic Measurement business (Keysight Technologies, Inc.) | Item_1_Business f5-10k / GLM-5.3-flash-HTML | Spin-off of the entire electronic measurement business: 100% of Keysight common shares distributed to Agilent stockholders on November 1, 2014 (one day after fiscal year-end), one Keysight share for every two Agilent shares. Electronic measurement business employed approximately 8,300 at October 31, 2014; MD&A states Agilent headcount will be roughly 12,000 following the separation. Keysight results will be reported as discontinued operations beginning Q1 2015. | ||
| 2014-10-31 | restructuring | in_progress | 300 | 2014-10-31 | 2015-10-31 | United Kingdom and United States (California) | Life Sciences and Diagnostics — Nuclear Magnetic Resonance (NMR) product line | USD 68 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Decision made in fourth quarter of fiscal 2014; charge comprises $16M workforce reduction, $19M asset impairments, $33M inventory and other special charges. About 300 jobs expected to be eliminated mostly within 12 months; restructuring accrual $17M at year-end, $2M paid in FY2014. | |
| 2014-10-31 | restructuring | in_progress | 400 | 2013-04-30 | 2015-01-31 | United States and international | Enterprise-wide targeted restructuring program | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Program announced in second quarter of fiscal 2013 (original target 450 employees, reduced to 400 after about 50 redeployed). FY2014 activity only: $4M charge reversal and $17M cash payments; approximately 70 employees (including Keysight) pending termination at October 31, 2014. Announcement date approximate — filing states only the quarter. | ||
| 2014-10-31 | restructuring | in_progress | 250 | 2015-01-31 | Not specified | Manufacturing operations streamlining | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Announcement date not disclosed. Combined with the targeted program, total headcount reductions are approximately 650 positions; international completion expected by end of first quarter of fiscal 2015. | |||
| 2014-10-31 | divestiture_reduction | completed | 8,300 | 2013-09-19 | 2014-11-01 | Worldwide | Electronic Measurement business (distributed as Keysight Technologies, Inc.) | Item_1_Business f5-10k / MiMo-V2.6-Flash-fp8-HTML | Count is the electronic measurement business headcount at October 31, 2014, transferred with the spin-off completed November 1, 2014 (one Keysight share per two Agilent shares). Filing does not state a Keysight-specific headcount; post-separation Agilent headcount expected to be approximately 12,000. Pre-separation costs of $191M incurred in FY2014. | ||
| 2014-10-31 | restructuring | in_progress | 300 | 2014-10-01 | 2015-10-31 | United Kingdom and California | Life Sciences and Diagnostics (NMR Business) | USD 68 (millions) | Item 1. Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | In the fourth quarter of 2014, Agilent announced it is exiting its NMR business. The company expects that this decision will eliminate about 300 jobs, mostly within the next 12 months. Charges of approximately $68 million were incurred. | |
| 2014-10-31 | restructuring | in_progress | 400 | 2013-04-01 | 2015-01-31 | Global | All Segments | Item 7. MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | In the second quarter of 2013, Agilent accrued for a targeted restructuring program to reduce total headcount by approximately 450 regular employees. As a result of the Keysight separation, approximately 50 employees were redeployed, reducing the total headcount under this plan to 400 employees. Internationally, almost all activities expected to be completed by the end of the first quarter of fiscal 2015. | ||
| 2014-10-31 | restructuring | in_progress | 250 | Global | Manufacturing | Item 7. MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | As part of streamlining manufacturing operations, Agilent anticipates the reduction of approximately 250 positions to reduce annual cost of sales. | ||||
| 2014-10-31 | restructuring | in_progress | 300 | 2014-10-31 | 2015-10-31 | United Kingdom, California | Life Sciences and Diagnostics (NMR Business) | USD 68 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Exit of Nuclear Magnetic Resonance (NMR) business. Charges of approximately $68 million incurred for year ended Oct 31, 2014. Elimination of about 300 jobs, mostly within next 12 months. | |
| 2014-10-31 | restructuring | in_progress | 400 | 2013-04-01 | 2015-01-31 | Global | Corporate | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Targeted restructuring program announced Q2 2013 to reduce headcount by approx 450 regular employees. Reduced to 400 employees after redeployment of 50. Expected to result in approx $50 million reduction in annual cost of sales and operating expenses. | ||
| 2014-10-31 | restructuring | in_progress | 250 | Global | Manufacturing | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Streamlining manufacturing operations. Anticipated reduction of approx 250 positions to reduce annual cost of sales. | ||||
| 2014-10-31 | restructuring | in_progress | 300 | NMR [Member] | USD 68,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | Expected positions to be eliminated | ||||
| 2014-10-31 | restructuring | in_progress | Cost of Sales [Member] | USD 45,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | USD 64,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2014-10-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 15,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 4,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | Other Restructuring [Member] / NMR [Member] | USD 33,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | Employee Severance [Member] / NMR [Member] | USD 16,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | Asset impairment [Member] / NMR [Member] | USD 19,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2014-10-31 | restructuring | in_progress | 650 | Manufacturing Streamline and Targeted Restructuring Plans [Member] | restructuring_footnote f5-10k / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-10-31 | restructuring | in_progress | 250 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10k / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-07-31 | restructuring | in_progress | 400 | 2015-01-31 | Global (U.S. substantially complete; remaining actions international) | Corporate-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Targeted workforce reduction originally covering about 450 employees (~2% of global workforce), announced in fiscal Q2 2013; roughly 50 employees were redeployed in connection with the Keysight separation, reducing the plan to 400. Approximately 140 employees were pending termination as of 2014-07-31. Restructuring accrual was $6M at 2014-07-31 (after a $4M reversal and $14M of cash payments YTD); expected annual cost savings of about $50M. International actions expected to complete by end of fiscal Q1 2015. | |||
| 2014-07-31 | restructuring | in_progress | 250 | 2015-01-31 | Global | Manufacturing | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Manufacturing streamlining action previously announced by the filer; no announcement date stated. Combined with the targeted workforce reduction, total headcount reductions are approximately 650 positions. No separate charge disclosed for this component. | |||
| 2014-07-31 | divestiture_reduction | announced | 2013-09-19 | 2014-11-30 | Global | Electronic Measurement (Keysight Technologies) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Spin-off of the electronic measurement business as Keysight Technologies. Substantially all EM assets, liabilities and operations were transferred to Keysight effective 2014-08-01 (after period end); tax-free pro rata distribution expected early November 2014. Headcount transferring with the business is not quantified. Pre-separation costs of $123M were incurred in the nine months ended 2014-07-31, including costs of new employees recruited to operate the two separate companies. | |||
| 2014-07-31 | restructuring | in_progress | 650 | 2013-04-30 | 2015-01-31 | Global | Global | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Targeted restructuring and manufacturing streamlining reducing total headcount by approximately 650 positions. Approximately 140 employees pending termination as of July 31, 2014. Majority of international activities expected to complete by end of Q1 FY2015. | ||
| 2014-07-31 | restructuring | in_progress | Cost of Sales [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-07-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-07-31 | restructuring | in_progress | 650 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-07-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-07-31 | restructuring | in_progress | 250 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-07-31 | restructuring | in_progress | 400 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-04-30 | restructuring | in_progress | 400 | 2015-01-31 | Global | Corporate-wide (targeted headcount reduction) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Program originally targeted ~450 employees (~2% of global workforce); ~50 redeployed due to Keysight separation, reducing plan to 400. Announced in second quarter of fiscal 2013 (exact date not disclosed). Restructuring accrual was $8M at 2014-04-30 after a $4M reversal in the six-month period; ~$41M paid cumulatively under both actions per MD&A. ~160 employees pending termination at quarter-end. Majority of international activity expected complete by end of fiscal Q1 2015. | |||
| 2014-04-30 | restructuring | in_progress | 250 | 2015-01-31 | Global | Manufacturing (manufacturing streamlining) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Manufacturing streamlining to reduce annual cost of sales; announcement date not disclosed in this filing. U.S. activities substantially complete; international activities expected to complete by end of fiscal Q1 2015. Combined with targeted restructuring, total planned reductions are approximately 650 positions. | |||
| 2014-04-30 | restructuring | in_progress | 650 | 2013-07-01 | 2015-01-31 | Global | Global | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Total headcount reductions from targeted restructuring and manufacturing streamlining. Approximately 160 employees pending termination as of April 30, 2014. Majority of international activities expected to complete by end of Q1 FY2015. | ||
| 2014-04-30 | restructuring | in_progress | Employee Severance [Member] | USD -4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-04-30 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-04-30 | restructuring | in_progress | Cost of Sales [Member] | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-04-30 | restructuring | in_progress | 650 | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-04-30 | restructuring | in_progress | Research and Development Expense [Member] | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-04-30 | restructuring | in_progress | 250 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-04-30 | restructuring | in_progress | 400 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-01-31 | restructuring | in_progress | 400 | 2% | 2014-10-31 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Targeted program originally sized at ~450 employees (~2% of global workforce), accrued in fiscal Q2 2013; reduced to 400 after ~50 employees were redeployed following the Keysight separation announcement. Approximately 180 employees across all actions were pending termination at January 31, 2014. Restructuring accrual balance was $12M at quarter-end (from $24M at October 31, 2013), reflecting a $4M reversal and $8M of cash payments in the quarter; filer expects the majority of international actions complete by end of fiscal 2014 second half and an approximately $50M annual cost reduction when complete. | ||
| 2014-01-31 | restructuring | in_progress | 250 | 2014-10-31 | Global | Manufacturing | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Manufacturing streamlining actions described as previously announced; no separate announcement date or charge disclosed. Filer states U.S. activities substantially complete and international activities largely complete by end of fiscal 2014 second half. Combined with the targeted program, total reductions are approximately 650 positions. | |||
| 2014-01-31 | divestiture_reduction | announced | 2013-09-19 | 2014-11-30 | Global | Electronic Measurement | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Planned tax-free spin-off of the electronic measurement business into Keysight Technologies, expected to complete early November 2014; no headcount associated with the separation is quantified in the filing. Filer expects $140M of pre-separation expenses in fiscal 2014. | |||
| 2014-01-31 | restructuring | in_progress | 650 | 2013-04-01 | 2014-07-31 | Global | All segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Targeted restructuring and manufacturing streamlining totaling approximately 650 positions. 50 employees redeployed, reducing headcount under plan to 400. 180 employees pending termination as of Jan 31, 2014. Majority of international activities expected to complete by end of second half of fiscal 2014. | ||
| 2014-01-31 | restructuring | in_progress | Employee Severance [Member] | USD -4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-01-31 | restructuring | in_progress | 650 | USD -4,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-01-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD -2,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-01-31 | restructuring | in_progress | Cost of Sales [Member] | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-01-31 | restructuring | in_progress | Research and Development Expense [Member] | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2014-01-31 | restructuring | in_progress | 250 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2014-01-31 | restructuring | in_progress | 400 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-10-31 | restructuring | in_progress | 450 | 2% | 2013-02 | 2014-10-31 | USD 53 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Targeted program accrued in fiscal Q2 2013 in response to slow revenue growth, expected to cut total headcount by about 450 regular employees (~2 percent of global workforce). Approximately 250 employees were terminated and $29 million paid as of October 31, 2013. The $53 million FY2013 workforce-reduction accrual covers both this program and the manufacturing-streamlining action (combined ~700 positions) and is not separately allocated between them. U.S. activities substantially complete at fiscal year-end; international activities expected largely complete by end of fiscal H2 2014. | ||
| 2013-10-31 | restructuring | in_progress | 250 | 2014-10-31 | Manufacturing | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Streamlining of manufacturing operations, previously announced (specific announcement date not disclosed), anticipated to reduce approximately 250 positions to lower annual cost of sales; 100 employees terminated as of October 31, 2013. Combined with the targeted restructuring program, total expected headcount reduction is approximately 700 positions; the combined FY2013 workforce-reduction accrual was $53 million (recorded under the targeted-program record). Expected completion of the majority of international activities by end of fiscal H2 2014. | ||||
| 2013-10-31 | divestiture_reduction | announced | 2013-09-19 | 2014-11 | Electronic Measurement | Item_1_Business f5-10k / GLM-5.3-flash-HTML | Planned tax-free pro rata spin-off of the electronic measurement business into a separate public company, announced September 19, 2013 and expected early in November 2014. No affected-employee count is disclosed; the EM business employed approximately 8,300 people at fiscal year-end 2013 and would transfer out of the Agilent reporting entity. Company expects $100 million of pre-separation expenses in fiscal 2014 (transaction-related, not a workforce severance charge). | ||||
| 2013-10-31 | restructuring | in_progress | 450 | 2% | 2013-01-31 | 2014-10-31 | Worldwide (U.S. substantially complete; international wind-down through fiscal 2014) | Company-wide (approximately 2% of global workforce) | USD 53 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Targeted program accrued in Q2 FY2013 (quarter ended 2013-01-31; exact announcement date not disclosed) to reduce headcount by approximately 450 regular employees; expected to reduce annual cost of sales and operating expenses by approximately $50 million. Approximately 250 employees terminated and $29 million paid as of 2013-10-31. The $53 million charge is the total FY2013 restructuring accrual covering both this program and the manufacturing streamlining action below. |
| 2013-10-31 | restructuring | in_progress | 250 | 2014-10-31 | Worldwide | Manufacturing operations streamlining | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Previously announced manufacturing streamlining anticipated to reduce approximately 250 positions to lower annual cost of sales; 100 employees terminated as of 2013-10-31. Announcement date not disclosed in this filing. Combined with the targeted program, total headcount reductions are approximately 700 positions. | |||
| 2013-10-31 | restructuring | in_progress | 450 | 2% | 2013-04-01 | 2014-10-31 | Global | All segments | USD 53 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Targeted restructuring program expected to reduce headcount by approx 450 regular employees (2% of global workforce). Accrued $53 million in FY2013. Internationally, majority expected to complete by end of second half of fiscal 2014. |
| 2013-10-31 | restructuring | in_progress | 250 | 2013-04-01 | Global | Manufacturing | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Streamlining of manufacturing operations anticipated to reduce approx 250 positions to reduce annual cost of sales. No specific charge disclosed separately from the $53M total restructuring accrual. | |||
| 2013-10-31 | restructuring | in_progress | 450 | 2% | 2013-04-01 | 2014-10-31 | Global | Global | USD 53 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Targeted restructuring program announced in Q2 2013 to reduce headcount by approx 450 regular employees (2% of global workforce). Accrued $53 million. As of Oct 31, 2013, approx 250 employees terminated under this program. |
| 2013-10-31 | restructuring | in_progress | 250 | 2013-04-01 | 2014-10-31 | Global | Manufacturing | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Streamlining of manufacturing operations to reduce approx 250 positions. As of Oct 31, 2013, 100 employees terminated under this streamlining. | ||
| 2013-10-31 | restructuring | in_progress | Employee Severance [Member] | USD 53,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-10-31 | restructuring | in_progress | 700 | USD 53,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-10-31 | restructuring | in_progress | 100 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-10-31 | restructuring | in_progress | 250 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | 450 | 2% | 2013-04-30 | 2013-10-31 | Global | All segments (approximately 2% of global workforce) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Targeted restructuring accrued in Q2 FY2013 (only quarter of announcement disclosed); expected to reduce annual cost of sales and operating expenses by approximately $50 million. A combined $56 million restructuring accrual was recorded for the nine months ended July 31, 2013 covering this program and the manufacturing streamlining below; the charge is not split between the two programs. Approximately 200 employees terminated and $15 million paid as of July 31, 2013 (combined across both actions). Announcement date reflects Q2 FY2013 end; exact date not disclosed. | |
| 2013-07-31 | restructuring | in_progress | 250 | 2013-04-30 | 2013-10-31 | Global | Manufacturing operations | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Manufacturing streamlining previously announced; positions to be reduced to lower annual cost of sales. Combined with the targeted restructuring, total headcount reductions of approximately 700 positions. Announcement date reflects Q2 FY2013 end; exact announcement date not disclosed. | ||
| 2013-07-31 | restructuring | in_progress | 450 | 2% | 2013-04-01 | 2013-10-31 | Global | All segments | USD 56 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Targeted restructuring program announced in Q2 2013 to reduce headcount by approx. 450 regular employees (2% of global workforce). Accrued $56 million for nine months ended July 31, 2013. Approx. 200 employees terminated and paid as of July 31, 2013. Expected completion by end of fiscal 2013. |
| 2013-07-31 | restructuring | in_progress | 250 | 2013-04-01 | 2013-10-31 | Global | Manufacturing | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Streamlining of manufacturing operations anticipated to reduce approx. 250 positions. Included in total headcount reduction of approx. 700 positions. | ||
| 2013-07-31 | restructuring | in_progress | Employee Severance [Member] | USD 56,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | Research and Development Expense [Member] | USD 9,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | 200 | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | Cost of Sales [Member] | USD 1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD -1,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-07-31 | restructuring | in_progress | 250 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-07-31 | restructuring | in_progress | 450 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-04-30 | restructuring | in_progress | 450 | 2% | 2013-04-30 | 2013-10-31 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Targeted restructuring program accrued in Q2 FY2013 in response to slow revenue growth; approximately 450 regular employees, about 2% of global workforce. Exact announcement date not disclosed; stated only as second quarter of fiscal 2013 (date shown is quarter end). Combined restructuring charge for this program and the manufacturing streamlining action was $55 million for the three and six months ended April 30, 2013; charge not split between components. Timing and scope of reductions vary by local legal requirements. | |
| 2013-04-30 | restructuring | in_progress | 170 | 2013-04-30 | 2013-10-31 | Manufacturing | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Previously announced manufacturing streamlining: reduction of approximately 170 positions to reduce annual cost of sales. Combined with the targeted restructuring, total headcount reductions of approximately 600 positions; majority expected complete by end of fiscal 2013. Combined charge of $55 million not split between components. Exact announcement date not disclosed; date shown is quarter end. | |||
| 2013-04-30 | restructuring | in_progress | 450 | 2% | 2013-04-30 | 2013-10-31 | Global | All segments | USD 55 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Targeted restructuring program to reduce headcount by approx. 450 regular employees (2% of global workforce). Expected to reduce annual expenses by approx. $50 million. Majority of actions expected to complete by end of fiscal year 2013. |
| 2013-04-30 | restructuring | in_progress | 170 | 2013-04-30 | 2013-10-31 | Global | Manufacturing | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Streamlining manufacturing operations, reducing approx. 170 positions to reduce annual cost of sales. Included in total headcount reduction of approx. 600 positions. | ||
| 2013-04-30 | restructuring | in_progress | Employee Severance [Member] | USD 55,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-04-30 | restructuring | in_progress | Research and Development Expense [Member] | USD 8,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-04-30 | restructuring | in_progress | 600 | USD 55,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-04-30 | restructuring | in_progress | Cost of Sales [Member] | USD 18,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-04-30 | restructuring | in_progress | Selling, General and Administrative Expenses [Member] | USD 29,000,000 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | ||||||
| 2013-04-30 | restructuring | in_progress | 450 | Targeted Restructuring Plan [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2013-04-30 | restructuring | in_progress | 170 | Manufacturing Streamlining [Member] | restructuring_footnote f5-10q / no-ai-xblr | Expected positions to be eliminated | |||||
| 2012-10-31 | acquisition_addition | completed | 2012-05-16 | 2012-06-21 | Denmark | Diagnostics and Genomics | MD&A f5-10k / GLM-5.3-flash-HTML | Dako A/S acquisition completed June 21, 2012 under a share purchase agreement dated May 16, 2012; total consideration approximately $2.143 billion ($1.4 billion to the seller and $743 million to satisfy Dako's outstanding debt), funded with existing cash. Dako was combined into the newly formed Diagnostics and Genomics segment. No Dako employee count was disclosed; MD&A attributes a significant proportion of the fiscal 2012 headcount increase to this acquisition. | |||
| 2012-10-31 | restructuring | in_progress | 2009 | 2014-10-31 | USD 4 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY 2009 Plan, announced in the first half of 2009. No restructuring or workforce reduction expense was recorded in fiscal 2012; current-year activity consisted solely of $4 million of cash payments on excess-facility lease obligations. Workforce reduction payments were largely complete in fiscal 2010. Remaining accrual of $11 million at October 31, 2012 relates to consolidation of excess facilities, with payments expected primarily complete by end of fiscal 2014. No fiscal 2012 headcount reduction is attributed to this program. | ||||
| 2012-10-31 | acquisition_addition | completed | 2012-05-16 | 2012-06-21 | Denmark | Diagnostics and Genomics | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of 100% of Dako A/S for approximately $2,143 million; headcount added through the acquisition is not disclosed. Consolidated headcount rose from approximately 18,700 (FY2011) to approximately 20,500 (FY2012), with a significant portion of the increase attributed to Dako. | |||
| 2012-10-31 | restructuring | in_progress | 2014-10-31 | Global | Enterprise | USD 0 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2009 Plan remained open with an $11 million accrual balance at fiscal year-end; no restructuring expense and no employees affected recorded in fiscal 2012. Remaining cash payments relate to lease obligations for consolidated facilities, expected to be substantially complete by end of fiscal 2014. | |||
| 2012-10-31 | acquisition_addition | completed | 2012-06-21 | Global | Diagnostics and Genomics | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Dako A/S completed June 21, 2012. Significant proportion of headcount increase in 2012 compared to 2011 attributed to this acquisition. | ||||
| 2012-10-31 | restructuring | completed | 2009-01-01 | 2014-10-31 | Global | Corporate | USD 0 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY 2009 Plan workforce reduction payments largely complete in FY 2010. Lease payments primarily complete by end of FY 2014. No income statement expense recorded in FY 2012. | ||
| 2012-10-31 | restructuring | completed | 2009-04-01 | 2014-10-31 | Global | All Segments | USD 0 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in fiscal 2010. Lease payments expected to be complete by end of fiscal 2014. No income statement expense recorded in 2012. | ||
| 2012-10-31 | acquisition_addition | completed | 2012-06-21 | 2012-06-21 | Denmark | Diagnostics and Genomics | business_combinations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Acquisition of Dako A/S on June 21, 2012. Significant proportion of headcount increase in 2012 attributed to this acquisition. | |||
| 2012-10-31 | restructuring | in_progress | Inventory Charges [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-10-31 | restructuring | in_progress | Employee Severance [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-10-31 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2012-10-31 | restructuring | in_progress | Impairment Of Long Lived Assets Held For Use And Purchased Intangible Assets [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-10-31 | restructuring | in_progress | Facility Closing [Member] | USD 0 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | ||||||
| 2012-07-31 | acquisition_addition | completed | 2012-05-16 | 2012-06-21 | Denmark | Diagnostics and Genomics | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Dako A/S acquired June 21, 2012 for approximately $2,144 million; no employee count disclosed. MD&A attributes most of the headcount increase to 20,200 from this acquisition | |||
| 2012-07-31 | acquisition_addition | completed | 2012-06-21 | Denmark | Diagnostics and Genomics | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Dako A/S completed on June 21, 2012. Headcount increase attributed to this acquisition, though specific employee count not disclosed. | ||||
| 2012-07-31 | restructuring | in_progress | USD 0 (absolute) | restructuring_footnote f5-10q / no-ai-xblr | |||||||
| 2012-04-30 | acquisition_addition | announced | 2012-05-16 | Denmark | Life Sciences (diagnostics/pathology) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter agreement to acquire 100% of Dako A/S for cash enterprise value of approximately $2.2 billion; no employee count disclosed. FTC granted early termination of HSR waiting period on 2012-05-30; other closing conditions pending. | ||||
| 2012-01-31 | acquisition_addition | completed | Life Sciences | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Halo Genomics acquisition cited as expanding the SureSelect portfolio; no headcount added disclosed | ||||||
| 2012-01-31 | acquisition_addition | completed | Life Sciences | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | BioSystem Development acquisition cited for microchromatography sample-prep capability; no headcount added disclosed | ||||||
| 2011-10-31 | reduction_in_force | completed | 2009 | USD 1 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Workforce-reduction component of the multi-year FY 2009 restructuring plan announced in the first half of 2009. Fiscal 2011 activity was a $1M charge and $9M of cash payments, with the related liability fully settled by October 31, 2011; severance payments were largely complete in fiscal 2010. Employee counts not disclosed; the charge shown is the current-year portion of the program, not cumulative. | |||||
| 2011-10-31 | restructuring | in_progress | 2009 | 2014-10-31 | USD 1 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Consolidation-of-excess-facilities component of the FY 2009 plan; fiscal 2011 included a $1M charge and $12M of lease-related payments, leaving a $15M accrual at October 31, 2011. Lease payments expected to be primarily complete by the end of fiscal 2014. | ||||
| 2011-10-31 | restructuring | in_progress | 2014-10-31 | Global | Enterprise-wide | USD 2 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2009 Plan announced first half of fiscal 2009; FY2011 expense of $2M (workforce reduction $1M, excess facilities $1M). Workforce reduction payments largely complete in fiscal 2010; lease payments expected complete by end of fiscal 2014. Employees affected in FY2011 not disclosed. | |||
| 2011-10-31 | acquisition_addition | completed | Not disclosed | Life Sciences; Chemical Analysis | USD 96 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Three businesses acquired during fiscal 2011 (A2 Technologies, Lab901, Biocius Life Sciences) for total cost of $96 million net of cash acquired; headcount added not disclosed. Charge value represents acquisition cost, not a severance or restructuring charge. | ||||
| 2011-10-31 | restructuring | in_progress | 2009-01-01 | 2014-10-31 | Global | All segments | USD 2 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of FY 2014. Total restructuring, asset impairments and other special charges recorded in FY 2011 were $2 million. | ||
| 2011-10-31 | acquisition_addition | completed | 2010-05-14 | Global | Life Sciences and Chemical Analysis | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Varian, Inc. completed May 14, 2010. Varian employees integrated into Life Sciences and Chemical Analysis segments. Headcount impact included in segment totals. | ||||
| 2011-10-31 | divestiture_reduction | completed | 2010-05-01 | Global | Electronic Measurement | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of Network Solutions Division (NSD) to JDS Uniphase Corporation completed May 1, 2010. NSD employees transferred to JDSU. | ||||
| 2011-10-31 | divestiture_reduction | completed | 2010-02-02 | Global | Life Sciences | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of Hycor Biomedical Inc. to Linden LLC completed February 2, 2010. Hycor employees transferred to Linden LLC. | ||||
| 2011-10-31 | restructuring | in_progress | 2009-04-01 | 2014-10-31 | Global | All segments | USD 2 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of FY 2014. $2 million in restructuring charges recorded in FY 2011. | ||
| 2011-10-31 | acquisition_addition | completed | 2010-05-14 | 2010-05-14 | Global | Life Sciences and Chemical Analysis | business_combinations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Acquired Varian, Inc. on May 14, 2010. Headcount added not explicitly quantified in employee count, but included in total workforce. | |||
| 2011-10-31 | acquisition_addition | completed | 2011-10-31 | 2011-10-31 | Global | Life Sciences | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Acquired A2 Technologies, Lab901 and Biocius Life Sciences Inc. during fiscal year 2011. Headcount added not explicitly quantified. | |||
| 2011-10-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Global | Electronic Measurement | discontinued_operations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Sold Network Solutions Division (NSD) to JDS Uniphase Corporation on May 1, 2010. Headcount removed not explicitly quantified. | |||
| 2011-10-31 | divestiture_reduction | completed | 2010-02-02 | 2010-02-02 | Global | Life Sciences | discontinued_operations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Sold Hycor Biomedical Inc. to Linden LLC on February 2, 2010. Headcount removed not explicitly quantified. | |||
| 2011-07-31 | restructuring | in_progress | 2009-01-01 | 2014-10-31 | Global | Corporate and Divisional | USD 2 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments expected to be complete by end of fiscal 2014. $2 million expense recorded for nine months ended July 31, 2011. | ||
| 2011-07-31 | restructuring | in_progress | 2005-10-01 | 2012-07-31 | Global | Corporate and Divisional | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2005 restructuring program largely complete. Remaining obligations relate primarily to lease obligations expected to be satisfied over approximately the next year. | |||
| 2011-04-30 | acquisition_addition | completed | Life Sciences; Chemical Analysis | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | A2 Technologies, Lab901 and Biocius Life Sciences acquired during the six months ended April 30, 2011 for $96 million total consideration net of cash acquired; no employee counts disclosed | ||||||
| 2011-04-30 | restructuring | in_progress | 2009-01-01 | 2014-10-31 | Global | Corporate and Divisional | USD 23 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Remaining obligations relate primarily to lease obligations expected to be satisfied by end of fiscal 2014. Total restructuring accrual balance was $23 million as of April 30, 2011. | ||
| 2011-04-30 | acquisition_addition | completed | 2010-05-14 | Global | Life Sciences and Chemical Analysis | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Varian, Inc. completed May 14, 2010. Headcount increased from approx. 16,100 to 18,500 mainly due to this acquisition. | ||||
| 2011-04-30 | acquisition_addition | completed | 2011-04-30 | Global | Various | USD 96 (millions) | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Acquired A2 Technologies, Lab901, and Biocius Life Sciences Inc. in the three and six months ended April 30, 2011 for $96 million total consideration. | |||
| 2011-01-31 | acquisition_addition | completed | 2009-07-26 | 2010-05-14 | Global | Life Sciences; Chemical Analysis | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Merger completed May 14, 2010; consideration approximately $1,507 million plus option/award settlements. No employee count disclosed. MD&A attributes most of the year-over-year headcount increase (16,350 to 18,385) to this acquisition. | |||
| 2011-01-31 | restructuring | in_progress | 2009-01-01 | 2014-10-31 | Outside the United States | Electronic Measurement | USD 2 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2009 Plan: a small number of non-U.S. Electronic Measurement employees still pending termination at quarter end; no count disclosed. Total restructuring accrual balance $28 million at 2011-01-31; $2 million expense recognized in the quarter. Workforce reduction payments largely complete in FY2010; lease payments expected complete by end of FY2014. Announcement date approximate (program announced in first half of 2009). | ||
| 2011-01-31 | divestiture_reduction | completed | Global | Electronic Measurement (network solutions); Life Sciences (Hycor) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | MD&A references recently divested network solutions and Hycor businesses as reducing reported orders/revenue growth; no headcount removed disclosed and no divestiture footnote in this filing. | |||||
| 2011-01-31 | restructuring | in_progress | 2009-04-01 | 2014-10-31 | Outside of the U.S. | Electronic Measurement | USD 2 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan. Small number of employees pending termination. Lease payments expected complete by end of fiscal 2014. | ||
| 2010-10-31 | restructuring | in_progress | 2009 | 2014-10-31 | Worldwide | Global infrastructure organization and electronic measurement segment | USD 64 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year FY 2009 Plan announced in the first half of fiscal 2009; figures captured are current-year (FY2010) activity. FY2010 income statement expense of $64M comprised $39M workforce reduction, $19M consolidation of excess facilities and $6M asset impairment. FY2010 cash payments were $92M. Workforce reduction payments, primarily severance, largely complete in FY2010; supplier inventory payments expected complete in FY2011; lease payments primarily complete by end of fiscal 2014. A small number of electronic measurement employees remained pending termination at October 31, 2010; remaining accrual of $35M ($8M workforce reduction, $26M excess facilities, $1M inventory special charges). Employee counts affected were not disclosed in this filing. | ||
| 2010-10-31 | acquisition_addition | completed | 2009-07-26 | 2010-05-14 | Life Sciences and Chemical Analysis (Varian, Inc.) | USD 102 (millions) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition of Varian, Inc. completed May 14, 2010 for total cash purchase price of approximately $1.5 billion ($52 per share). Specific headcount added was not disclosed; MD&A attributes the fiscal 2010 headcount increase (from approximately 16,800 to approximately 18,500) to this acquisition. Goodwill from the acquisition was allocated primarily to Life Sciences ($184M) and Chemical Analysis ($603M). Associated value shown is fiscal 2010 acquisition and integration costs directly related to the merger, substantially recorded in selling, general and administrative expenses. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-02-02 | 2010-02-02 | Life Sciences — Hycor Biomedical Inc. | other f5-10k / GLM-5.3-flash-HTML | Hycor Biomedical Inc., an in-vitro diagnostics maker within the life sciences business, sold to Linden LLC, a Chicago-based healthcare private equity firm, on February 2, 2010. Number of employees removed not disclosed. Hycor-specific proceeds not individually disclosed; total fiscal 2010 divestiture proceeds of $205M related primarily to the network solutions and Hycor businesses. Related intangible impairments of $13M and goodwill reduction of $1M were recorded in connection with the divestiture. | ||||
| 2010-10-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Electronic Measurement — Network Solutions Division (NSD) | USD 132 (millions) | other f5-10k / GLM-5.3-flash-HTML | Network Solutions Division (network assurance, network protocol test and drive test products) sold to JDS Uniphase Corporation on May 1, 2010. Number of employees removed not disclosed. Associated value is a net gain on sale of $132 million (a gain, not a charge); JDSU paid $160 million. Results of NSD operations were not significant to fiscal 2010 income from operations. Goodwill reduction of $13M related to this divestiture. | |||
| 2010-10-31 | restructuring | in_progress | 2009-06-30 | 2014-10-31 | Global | Global infrastructure organization and electronic measurement | USD 39 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2009 Plan announced in first half of FY2009; FY2010 workforce-reduction expense of $39M recorded, with a small number of electronic measurement employees still pending termination at year-end; lease payments expected to run through fiscal 2014. Announcement date is approximate (first half of fiscal 2009). | ||
| 2010-10-31 | acquisition_addition | completed | 2009-07-26 | 2010-05-14 | Global | Life Sciences and Chemical Analysis | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Varian acquisition closed 2010-05-14 for ~$1.5B; MD&A attributes the increase in headcount from 16,800 to 18,500 to this acquisition, but no employee count is disclosed for Varian. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Global | Electronic Measurement — Network Solutions Division | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | NSD sold to JDS Uniphase for $160M with a $132M net gain; no employee count disclosed. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-02-02 | 2010-02-02 | Global | Life Sciences — Hycor Biomedical Inc. | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Hycor sold to Linden LLC; no employee count disclosed. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-05-19 | 2010-05-19 | Global | Chemical Analysis — Varian laboratory GC, triple quad GC-MS, ICP-MS and Agilent micro GC businesses | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Divestitures required as conditions of European Commission merger approval and FTC consent order, sold for ~$33M; no employee count disclosed. | |||
| 2010-10-31 | restructuring | in_progress | 2009-04-01 | 2014-10-31 | Global | Global Infrastructure Organization and Electronic Measurement | USD 64 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in fiscal 2010. Lease payments primarily complete by end of fiscal 2014. Small number of employees within electronic measurement pending termination as of October 31, 2010. Total restructuring, asset impairments and other special charges were $64 million in 2010. | ||
| 2010-10-31 | acquisition_addition | completed | 2010-05-14 | 2010-05-14 | Global | Life Sciences and Chemical Analysis | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase in 2010 compared to 2009 was due to the Varian acquisition. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Global | Electronic Measurement | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of Network Solutions Division (NSD) completed May 1, 2010. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-02-02 | 2010-02-02 | Global | Life Sciences | Item_1_Business f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of Hycor Biomedical Inc. completed February 2, 2010. | |||
| 2010-10-31 | restructuring | in_progress | 2009-04-01 | 2014-10-31 | Global | All segments | USD 64 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Workforce reduction payments largely complete in FY 2010. Lease payments primarily complete by end of FY 2014. Small number of employees in electronic measurement pending termination as of Oct 31, 2010. Total restructuring charges in FY 2010 were $64 million. | ||
| 2010-10-31 | acquisition_addition | completed | 2010-05-14 | 2010-05-14 | Global | Life Sciences and Chemical Analysis | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase attributed to this acquisition in MD&A. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Global | Electronic Measurement | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Sale of Network Solutions Division (NSD) to JDS Uniphase Corporation completed May 1, 2010. | |||
| 2010-10-31 | divestiture_reduction | completed | 2010-02-02 | 2010-02-02 | Global | Life Sciences | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Sale of Hycor Biomedical Inc. to Linden LLC completed February 2, 2010. | |||
| 2010-10-31 | restructuring | in_progress | USD 39,000,000 (absolute) | restructuring_footnote f5-10k / no-ai-xblr | |||||||
| 2010-07-31 | acquisition_addition | completed | 3,200 | 2010-05-14 | 2010-05-14 | Global | Life Sciences; Chemical Analysis | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Approximate headcount added via the Varian, Inc. merger completed May 14, 2010; figure is stated as approximate in the MD&A headcount discussion. Business combination footnote (Note 3) does not disclose an employee count. | ||
| 2010-07-31 | restructuring | in_progress | 2009 | 2010-10-31 | Global | Electronic Measurement | USD 56 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan announced in the first half of 2009. Fewer than 100 employees in electronic measurement remained pending termination as of July 31, 2010; exact count not disclosed. Associated charge is total restructuring, asset impairment and other special charges recorded across all plans for the nine months ended July 31, 2010 (quarterly figure was $6 million). Restructuring accrual balance was $37 million at July 31, 2010. Workforce reduction payments expected largely complete by fiscal year-end 2010. | ||
| 2010-07-31 | divestiture_reduction | completed | 2010-05-01 | 2010-05-01 | Global | Electronic Measurement — Network Solutions Division | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Headcount removed through the divestiture not disclosed; filing states NSD results were not significant to income from operations. | |||
| 2010-07-31 | divestiture_reduction | completed | 2010-05-19 | 2010-05-19 | Global | Chemical Analysis — Varian laboratory GC, triple quadrupole GC-MS, ICP-MS businesses and Agilent micro GC | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Regulatory-mandated divestiture (European Commission merger approval and FTC consent order) completed May 19, 2010 for approximately $42 million; associated headcount not disclosed. | |||
| 2010-07-31 | restructuring | in_progress | 2009-01-01 | 2010-10-31 | Global | Electronic Measurement | USD 56 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Less than 100 employees within electronic measurement pending termination as of July 31, 2010. Workforce reduction payments expected largely complete by end of fiscal 2010. | ||
| 2010-07-31 | acquisition_addition | completed | 3,200 | 2010-05-14 | 2010-05-14 | Global | Life Sciences, Chemical Analysis | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Varian, Inc. completed May 14, 2010. Headcount increase includes approximately 3,200 Varian employees. | ||
| 2010-04-30 | restructuring | in_progress | 150 | 2010-10-31 | Electronic Measurement | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan announced in the first half of 2009 (exact date not disclosed); count reflects employees still pending termination at April 30, 2010. Workforce reduction payments expected largely complete by fiscal year-end 2010; lease payments over approximately four years. Restructuring accrual balance was $50 million at April 30, 2010 (all plans combined, not program-specific). | ||||
| 2010-04-30 | acquisition_addition | announced | 2010-05-14 | 2010-05-14 | Life Sciences / Chemical Analysis | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter acquisition completed May 14, 2010 for approximately $1.5 billion; acquired headcount not disclosed in this filing. Initial purchase price accounting incomplete. | ||||
| 2010-04-30 | divestiture_reduction | announced | 2010-05-01 | 2010-05-01 | Electronic Measurement — Network Solutions Division | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter divestiture completed May 1, 2010 for $165 million; associated headcount not disclosed. | ||||
| 2010-04-30 | divestiture_reduction | announced | 2010-05-19 | 2010-05-19 | Chemical Analysis — divested GC, GC-MS, ICP-MS and micro GC businesses | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter sale completed May 19, 2010 for approximately $40 million; associated headcount not disclosed. A related divestiture during the quarter reduced other intangibles by $13 million, with headcount impact not disclosed. | ||||
| 2010-04-30 | restructuring | in_progress | 2009-01-01 | 2010-10-31 | Global | Electronic Measurement | USD 50 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in first half of 2009. Approximately 150 employees within electronic measurement pending termination as of April 30, 2010. Workforce reduction payments expected largely complete by end of fiscal 2010. Total restructuring and other special accruals were $50 million. | ||
| 2010-01-31 | restructuring | in_progress | 3,800 | 2008-12 | 2010-06-30 | Global | Global infrastructure organization and electronic measurement segment | USD 315 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan consolidates actions announced December 2008, February 2009 and March 2009; approximately 3,800 regular positions to be eliminated, with expected annual savings of about $525 million. Approximately 300 electronic measurement employees remained subject to termination at January 31, 2010; $34 million of charges incurred in the quarter. Program disclosed only as a consolidated total. | |
| 2010-01-31 | divestiture_reduction | announced | 2010-02-11 | Electronic Measurement — Network Solutions Division | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement to sell the Network Solutions Division to JDS Uniphase for $165 million cash, subject to closing conditions and regulatory approval; associated headcount not disclosed. | |||||
| 2010-01-31 | restructuring | in_progress | 3,800 | 2009-03-01 | 2010-06-30 | Global | Global workforce | USD 34 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in Q1-Q2 2009. Total headcount reductions approx 3,800. $34M charges incurred in Q1 2010. Completion expected by Q2 2010. | |
| 2010-01-31 | divestiture_reduction | announced | 2010-02-11 | Electronic Measurement | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Agreement to sell Network Solutions Division to JDSU for $165M. Employee count not disclosed. | |||||
| 2009-10-31 | restructuring | in_progress | 3,800 | 2008-12 | 2010-04-30 | Global | Global Infrastructure Organization; Electronic Measurement; Semiconductor and Board Test | USD 315 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY 2009 Plan announced December 2008 with about 500 initial position reductions, then expanded in February and March 2009 by roughly 3,300 additional positions across the global infrastructure organization and the electronic measurement and semiconductor and board test segments, including exit of the inspection businesses. Aggregate expected pre-tax charges about $315 million; $267 million incurred in fiscal 2009 ($202 million workforce reduction, $18 million facilities consolidation, $27 million asset impairments, $20 million inventory-related charges). Majority of activities completed by October 31, 2009 with remainder expected by end of fiscal Q2 2010; about 600 electronic measurement employees were pending termination at year-end. Expected annual operating savings about $525 million. Position counts are approximate regular-employee reductions for the full plan; percent of workforce not disclosed. | |
| 2009-10-31 | restructuring | in_progress | 3,800 | 2008-12-01 | 2010-04-30 | Global | Global infrastructure organization; electronic measurement; semiconductor and board test | USD 315 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan: announced Dec 2008, expanded Feb 2009 and Mar 2009. Approximately $315M expected pre-tax charges in aggregate; $267M incurred in FY2009 (incl. $27M asset impairments, $20M inventory special charges). Workforce reductions of ~3,800 regular positions; majority of actions complete by 2009-10-31 with remainder expected by end of Q2 FY2010. Approximately 600 electronic measurement employees pending termination at year-end. | |
| 2009-10-31 | other | completed | 2009-01-01 | 2009-10-31 | Global | Company-wide | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Company-wide wage reductions implemented January 2009, generating approximately $70M of cash savings in FY2009; fully restored to all employees effective 2009-11-01. No headcount reduction associated. | |||
| 2009-10-31 | restructuring | in_progress | 3,800 | 2008-12-01 | 2010-04-30 | Global | Global Infrastructure, Electronic Measurement, Semiconductor and Board Test | USD 315 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY 2009 Plan announced Dec 2008, expanded Feb/Mar 2009. Expected to result in workforce reductions of approx 3,800 regular positions and annual operating savings of approx $525 million. Total pre-tax charges approx $315 million. Majority completed by Oct 31, 2009; remainder expected by end of Q2 FY2010. Approx 600 employees in electronic measurement pending termination as of Oct 31, 2009. | |
| 2009-10-31 | restructuring | in_progress | 3,800 | 2008-12-01 | 2010-06-30 | Worldwide | All Segments | USD 315 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in Dec 2008, expanded Feb/Mar 2009. Expected to result in workforce reductions of approximately 3,800 regular positions and pre-tax charges of approx $315 million. Majority completed by Oct 31, 2009; remainder expected by end of Q2 FY2010. | |
| 2009-07-31 | restructuring | in_progress | 3,800 | 2008-12-01 | 2010-04-30 | Global | Global infrastructure organization; electronic measurement; semiconductor and board test | USD 315 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan announced December 2008 and expanded February and March 2009 (announcement date shown is the initial announcement). Approximately 2,000 of the 3,800 positions had left Agilent as of 2009-07-31; majority of actions expected complete by 2009-10-31, remainder by end of fiscal Q2 2010. $210M of the ~$315M expected pre-tax charges incurred in the nine months ended 2009-07-31; expected annual operating savings ~$525M. Includes $24M asset impairments and $22M inventory special charges. | |
| 2009-07-31 | acquisition_addition | announced | 2009-07-26 | 2009-12-31 | Global | Bio-analytical measurement (life science and applied markets) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Merger agreement dated 2009-07-26; estimated $1.5B total purchase price at $52.00 cash per Varian share plus cashed-out options and assumed debt. No headcount added disclosed; closing subject to Varian shareholder approval and U.S./EU antitrust clearance, expected before calendar year-end 2009. | |||
| 2009-07-31 | restructuring | in_progress | 3,800 | 2009-02-01 | 2010-04-30 | Global | Global Infrastructure Organization, Electronic Measurement, Semiconductor and Board Test | USD 315 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in Q1 2009 and expanded in Q2 2009. Total headcount reductions of approximately 3,800 positions. Approximately 2,000 employees had left as of July 31, 2009. Majority of actions expected complete by Oct 31, 2009, remainder by Q2 FY2010. Aggregate pre-tax charges expected ~$315 million. | |
| 2009-04-30 | restructuring | in_progress | 3,800 | 2008-12 | 2010-04-30 | Global | Global infrastructure organization; electronic measurement; semiconductor and board test | USD 315 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan announced Dec 2008, expanded Feb 2009 and Mar 2009; ~3,800 regular positions to be eliminated, expected annual savings ~$525M. ~650 employees had left as of 2009-04-30; $134M of charges incurred in six months ended 2009-04-30. Majority of activities expected complete by 2009-10-31, remainder by end of Q2 FY2010. | |
| 2009-04-30 | plant_closure | announced | 2009-02 | Global | Semiconductor and board test — inspection businesses | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Feb 2009 announcement to exit the inspection businesses in the semiconductor and board test segment; $23M of special charges for excess inventory and $17M of asset impairments recorded in six months ended 2009-04-30. Headcount impact not separately disclosed; part of the consolidated FY 2009 Plan. | ||||
| 2009-04-30 | restructuring | in_progress | 3,800 | 2008-12-01 | 2010-04-30 | Global | Global workforce, Electronic Measurement, Semiconductor and Board Test, Global Infrastructure Organization | USD 315 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced Dec 2008, expanded Feb/Mar 2009. Total headcount reductions approx 3,800. Approx 650 employees left as of Apr 30, 2009. Majority of activities expected to complete by Oct 31, 2009, remainder by end of Q2 FY2010. Expected aggregate pre-tax charges approx $315 million. | |
| 2009-01-31 | restructuring | in_progress | 500 | 2008-12 | 2009-10-31 | Global | Global workforce of regular employees | USD 48 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY 2009 Plan announced December 2008; also eliminates 300 temporary positions. $48M charged in Q1 FY2009 (incl. $13M asset impairments, $22M excess inventory special charges), with ~$107M expected for the remainder of FY2009; ~250 of the positions notified as of 2009-01-31. Expected annual savings ~$65M from this initial program. Combined with the February 2009 expansion, aggregate pre-tax charges expected ~$155M and annual savings ~$215M across ~1,100 positions. | |
| 2009-01-31 | restructuring | announced | 600 | 2009-02-17 | 2009-10-31 | Global | Semiconductor & Board Test (inspection businesses: automated optical inspection, automated X-ray inspection) and Global Infrastructure Organization | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter expansion of the FY 2009 Plan announced 2009-02-17, bringing total planned reductions to ~1,100 regular positions. Exited inspection businesses had combined revenue of ~$55M for FY2008. Combined program expected to record ~$155M aggregate pre-tax charges, mostly cash; expected annual savings ~$150M from these additional actions. | ||
| 2009-01-31 | restructuring | in_progress | 500 | 2008-12-01 | 2009-10-31 | Global | Global workforce of regular employees | USD 48 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY 2009 Plan announced in Q1 2009 (Dec 2008) to reduce ~500 regular positions. $48M total charges recorded in Q1 2009 ($13M workforce reduction, $22M inventory/special charges, $13M asset impairments). About 250 employees notified as of Jan 31, 2009. | |
| 2009-01-31 | restructuring | announced | 600 | 2009-02-17 | 2009-10-31 | Global | Semiconductor and board test segment; Global infrastructure organization | USD 155 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Additional actions announced Feb 17, 2009 to exit inspection businesses and restructure global infrastructure. Reduces ~600 regular positions. Combined with prior plan, total headcount reduction is ~1,100. Aggregate pre-tax charges expected ~$155M. | |
| 2008-10-31 | acquisition_addition | completed | 2007-12-18 | United States (California) | Bio-analytical measurement (lab automation / robotics) | USD 111 (millions) | other f5-10k / GLM-5.3-flash-HTML | Acquisition of Velocity11, a designer, manufacturer and marketer of robotic solutions, completed December 18, 2007 (first quarter of fiscal 2008) for approximately $111 million in cash for 100 percent of outstanding shares and vested employee options. Number of employees added through the acquisition is not disclosed. The $111 million is purchase consideration (charge label 'other'), not a severance or restructuring charge. | |||
| 2008-10-31 | restructuring | in_progress | 2005 | USD -4 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY2005 Plan (announced in the fourth quarter of fiscal 2005) is largely complete. Fiscal 2008 activity: net restructuring/asset impairment charge of $(4) million (a first-quarter credit from reducing the estimated excess-facilities liability), $18 million of cash payments, and a $10 million accrual remaining at October 31, 2008, entirely related to consolidation of excess facilities. The workforce-reduction component required no fiscal 2008 charges and was fully settled ($1 million cash payment, balance zero). Employee counts were disclosed only in prior fiscal years. Remaining obligations are primarily lease obligations expected to be satisfied over approximately the next three years. Charge value shown as fiscal-2008 net credit. | |||||
| 2008-10-31 | restructuring | announced | 500 | 2008-12-12 | 2009-10-31 | Global | USD 55 (millions) | subsequent_events f5-10k / GLM-5.3-flash-HTML | Regular-positions component of a targeted restructuring approved December 12, 2008 in response to deteriorating economic conditions; the program comprises approximately 500 regular and 300 temporary positions (see companion record). Majority of activities expected complete by May 31, 2009, remainder by October 31, 2009. The approximately $55 million pre-tax charge (mostly employee severance; substantially all cash) relates to the entire program and is recorded on this record only to avoid double counting. | ||
| 2008-10-31 | restructuring | announced | 300 | 2008-12-12 | 2009-10-31 | Global | subsequent_events f5-10k / GLM-5.3-flash-HTML | Temporary-positions component of the same December 12, 2008 targeted restructuring program disclosed as a subsequent event; the approximately $55 million total program charge is captured on the companion regular-positions record. | |||
| 2008-10-31 | restructuring | in_progress | 2005-10-31 | Global | Company-wide | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan announced in Q4 2005 and described as largely complete; no headcount reduction attributed to FY2008. FY2008 activity was a $4M reduction to the excess-facilities accrual and $18M of cash payments, leaving a $10M balance at year-end, with remaining obligations relating to lease obligations over roughly three years. | ||||
| 2008-10-31 | restructuring | announced | 800 | 2008-12-12 | 2009-10-31 | Global | Businesses most severely impacted by the economic downturn | USD 55 (millions) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Targeted restructuring approved after fiscal year-end; comprises approximately 500 regular and 300 temporary positions, mostly severance. Majority of activities expected complete by 2009-05-31 with the remainder by 2009-10-31. | |
| 2008-10-31 | acquisition_addition | completed | 2007-12-18 | 2007-12-18 | Bio-Analytical Measurement (laboratory automation and robotics) | USD 111 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Velocity11 acquisition closed in Q1 FY2008 for approximately $111 million cash; acquired headcount not disclosed. Seven acquisitions plus a minority-interest buyout occurred in FY2008 ($103M of intangibles, $67M of goodwill); no aggregate acquired headcount disclosed. | |||
| 2008-10-31 | restructuring | announced | 800 | 2008-12-12 | 2009-10-31 | Global | Agilent businesses most severely impacted by economic downturn | USD 55 (millions) | subsequent_events f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Announced December 12, 2008. Global workforce reduced by approximately 500 regular and 300 temporary positions. Majority of activities expected to be completed by May 31, 2009, remainder by October 31, 2009. Pre-tax restructuring charges of approximately $55 million, mostly related to employee severance. | |
| 2008-10-31 | restructuring | in_progress | 2008-12-12 | 2009-10-31 | Global | USD 55 (millions) | subsequent_events f5-10k / Qwen3.6-27B-Q8_0 | Announced Dec 12, 2008. Expected reduction of approx 500 regular and 300 temporary positions. Majority of activities expected by May 31, 2009. | |||
| 2008-07-31 | restructuring | completed | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan announced in Q4 2005 is complete; no employee counts disclosed. Remaining $12M accrual (down from $32M at Oct 31, 2007) relates primarily to lease obligations over roughly four years. No restructuring charges in Q3 FY2008; nine-month activity included a $4M benefit from reduced excess-facility estimates and $16M of cash payments. | |||||||
| 2008-07-31 | restructuring | in_progress | Consolidation of Excess Facilities | USD -4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed. | |||||
| 2008-04-30 | restructuring | in_progress | 2005-10-01 | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan announced in Q4 2005 is largely complete; no employee-affected count disclosed. Six months ended April 30, 2008 shows no workforce-reduction income statement expense (accrual reduced from $1M to $0 via cash payments); remaining obligations are primarily lease obligations expected to be satisfied over approximately the next four years. Restructuring accrual total was $20M at April 30, 2008 (down from $32M at October 31, 2007), including a $4M reduction in the excess-facilities estimate due to property market changes. | ||||||
| 2008-04-30 | acquisition_addition | completed | 2007-12-18 | 2007-12-18 | Bio-analytical Measurement | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Velocity11 (robotic solutions designer/manufacturer) completed December 18, 2007 for approximately $111 million cash; headcount added not disclosed. MD&A attributes the year-over-year headcount increase (approximately 18,900 to approximately 19,500) entirely to acquisitions. | ||||
| 2008-04-30 | restructuring | in_progress | USD -4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed. | ||||||
| 2008-01-31 | restructuring | in_progress | 2005-10-01 | USD 1 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan announced in Q4 2005 is largely complete; remaining obligations are primarily lease obligations expected to be satisfied over about four years. $1 million accrued at January 31, 2008 for amounts payable to employees impacted by the plan, expected to be paid within two quarters. No employees-affected count disclosed for the current quarter. | |||||
| 2008-01-31 | acquisition_addition | completed | 2007-12-18 | 2007-12-18 | Bio-analytical Measurement | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Velocity11 (robotic solutions designer/manufacturer) completed December 18, 2007 for approximately $111 million cash; results included from date of acquisition. Headcount added through the acquisition is not disclosed. | ||||
| 2008-01-31 | restructuring | in_progress | USD -4 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Reduction in estimated liability for consolidation of excess facilities due to changes in underlying property markets. No employee count disclosed for this specific adjustment. | ||||||
| 2007-10-31 | restructuring | in_progress | 2005 | USD 12 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Multi-year plan launched in Q4 fiscal 2005 to cut workforce and facility footprint after semiconductor divestitures. Fiscal 2007 charge of $12M comprises $17M workforce-reduction expense offset by a $5M net release of the excess-facility accrual (sub-lease recovery improvement). Workforce-reduction component substantially complete at fiscal year-end with only $1M accrued; cash payments of $51M made in fiscal 2007 ($29M workforce, $22M facilities). Excess-facility payments expected to continue roughly four more years; no employee count disclosed for fiscal 2007 activity. | |||||
| 2007-10-31 | reduction_in_force | in_progress | USD 35 (millions) | MD&A f5-10k / GLM-5.3-flash-HTML | Ongoing, independent business-realignment workforce actions (explicitly not a formal restructuring plan), each individually immaterial. Approximately $35M of workforce management charges incurred in fiscal 2007, with roughly $20M of additional charges expected in fiscal 2008. Company-wide; general infrastructure/shared services headcount fell about 230 during the year to approximately 2,500. | ||||||
| 2007-10-31 | acquisition_addition | completed | 2007-06-06 | Bio-analytical Measurement (life sciences) | USD 252 (millions) | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Date shown is the completion date per Note 13; the deal was first announced in Q2 fiscal 2007. Acquired Stratagene Corporation for approximately $252M in cash (100% of common shares and vested options). Headcount added through the acquisition was not disclosed; Stratagene contributed about 2% of bio-analytical segment revenue growth in fiscal 2007. Associated charge reflects the aggregate purchase price, not a severance charge. | ||||
| 2007-10-31 | restructuring | in_progress | 2005-10-01 | Global | Corporate-wide (2005 Plan) | USD 17 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY2007 workforce-reduction expense of $17M under the 2005 Plan; total FY2007 restructuring charge was $12M (workforce $17M plus a $5M net release on excess facilities). Workforce-reduction component substantially complete with a $1M accrual remaining at year-end; facility-consolidation payments continue over the next four years. Employees affected in FY2007 not disclosed. | |||
| 2007-10-31 | restructuring | in_progress | 2008-10-31 | Global | Enterprise-wide workforce management actions | USD 35 (millions) | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Independent workforce-management actions taken during FY2007 (not part of a formal restructuring plan), individually immaterial; approximately $35M incurred in 2007 with a further charge of approximately $20M expected in 2008. Employees affected not disclosed. | |||
| 2007-10-31 | acquisition_addition | completed | 2007-06-06 | 2007-06-06 | United States | Bio-Analytical Measurement (life sciences) | USD 252 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Stratagene completed June 6, 2007 for approximately $252M cash; headcount added through the acquisition not disclosed. Purchase price shown for context, not a workforce charge. | ||
| 2007-10-31 | restructuring | in_progress | 2005-10-01 | Global | All segments | USD 12 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2005 Plan restructuring charges of $12 million recorded in 2007. Workforce reduction component substantially complete; facility consolidation continues. | |||
| 2007-10-31 | restructuring | in_progress | 2005-10-01 | Global | All segments | USD 17 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Workforce reduction expenses of $17 million recorded in 2007 under the 2005 Plan. | |||
| 2007-10-31 | acquisition_addition | completed | 2007-06-01 | Global | Bio-analytical Measurement | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Acquisition of Stratagene Corporation completed in June 2007. Headcount increase predominantly due to acquisitions. | ||||
| 2007-10-31 | restructuring | in_progress | Global | General Infrastructure | USD 35 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Total workforce management charges of approximately $35 million incurred in 2007 for independent actions not constituting a formal restructuring plan. | ||||
| 2007-10-31 | restructuring | completed | 2005-10-01 | Worldwide | General Infrastructure and Shared Services | USD 12 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | 2005 Plan restructuring charges of $12 million in 2007. Workforce reduction expenses were $17 million. Workforce reduction component is substantially complete. General infrastructure headcount decreased by approximately 230 employees from one year ago. | |||
| 2007-10-31 | other | completed | Worldwide | Various | USD 35 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Total workforce management charges of approximately $35 million incurred in 2007 for independent actions not constituting a formal restructuring plan. | ||||
| 2007-07-31 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | Global | Enterprise-wide (workforce alignment following semiconductor divestiture and Verigy spin-off) | USD 16 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan: $16M in charges for the nine months ended July 31, 2007 (zero in the quarter), mostly for individuals notified before October 31, 2006; about $1M of future charges expected. Restructuring accrual of $42M at quarter-end. Number of employees affected not disclosed in this filing. | ||
| 2007-07-31 | restructuring | in_progress | 2007-07-31 | Global | Enterprise-wide workforce realignment | USD 20 (millions) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Independent post-FY2005 workforce management actions (not a formal restructuring plan), each individually immaterial; approximately $20M total charges to date, majority recognized in the third quarter, with about $3M of future charges expected. Employee counts not disclosed. | |||
| 2007-07-31 | acquisition_addition | completed | 2007-06-06 | 2007-06-06 | United States | Bio-analytical Measurement (life sciences) | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Stratagene Corp. closed June 6, 2007 for approximately $252M cash; headcount added through the acquisition not disclosed. | |||
| 2007-07-31 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | Global | Various | USD 16 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY2005 Plan charges incurred in the nine months ended July 31, 2007. Mostly associated with individuals notified prior to Oct 31, 2006. Completion expected by end of fiscal 2007. | ||
| 2007-07-31 | restructuring | in_progress | Global | Various | USD 20 (millions) | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Post-FY2005 Plan workforce management actions. Total charges expected approx $20 million, majority recognized in Q3. Future charges approx $3 million expected. | ||||
| 2007-04-30 | restructuring | in_progress | 2007-10-31 | Global | Company-wide | USD 16 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan announced in fiscal Q4 2005 (exact announcement date not disclosed) to align workforce with reduced revenue base after semiconductor divestiture and Verigy spin-off; voluntary and involuntary terminations. Charges of $7M in Q2 and $16M in the six months ended April 30, 2007; workforce-reduction accrual of $4M at April 30, 2007 (total restructuring accrual $48M including excess-facility component). Approximately $1M of additional charges expected for previously notified individuals; completion expected by end of fiscal 2007. No employee count disclosed. | |||
| 2007-04-30 | restructuring | in_progress | Global | Company-wide | USD 3 (millions) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-FY2005 Plan workforce management actions; filer states these do not constitute a formal restructuring plan because each action is individually immaterial. Approximately $18M of workforce management charges expected over the next year, of which approximately $3M was recorded in Q2 2007. No employee count disclosed. | ||||
| 2007-04-30 | acquisition_addition | announced | 2007-04-05 | 2007-06-30 | United States | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Definitive agreement to acquire Stratagene Corporation (La Jolla, California), a life sciences company, for $10.94 per share in cash, approximately $250M aggregate; expected to close in early June 2007. Headcount added not disclosed. | ||||
| 2007-04-30 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY2005 Plan charges for Q2 2007. Completion of workforce reduction expected by end of fiscal 2007. | ||||
| 2007-04-30 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | USD 16 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY2005 Plan charges for YTD 2007. Completion of workforce reduction expected by end of fiscal 2007. | ||||
| 2007-04-30 | restructuring | in_progress | USD 3 (millions) | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Workforce management charges recorded in Q2 2007, part of approx $18M expected over next year. | ||||||
| 2007-01-31 | restructuring | in_progress | 2007-10-31 | Global | Corporate-wide (continuing operations) | USD 9 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY2005 Plan workforce reduction announced in Q4 FY2005 to align workforce with smaller revenue base after semiconductor divestiture and Verigy spin-off; $9M charged in Q1 FY2007, mostly for individuals notified before 2006-10-31; approximately $5M of future charges expected; no employees-affected count disclosed; restructuring accrual was $58M at quarter-end | |||
| 2007-01-31 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | Global | Workforce Reduction | USD 9 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY2005 Plan charges incurred in Q1 2007 mostly associated with individuals notified prior to Oct 31, 2006. Completion expected by end of fiscal 2007. | ||
| 2006-10-31 | restructuring | in_progress | 2007 | Global (facility impairments primarily Germany and the US) | General infrastructure / shared services primarily; FY2006 charges span cost of products and services, R&D, and SG&A | USD 186 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Program launched in Q4 fiscal 2005 to align workforce with smaller post-divestiture size; focused on shared-services cost reduction (target ~$450M infrastructure cost reduction, actions completed in FY2006). FY2006 charges of $186M comprise $111M workforce reduction, $33M excess facility consolidation, and $42M asset impairments; $172M in continuing operations ($28M COGS, $21M R&D, $123M SG&A) and $14M in Verigy discontinued operations. Severance accrual $13M at fiscal year-end (down from $44M); restructuring cash payments $166M in FY2006 (of which $142M workforce reduction severance). Workforce reduction expected substantially complete in fiscal 2007; lease payments on excess facilities continue approximately five more years. Employee headcount affected not explicitly disclosed; general infrastructure headcount fell ~1,160 year-over-year to ~2,750. Table aggregates Prior Plans (2001-2003), whose workforce reduction portion was completed in fiscal 2005. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-14 | 2005-12-01 | Global | Semiconductor products business | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Sale to Avago Technologies Ltd. completed December 1, 2005 for approximately $2.6 billion cash ($2,559 million net of working capital adjustments); pre-tax gain on sale $1,816 million. Business reflected as discontinued operations for all periods; transferred employee headcount not disclosed. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-15 | 2006-10-31 | Global | Semiconductor test solutions business (Verigy Ltd.) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Separation of Verigy into a stand-alone public company; IPO of approximately 8.7 million ordinary shares (~15% of outstanding) completed June-July 2006 for net proceeds of $121 million. Remaining 85% (~50 million shares) distributed to Agilent stockholders on October 31, 2006 via pro rata non-cash dividend reducing retained earnings by $310 million; market value of distributed shares approximately $840 million. Business reflected as discontinued operations; transferred employee headcount not disclosed. | |||
| 2006-10-31 | restructuring | in_progress | 2005-10-31 | 2007-10-31 | Global | Corporate infrastructure and shared services | USD 111 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 2005 Plan workforce-reduction component; $111M of the $186M total FY2006 restructuring and asset impairment charges. Workforce accrual $13M at 2006-10-31 (down from $44M); workforce portion expected substantially complete in fiscal 2007. Employees affected not disclosed. | ||
| 2006-10-31 | plant_closure | in_progress | 2005-10-31 | 2011-10-31 | Germany and United States | Corporate facilities | USD 33 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Excess-facility consolidation component of the same 2005 Plan; FY2006 expense also included $42M of asset impairment charges (primarily Germany and U.S. facilities), all within the $186M program total. Facility accrual $58M at year-end; lease payments expected to continue roughly five years. | ||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-14 | 2005-12-01 | Global | Semiconductor products business | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale to Avago Technologies completed 2005-12-01 for ~$2.6B cash; headcount transferred not disclosed. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-15 | 2006-10-31 | Global | Semiconductor test solutions business (Verigy) | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Verigy separated 2006-06-01, IPO June-July 2006, remaining ~85% stake distributed to stockholders 2006-10-31; headcount removed not disclosed. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-12 | 2005-11-28 | Global | Lumileds Lighting joint venture (equity interest) | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of Agilent's ~47% stake to Philips for $949M plus $51M debt repayment; headcount impact not disclosed. | |||
| 2006-10-31 | restructuring | in_progress | 2005-10-01 | 2007-10-31 | Global | General Infrastructure and Shared Services | USD 186 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2005 Plan launched in Q4 2005 to reduce workforce and facility footprint. In 2006, recorded $186 million in restructuring and asset impairment charges ($111 million for workforce reduction). Workforce reduction portion expected to be substantially completed in fiscal year 2007. | ||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-15 | 2006-10-31 | Global | Semiconductor Test Solutions | discontinued_operations_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Spin-off of semiconductor test solutions business (Verigy) completed on October 31, 2006. Employees transferred to Verigy. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-14 | 2005-12-01 | Global | Semiconductor Products | discontinued_operations_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of semiconductor products business to Avago completed in December 2005. Employees transferred to Avago. | |||
| 2006-10-31 | restructuring | in_progress | 2005-10-31 | 2007-10-31 | Worldwide | General Infrastructure and Shared Services | USD 186 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | 2005 Plan launched in Q4 2005 to reduce workforce and facility footprint. Workforce reduction portion expected to be substantially completed in fiscal 2007. Includes $111M workforce reduction and $75M facility/impairment charges in 2006. | ||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-14 | 2005-12-01 | Worldwide | Semiconductor Products | discontinued_operations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Sale of semiconductor products business to Avago completed December 1, 2005. Headcount removed not explicitly quantified in employee count, but business reported as discontinued. | |||
| 2006-10-31 | divestiture_reduction | completed | 2005-08-15 | 2006-10-31 | Worldwide | Semiconductor Test Solutions | discontinued_operations_footnote f5-10k / Qwen3.6-27B-Q8_0 | Spin-off of Verigy (semiconductor test solutions) completed October 31, 2006. Headcount removed not explicitly quantified in employee count, but business reported as discontinued. | |||
| 2006-07-31 | restructuring | in_progress | 2005-10-31 | 2007-10-31 | Global | Corporate-wide (workforce and excess facilities) | USD 145 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY05 Plan announced in Q4 FY2005 to align workforce with smaller revenue base; nine-month charge of $145M comprises $95M workforce reduction, $24M excess facilities, $26M impairments. Execution of workforce component expected to complete during fiscal 2007; no employee count disclosed. Restructuring accrual was $76M at July 31, 2006. | ||
| 2006-07-31 | divestiture_reduction | in_progress | 2005-08-15 | 2006-10-31 | Global | Semiconductor Test Solutions (Verigy Ltd.) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Spin-off of Verigy; IPO of 8.7M shares at $15 completed in Q3 FY2006, leaving Agilent with ~85% (~50M shares). Distribution of remaining shares expected by end of fiscal 2006; no headcount count disclosed. Separation date June 1, 2006. | |||
| 2006-07-31 | divestiture_reduction | completed | 2005-10-31 | 2005-12-01 | Global | Semiconductor Products business (sold to Avago Technologies Ltd.) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Divestiture completed December 1, 2005 for ~$2,559M cash proceeds; results reported as discontinued operations for all periods. No employee count disclosed; action occurred in Q1 FY2006 but is described throughout this filing. | |||
| 2006-07-31 | plant_closure | completed | 2006-04-25 | 2006-10-31 | United States (Palo Alto and San Jose, California) | Corporate facilities consolidation | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of Palo Alto headquarters completed May 2006 ($98.5M consideration, $65M gain) with leaseback through move to Santa Clara campus in Q4 FY2006; San Jose site sold in Q2 FY2006 ($88M, $56M gain). Part of excess-facilities consolidation; no employee count disclosed. | |||
| 2006-07-31 | restructuring | in_progress | 2005-10-31 | 2007-10-31 | Global | All segments | USD 145 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY05 Plan launched in Q4 2005 to align workforce with smaller revenue base following semiconductor divestiture. Includes voluntary and involuntary terminations. Workforce reduction execution expected to complete in fiscal 2007. Total charges for nine months ended July 31, 2006 were $145 million ($95M workforce, $24M facilities, $26M impairments). | ||
| 2006-04-30 | restructuring | in_progress | 2006-10-31 | Global | Enterprise-wide (workforce reduction component of FY05 Plan) | USD 70 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY05 Plan workforce reduction component: $70M charge for six months ended April 30, 2006 ($70M of which is the total charge line); $81M cash payments made; accrual balance $33M at April 30, 2006. Voluntary and involuntary terminations; no employee count disclosed. Announced in Q4 FY2005 to align workforce with smaller revenue base after semiconductor products divestiture and planned STS spin-off. | |||
| 2006-04-30 | restructuring | in_progress | 2011-04-30 | Global | Facilities / real estate (consolidation of excess facilities) | USD 13 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Facility consolidation component of FY05 Plan: $13M charge for six months ended April 30, 2006; accrual $50M at April 30, 2006; lease payments expected over next five years. Includes $22M impairment charges for two sites (one California, one Germany) recorded in Q2 FY2006. San Jose site sold in Q2 FY2006 for $88M consideration with $56M gain. No employee counts disclosed. | |||
| 2006-04-30 | divestiture_reduction | completed | 2005-12-01 | Global | Semiconductor products business (sold to Avago Technologies Ltd.) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Divestiture completed December 1, 2005 for approximately $2,565M cash proceeds; results reported as discontinued operations for all periods. Headcount removed through the sale is not disclosed. | ||||
| 2006-04-30 | divestiture_reduction | announced | 2005-08-15 | 2006-10-30 | Global | Semiconductor test solutions (Verigy) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Spin-off announced August 15, 2005; separation agreements dated May 31/June 1, 2006 set a June 1, 2006 separation date; distribution of Agilent shares in Verigy expected complete by end of fiscal 2006, subject to conditions. Headcount transferring with the business is not disclosed. Related separation costs of $65M for six months ended April 30, 2006 (per segment reconciliation). | |||
| 2006-04-30 | restructuring | in_progress | 2005-10-31 | 2006-10-31 | Global | Corporate / Shared Services | USD 105 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY05 Plan launched in Q4 2005 to align workforce with smaller revenue base following semiconductor products divestiture. Includes voluntary and involuntary terminations. Expected completion by end of fiscal 2006. Total charge of $105M for six months ended April 30, 2006 includes $70M workforce reduction, $13M facility consolidation, and $22M asset impairments. | ||
| 2006-01-31 | restructuring | in_progress | 2005-10 | 2006-10-31 | Global | Enterprise-wide (voluntary and involuntary terminations) | USD 39 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | FY05 Plan launched in fiscal Q4 2005 to align workforce with smaller organization after semiconductor products divestiture and planned semiconductor test spin-off; $39M charge recorded in the quarter, all for workforce reduction; no employee count disclosed; restructuring accrual $80M at quarter-end ($37M workforce, $43M excess facilities) | ||
| 2006-01-31 | divestiture_reduction | completed | 2005-10 | 2005-12-01 | Global | Semiconductor products business | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Divestiture of semiconductor products business to Avago Technologies completed December 1, 2005 for approximately $2,579 million cash proceeds; no headcount transferred disclosed; related infrastructure headcount transfers to Avago referenced in MD&A without counts | |||
| 2006-01-31 | divestiture_reduction | announced | 2005-10 | 2006-10-31 | Global | Semiconductor Test Solutions (SOC and memory test) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Planned spin-off of semiconductor test solutions business by end of fiscal 2006 announced in fiscal Q4 2005; no employee count or spin-off related charge disclosed | |||
| 2006-01-31 | restructuring | in_progress | 2005-10-31 | 2006-10-31 | Global | Corporate / All Segments | USD 39 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | FY05 Plan launched in Q4 2005 to align workforce with smaller organizational size following semiconductor products divestiture. Consists of voluntary and involuntary terminations. Expected to be completed by end of fiscal 2006. $39M charge recorded in Q1 2006. | ||
| 2005-10-31 | restructuring | in_progress | 600 | 2006-10-31 | Worldwide (global infrastructure organization) | General infrastructure and shared services (e.g., finance, IT, workplace services) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY05 Plan infrastructure component, initiated during fiscal Q4 2005: ~600 of ~1,300 targeted infrastructure jobs notified by fiscal year-end, with ~700 more expected in fiscal 2006. Note 14 reports a combined FY05 Plan workforce-reduction charge of $96 million for fiscal 2005 ($52 million cash paid; $44 million accrued), not split by component; plan completion estimated at end of fiscal 2006. | |||
| 2005-10-31 | restructuring | in_progress | 900 | 2006-10-31 | Semiconductor test solutions: U.S., Germany, Japan; electronic measurement: U.S., U.K. | Semiconductor test solutions and electronic measurement businesses | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | FY05 Plan business-segment component: all ~900 segment job reductions notified as of October 31, 2005. Combined FY05 Plan program accounted for ~1,500 employees reduced or notified by fiscal year-end, with the $96 million fiscal-2005 workforce-reduction charge disclosed at program level in Note 14. | |||
| 2005-10-31 | divestiture_reduction | completed | 6,500 | 2005-08 | 2005-12 | Asia, U.S., Europe | Semiconductor products business | MD&A f5-10k / GLM-5.3-flash-HTML | Board approved divestiture in August 2005; asset sale to Avago Technologies Ltd. for approximately $2.66 billion completed December 2005 ($2.579 billion cash proceeds per Note 24). Includes approximately 6,500 regular employees transferring; ~200 additional infrastructure employees expected to move to the divested business in 2006. Option vesting was accelerated for that business's employees ($8 million charge in discontinued operations). | ||
| 2005-10-31 | divestiture_reduction | announced | 2005-08-15 | 2006-10-31 | Semiconductor test solutions business (SOC, SIP and memory test) | Item_1_Business f5-10k / GLM-5.3-flash-HTML | Spin-off via IPO announced August 15, 2005; IPO expected near mid-year 2006 and spin-off completion by end of fiscal 2006. Semiconductor test solutions segment employed ~1,600 at fiscal year-end 2005; a separate headcount-transfer figure is not disclosed. | ||||
| 2005-10-31 | restructuring | completed | 16,300 | 2001 | U.S., Korea, Japan, U.K. and other countries (~116 facilities exited) | All segments except bio-analytical measurement, plus infrastructure support services | USD 27 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | 2001/2002/2003 restructuring plans ('Prior Plans'); workforce-reduction portion completed mid-2005. Employee count is cumulative through fiscal year-end (plan inception through FY2005); fiscal-2005-specific reduction count not separately disclosed. Fiscal 2005 charges of $27 million ($10M workforce, $10M excess facilities, $7M asset impairment); excess-facilities consolidation expected to complete within five years. | ||
| 2005-10-31 | divestiture_reduction | completed | 2005-02 | Camera module business | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Camera module business sold in February 2005; results reported within discontinued operations alongside the semiconductor products business. Headcount impact not disclosed. | |||||
| 2005-10-31 | restructuring | in_progress | 600 | 2006-10-31 | Global | Corporate infrastructure (finance, IT, workplace services) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY05 Plan targets about 1,300 infrastructure jobs; approximately 600 employees notified by 2005-10-31, remaining 700 to be notified during fiscal 2006. Announced during fiscal Q4 2005 (exact date not disclosed). FY05 Plan total workforce charge of $96 million for fiscal 2005 is not allocated between sub-components. | |||
| 2005-10-31 | restructuring | in_progress | 900 | 2006-10-31 | United States, Germany, Japan, United Kingdom | Semiconductor Test Solutions and Electronic Measurement | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | All approximately 900 segment positions notified by 2005-10-31; semiconductor test reductions focused in the U.S., Germany and Japan, electronic measurement reductions in the U.S. and U.K. FY05 Plan total workforce charge of $96 million for fiscal 2005 covers both sub-components. | |||
| 2005-10-31 | restructuring | completed | 16,300 | 2005-06-30 | Global | All segments | USD 10 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Headcount is cumulative through fiscal year-end across the 2001-2003 plans, not fiscal 2005-only; workforce-reduction portion completed mid-2005. Charge shown is the fiscal 2005 workforce-reduction charge only (Prior Plans total fiscal 2005 charge was $27 million including $10 million facilities and $7 million impairment). | ||
| 2005-10-31 | plant_closure | in_progress | 2010-10-31 | United States, South Korea, Japan, United Kingdom and other countries | All segments | USD 10 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Approximately 116 production, support and sales facilities exited (over 4.6 million square feet, about 24% of worldwide property) is cumulative through fiscal year-end; charge shown is the fiscal 2005 lease-termination charge. Facility portion expected to complete within five years; no affected-employee count disclosed. | |||
| 2005-10-31 | divestiture_reduction | completed | 6,500 | 2005-08-14 | 2005-12-01 | Asia, United States, Europe | Semiconductor Products business (discontinued operation) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Approximately 6,500 regular employees transferred with the divestiture, completed after fiscal year-end. About 200 general infrastructure and shared services employees were expected to move to the divested business in 2006. | ||
| 2005-10-31 | divestiture_reduction | announced | 1,600 | 2005-08-15 | 2006-10-31 | Global | Semiconductor Test Solutions (SOC, SIP and memory test) | Item_1_Business f5-10k / MiMo-V2.6-Flash-fp8-HTML | Planned spin-off via IPO rather than a headcount reduction; affected count equals segment headcount at 2005-10-31. Expected completion by end of fiscal 2006. | ||
| 2005-10-31 | divestiture_reduction | completed | 2005-08-12 | 2005-11-28 | Global | Lumileds joint venture (47% interest) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of Agilent's Lumileds stake to Philips completed after fiscal year-end; no employee count disclosed for the joint venture. | |||
| 2005-10-31 | restructuring | in_progress | 1,500 | 2005-10-31 | 2006-10-31 | Global | Infrastructure and Business Segments | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | FY05 Plan initiated in Q4 2005. Includes ~600 infrastructure employees notified by year-end and ~900 segment employees notified by year-end. Total estimated reduction is ~1,500. Completion expected by end of fiscal 2006. | ||
| 2005-10-31 | divestiture_reduction | completed | 6,500 | 2005-08-15 | 2005-12-31 | Global | Semiconductor Products | subsequent_events f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Sale of semiconductor products business to Avago completed in December 2005. Divestiture includes approximately 6,500 regular employees. | ||
| 2005-10-31 | restructuring | in_progress | 1,300 | 2005-10-31 | 2006-10-31 | Global | Infrastructure | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | FY05 Plan: Reduce infrastructure-related employment by about 1,300 jobs. As of Oct 31, 2005, 600 notified; 700 expected in FY2006. | ||
| 2005-10-31 | restructuring | completed | 900 | 2005-10-31 | 2005-10-31 | Global | Semiconductor Test Solutions; Electronic Measurement | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | FY05 Plan: Job reductions within business segments. All 900 notified as of Oct 31, 2005. | ||
| 2005-10-31 | divestiture_reduction | completed | 6,500 | 2005-12-01 | 2005-12-01 | Global | Semiconductor Products | Item_7_MD&A f5-10k / Qwen3.6-27B-Q8_0 | Sale of semiconductor products business to Avago completed Dec 2005. Includes approx 6,500 regular employees. | ||
| 2005-07-31 | restructuring | in_progress | Global | Enterprise (plans announced 2001, 2002, 2003) | USD 54 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Total charge for nine months ended July 31, 2005; workforce reduction accrual balance was $25M at quarter-end, expected to be paid within 12 months. Substantially all workforce actions under prior plans completed; facility consolidation charges continue for five years. No employee counts disclosed. | ||||
| 2005-07-31 | voluntary_separation | in_progress | Global | Test and Measurement | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Voluntary Severance Program disclosed alongside traditional workforce reductions in test and measurement; no participant count or separate charge disclosed | |||||
| 2005-07-31 | restructuring | announced | 2005-08-15 | 2006-10-31 | Global | Corporate infrastructure | USD 200 (millions) | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan to cut infrastructure costs by more than $450M and about 1,300 infrastructure jobs via transfers, attrition and workforce reductions; also eliminates approximately 11 facilities, primarily tied to the semiconductor products sale. Implementation costs may be offset by asset sale proceeds; facility consolidation charges still under evaluation. Substantially complete by end of fiscal 2006. | ||
| 2005-07-31 | divestiture_reduction | announced | 2005-08-14 | 2005-10-31 | Global | Semiconductor Products | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreement to sell semiconductor products business to Argos Acquisition Pte. Ltd. for $2.66B, subject to adjustment and antitrust approvals; expected to close around fiscal year-end. No headcount disclosed; segment had net assets of $556M at July 31, 2005. Company will retain designated tax, environmental and warranty contingencies. | |||
| 2005-07-31 | divestiture_reduction | announced | 2005-08-12 | Global | Lumileds Lighting joint venture | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of Agilent's Lumileds stake to Philips for $948.5M plus repayment of about $51M debt; joint venture agreements terminate at closing. Carrying value of investment was about $40M at July 31, 2005. Subject to antitrust approval; no headcount disclosed. | ||||
| 2005-07-31 | divestiture_reduction | announced | 2005-08-15 | 2006-10-31 | Global | Automated Test — SOC and memory test businesses | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Planned spin-off of SOC and memory test businesses as soon as practical in fiscal 2006; considering IPO of about 19% followed by distribution of remaining 81% to shareholders. Businesses had $192M revenue in Q3 FY2005, of which SOC and memory test was about 60%. No headcount disclosed. | |||
| 2005-07-31 | restructuring | in_progress | 2005-08-15 | 2006-10-31 | Global | Infrastructure | USD 200 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Announced plan to reduce infrastructure costs by >$450M and infrastructure-related employment by about 1,300 jobs. Includes ~$200M implementation costs. Substantially complete by end of fiscal 2006. | ||
| 2005-07-31 | voluntary_separation | in_progress | Test and Measurement | Test and Measurement | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Workforce reduction charges relating to a Voluntary Severance Program in the test and measurement business. | |||||
| 2005-04-30 | restructuring | in_progress | Global | Enterprise | USD 13 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Covers the 2001 Plan and 2003 Plan, both winding down; charge is for the six months ended April 30, 2005 (three-month charge was $6 million). No employee counts disclosed; includes workforce reduction, excess facility consolidation and asset impairment components. Severance-type payments expected primarily within the next two quarters; lease payments over the next 5 years. | ||||
| 2005-04-30 | divestiture_reduction | completed | 2005-02-03 | 2005-02-03 | Global | Semiconductor Products (camera module business) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of camera module business completed February 3, 2005; historical segment amounts restated to exclude it. No headcount associated with the divestiture disclosed. | |||
| 2005-04-30 | plant_closure | completed | United States (Rohnert Park, California) | Manufacturing | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Manufacturing site sold during the quarter ended April 30, 2005; site had been previously impaired under the 2003 Plan. A $10 million gain was recorded in cost of products and services. No employee count disclosed. | |||||
| 2005-04-30 | restructuring | announced | Asia / United Kingdom | Semiconductor Products (navigation business; UK R&D site) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Company is moving its navigation business to Asia and closing a research and development site in the United Kingdom; no headcount figures or timing disclosed. | |||||
| 2005-04-30 | restructuring | in_progress | Asia | Automated Test | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Automated test divisions being combined for efficiencies; management and R&D project teams plus a significant portion of outsourced manufacturing test moving to Asia. No headcount figures disclosed. | |||||
| 2005-04-30 | restructuring | in_progress | USD 13 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Total charge of $13 million for the six months ended April 30, 2005, relating to the '2001 Plan' and '2003 Plan'. Plans are winding down; workforce reduction charges expected to continue for announced but not completed plans. | ||||||
| 2005-04-30 | plant_closure | completed | Rohnert Park, California | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Sold a manufacturing site previously impaired under the 2003 Plan. Recorded a gain of $10 million. | ||||||
| 2005-04-30 | plant_closure | in_progress | United Kingdom | Semiconductor Products | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Closing a research and development site in the United Kingdom. | |||||
| 2005-01-31 | restructuring | in_progress | 2005-10-31 | USD 6 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Covers the 2001 Plan and 2003 Plan wind-down; workforce reduction charge of $6M in the quarter (total restructuring and asset impairment charge $7M including $1M asset impairment). No employee counts disclosed; further workforce reduction charges expected through fiscal 2005, with lease payments over the next 5 years. Severance accrual balance was $12M at January 31, 2005. | |||||
| 2005-01-31 | divestiture_reduction | completed | 2004-10-27 | 2005-02-03 | Semiconductor Products | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale of the camera module business to Flextronics completed February 3, 2005; business represented about 15% of the segment's fiscal 2004 orders and revenue. No headcount impact disclosed; Agilent remains in the image sensor business. | ||||
| 2005-01-31 | voluntary_separation | announced | 1 | 2005-03-08 | 2005-04-01 | United States | Semiconductor Products | USD 1 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Settlement with Young K. Sohn, SVP and President of the Semiconductor Products Group, providing severance of $1,083,750 (18 months of base plus target short-term incentive) on voluntary termination; Dick Chang to lead the group on an interim basis. | |
| 2005-01-31 | restructuring | in_progress | 2001-10-01 | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Activity related to 2001 Plan and 2003 Plan. Total charge of $7 million recorded in Q1 2005. Key actions executed, plans winding down. Lease payments expected over next 5 years. | |||||
| 2004-10-31 | restructuring | in_progress | 5,800 | 2003-02-21 | 2005-06-30 | Primarily U.S. operations | All businesses; significant reductions in test and measurement and semiconductor products | USD 101 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Headcount is cumulative under the plan through fiscal 2004 (plan originally announced about 4,000 additional job cuts). FY2004 plan charges totaled $154M, of which $101M was workforce reduction (captured here); the remainder was $28M excess-facility consolidation and $25M asset impairment (see separate plant-closure record). Cumulative plan cost $462M through Oct 31, 2004; substantially complete with residual charges expected in H1 fiscal 2005; plan restructuring accrual was $44M at fiscal year-end. | |
| 2004-10-31 | plant_closure | in_progress | 2004 | California, United States | Test and Measurement (primarily) | USD 25 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Exit of a manufacturing site announced during fiscal Q2 2004 (Feb–Apr 2004); FY2004 asset impairment of $25M primarily related to this site (within the 2003 Plan's FY2004 charges — do not sum with the plan's $101M workforce charge). Additional impairment possible upon sale of the site; affected headcount not disclosed. | |||
| 2004-10-31 | restructuring | completed | 2,500 | 2002-08-19 | All regions | Primarily test and measurement (wireline manufacturing/field operations) and semiconductor products; also IT support services | USD 0 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Plan complete as of fiscal 2004. The 2,500-employee reduction was executed in fiscal 2002–2003; no new charges in FY2004, only $14M of residual severance cash payments. Cumulative plan cost $166M through Oct 31, 2004. | ||
| 2004-10-31 | restructuring | completed | 2001 | U.S., Korea, Japan, U.K. and other countries (facility exits) | Primarily test and measurement and semiconductor products; support-services reductions across all businesses | USD 7 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Initiated in fiscal Q4 2001 (Aug–Oct 2001); all key actions executed; no separate headcount disclosed for this plan. FY2004 activity was $7M of net charges from consolidating excess facilities (reduced estimated sublease income) — no workforce charges in FY2004. Cumulative plan cost $533M through Oct 31, 2004. Across all three plans, the company exited more than 115 production, support and sales facilities (over 4.6 million square feet, about 24% of worldwide property). | |||
| 2004-10-31 | acquisition_addition | completed | 2004-10-28 | Life Sciences and Chemical Analysis | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquisition of Silicon Genetics (life-science software) completed October 2004; about 772 thousand shares (~$18M) issued as consideration and ~$16M goodwill added in the Life Sciences segment. Acquired headcount not disclosed. One of three FY2004 acquisitions, all described by the filer as not significant. | |||||
| 2004-10-31 | divestiture_reduction | in_progress | 2004 | Semiconductor Products (camera module business) | MD&A f5-10k / GLM-5.3-flash-HTML | Agreement reached in fiscal Q4 2004 (Aug–Oct 2004) to sell camera-module inventory and fixed assets; sale pending as of the December 2004 filing date. Agilent will retain image-sensor intellectual property and continue selling image sensors but will cease producing assembled modules. Affected headcount not disclosed; FY2004 camera-module revenue was ~$300M and FY2004 included a $20M inventory charge related to this business. | |||||
| 2004-10-31 | restructuring | in_progress | 5,800 | 2003-02-21 | Primarily United States | All businesses, with significant reductions in Test and Measurement and Semiconductor Products | USD 154 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Cumulative through fiscal year-end 2004 (plan announced Feb 2003; total plan cost $462M, of which $308M in FY2003 and $154M in FY2004). FY2004 charges comprise $101M workforce reduction, $28M excess-facility consolidation and $25M asset impairment (California manufacturing site). Restructuring accrual for all plans was $87M at 2004-10-31. | ||
| 2004-10-31 | plant_closure | in_progress | 2001-10-31 | United States, Korea, Japan, United Kingdom and other countries | All segments — production, support and sales facilities | USD 7 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Cumulative through fiscal year-end 2004: more than 115 facilities exited representing over 4.6 million sq ft (~24% of worldwide property); total plan cost $533M ($154M in 2001, $357M in 2002, $15M in 2003, $7M in 2004). All key actions executed; lease payments continue over next five years. FY2004 charge reflects reduced sublease income estimates. | |||
| 2004-10-31 | restructuring | completed | 2002-08-19 | 2004-10-31 | All regions | Manufacturing and field operations serving wireline markets (Test and Measurement) and IT support services | USD 0 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Plan complete; no charges recorded in FY2004. Announced intention to reduce workforce by 2,500 to reach ~$1.6B quarterly operating cost structure. Cumulative plan cost $166M ($117M in 2002, $49M in 2003). | ||
| 2004-10-31 | divestiture_reduction | announced | 2004-10-27 | Not specified | Semiconductor Products — camera module business | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Agreement dated 2004-10-27 with Flextronics Sales and Marketing (A-P) Ltd. to sell inventory and fixed assets of the camera module business (~$300M of 2004 revenue). Agilent retains image sensor IP and R&D. Not expected to materially affect 2005 operating profits; no employee count disclosed. | ||||
| 2004-10-31 | acquisition_addition | completed | 2004-10-28 | 2004-10-28 | Not specified | Life Sciences and Chemical Analysis — software and informatics | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquired Silicon Genetics; 771,573 shares of Agilent common stock issued (approx. $18M value) as consideration. Adds GeneSpring, Varia and GeNet products. No employee count disclosed; acquisition immaterial to consolidated results. | |||
| 2004-10-31 | acquisition_addition | completed | Not specified | Automated Test — flat panel display test business | MD&A f5-10k / MiMo-V2.6-Flash-fp8-HTML | Entered the flat panel display test market through acquisition of IBM's flat panel display business during FY2004. No announcement date or employee count disclosed; three acquisitions in 2004 were immaterial individually and in aggregate. | |||||
| 2004-10-31 | restructuring | completed | 2001-10-01 | Worldwide | All segments | USD 7 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2001 Plan. Key actions executed. $7 million in net charges recorded in 2004 primarily due to reductions in estimated sublease income. | |||
| 2004-10-31 | restructuring | completed | 2002-10-01 | Worldwide | All segments | USD 0 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2002 Plan. Complete. No charges in 2004. | |||
| 2004-10-31 | restructuring | in_progress | 2003-02-21 | Worldwide | All segments | USD 154 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2003 Plan. $154 million in charges recorded in 2004 ($101M workforce, $25M asset impairment, $28M facility consolidation). Plan substantially complete. | |||
| 2004-10-31 | restructuring | completed | 2001-10-01 | Global | All segments | USD 7 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 2001 Plan. Key actions executed. $7 million in net charges/adjustments recorded in FY2004 primarily for facility consolidation. | |||
| 2004-10-31 | restructuring | completed | 2002-10-01 | Global | All segments | USD 0 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 2002 Plan. Complete. No charges recorded in FY2004. | |||
| 2004-10-31 | restructuring | in_progress | 2003-02-21 | 2005-04-30 | Global | All segments | USD 154 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 2003 Plan. $154 million total charge in FY2004 ($101M workforce, $28M facilities, $25M asset impairment). Substantially complete, with further costs expected in first half of FY2005. | ||
| 2004-07-31 | restructuring | in_progress | 5,600 | 2003-02-21 | Primarily United States | All segments; reductions concentrated in Test and Measurement and Semiconductor Products, plus support functions | USD 100 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Employee count is cumulative since the February 2003 announcement, not a quarterly figure. Plan described as substantially complete with additional charges expected in Q4 2004. Nine-month charge of $100M comprises $70M workforce reduction, $14M excess facilities, $16M asset impairment. Restructuring accrual for all plans was $75M at July 31, 2004. | ||
| 2004-07-31 | plant_closure | in_progress | Kobe, Japan | Production facility (2001 Plan — consolidation of excess facilities) | USD 7 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Nine months ended July 31, 2004 additional charge primarily related to sale of the Kobe production facility; no employee count disclosed. 2001 Plan accrual balance was $52M at July 31, 2004 with lease payments continuing over the next five years. | ||||
| 2004-07-31 | restructuring | in_progress | 2001-10-01 | Global | Test and Measurement; Semiconductor Products | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2001 Plan. Key actions executed. Additional $7M charge in nine months ended July 31, 2004 primarily relating to sale of production facility in Kobe, Japan. Lease payments continue over next five years. | |||
| 2004-07-31 | restructuring | completed | 2002-10-01 | Global | Test and Measurement; Semiconductor Products; IT Support | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2002 Plan. Target workforce reduction of 2,500 achieved as of July 31, 2004. Plan is complete. Zero charges in 2004. | |||
| 2004-07-31 | restructuring | in_progress | 2003-02-21 | Global | All Businesses | USD 100 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2003 Plan. Announced Feb 21, 2003. Workforce reduced by approx 5,600 as of July 31, 2004. Total charges for nine months ended July 31, 2004 were $100M ($70M workforce, $14M facilities, $16M asset impairment). Plan substantially complete, additional charges expected in Q4. | |||
| 2004-04-30 | restructuring | in_progress | 5,200 | 2003-02-21 | Primarily United States | All businesses; significant reductions in test and measurement and semiconductor products groups | USD 58 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced intent to cut about 4,000 jobs; actual reduction approximately 5,200 as of April 30, 2004. Charge of $58M is the six months ended April 30, 2004 total ($46M workforce, $8M facilities, $4M asset impairment); cumulative plan cost $366M. Expected $125M quarterly cost reduction already realized; further charges expected through 2004, completion date not disclosed. | ||
| 2004-04-30 | restructuring | in_progress | United States, Korea, Japan, United Kingdom and other countries | Test and measurement and semiconductor products groups, plus shared support services | USD 7 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan initiated in fiscal Q4 2001; exact announcement date not disclosed. Key actions executed; remaining activity is excess-facility consolidation. Charge is the six months ended April 30, 2004 adjustment for reduced expected sublease income. Cumulative plan cost $533M; lease payments continue for about five years. | ||||
| 2004-04-30 | restructuring | completed | 2,500 | 2002-08-19 | All regions | Manufacturing and field operations serving wireline markets within test and measurement, plus information technology support services | USD 0 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan complete; no charges recorded in fiscal 2004. Cumulative plan cost $166M; remaining $14M accrual paid down to zero during the six months ended April 30, 2004. | ||
| 2004-04-30 | plant_closure | announced | Rohnert Park, California, United States | Test and Measurement (manufacturing site) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced during the second quarter of fiscal 2004 (exact date not disclosed); production to be transferred to other company sites. Filer anticipates further asset impairment charges but does not quantify them or disclose affected-employee counts. | |||||
| 2004-04-30 | restructuring | in_progress | 2001-10-01 | Global | Test and Measurement; Semiconductor Products | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2001 Plan. Additional $7 million charge recorded in six months ended April 30, 2004 due to reductions in estimate of expected sublease income. | |||
| 2004-04-30 | restructuring | completed | 2002-10-01 | Global | Test and Measurement; Semiconductor Products | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2002 Plan. Plan is complete. Zero charge in 2004. | |||
| 2004-04-30 | restructuring | in_progress | 2003-02-21 | Global | All segments | USD 58 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2003 Plan. Total charge of $58 million for six months ended April 30, 2004, comprising $46 million workforce reduction, $8 million consolidation of excess facilities, and $4 million asset impairment. | |||
| 2004-01-31 | restructuring | in_progress | United States, Korea, Japan, United Kingdom and other countries | Primarily Test and Measurement and Semiconductor Products; support services across all businesses | USD 7 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | 2001 Plan initiated in fiscal Q4 2001; cumulative cost through 2004-01-31 was $533 million. All key actions executed, but facility consolidation continues with lease payments over the next five years. Q1 FY04 charge of $7 million reflected a reduction in estimated sublease income. Cumulative workforce reduction across all three plans was approximately 16,000 people (approximately 14,400 involuntary and approximately 1,600 net attrition). | ||||
| 2004-01-31 | restructuring | completed | 2,500 | 2002-08-19 | All regions | Manufacturing and field operations serving wireline markets within Test and Measurement; information technology support services | USD 0 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced intention to reduce workforce by 2,500 to reach a quarterly operating cost structure of approximately $1.6 billion. Approximately 2,500 positions reduced as of 2004-01-31 (cumulative since announcement, not quarterly). Plan described as substantially complete; no charge recorded in Q1 FY04. Cumulative cost through 2004-01-31 was $166 million. | ||
| 2004-01-31 | restructuring | in_progress | 5,000 | 2003-02-21 | Primarily United States | All businesses, with significant reductions in Test and Measurement and Semiconductor Products; research and development and support functions | USD 38 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced workforce reduction of approximately 4,000 jobs in addition to prior cuts, targeting quarterly operational costs of $1.45 billion. Approximately 5,000 positions reduced as of 2004-01-31 (cumulative since announcement, not quarterly). Q1 FY04 charge of $38 million comprised $31 million workforce reduction, $4 million facility consolidation and $3 million asset impairment. Cumulative cost through 2004-01-31 was $346 million. Company reports achieving its $1.4 billion quarterly operating cost target three quarters early. | ||
| 2004-01-31 | plant_closure | in_progress | United States, Korea, Japan, United Kingdom and other countries | Production, support and sales facilities across all segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | More than 110 production, support and sales facilities exited, representing more than 3.8 million square feet (about 20 percent of worldwide property). Cumulative across all plans, not a quarterly figure; lease payments continue over the next five years. Restructuring accrual was $94 million at 2004-01-31 versus $89 million at 2003-10-31. | |||||
| 2004-01-31 | restructuring | in_progress | 2001-10-01 | Global | Test and Measurement; Semiconductor Products | USD 7 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2001 Plan. Charge due to reductions in estimate of expected sublease income. Plan substantially complete but lease payments continue. | |||
| 2004-01-31 | restructuring | completed | 2002-10-01 | Global | Test and Measurement; Semiconductor Products | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2002 Plan. Substantially complete. No charges in Q1 2004. | |||
| 2004-01-31 | restructuring | in_progress | 2003-02-21 | Global | All segments | USD 38 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2003 Plan. Includes $31M workforce reduction, $4M facility consolidation, $3M asset impairment. Cumulative reduction of approx 5,000 jobs as of Jan 31, 2004. | |||
| 2003-10-31 | restructuring | completed | 8,400 | 2001 | Primarily test and measurement and semiconductor products; support-services reductions across all businesses | USD 526 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Cumulative through fiscal year-end since plan initiation in fiscal Q4 2001; risk-factor narrative separately cites approximately 8,000 positions announced in calendar 2001. Total cost of $526 million through October 31, 2003, of which $15 million was recorded in FY2003, primarily facility-consolidation adjustments. All key actions executed; lease payments on exited space continue for up to five years. Workforce reduction charges were $117 million (FY2001) and $175 million (FY2002). | |||
| 2003-10-31 | restructuring | in_progress | 2,400 | 2002-08-19 | 2004-01-31 | All regions | Manufacturing and field operations serving wireline markets (primarily test and measurement) and information technology support services; most segments affected | USD 166 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Plan announced targeting 2,500 positions to reach a ~$1.6 billion quarterly cost structure; approximately 2,400 reduced as of October 31, 2003 (cumulative through fiscal year-end). Total cost of $166 million, including $49 million recorded in FY2003 (workforce charges of $83 million in FY2002 and $44 million in FY2003). Filer describes the plan as substantially complete, with completion expected by fiscal Q1 2004 (quarter ending January 31, 2004). | |
| 2003-10-31 | restructuring | in_progress | 4,300 | 2003-02-21 | Primarily United States | All businesses; largest reductions in test and measurement and semiconductor products, plus production facilities, support services and R&D | USD 308 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Announced reduction of approximately 4,000 jobs to reach a $1.45 billion quarterly cost structure; approximately 4,300 reduced as of October 31, 2003. FY2003 charge of $308 million comprises $238 million workforce reduction, $13 million excess-facility consolidation and $57 million asset impairment ($234 million of workforce severance paid in cash during FY2003). Plan still being implemented; further costs expected in the first half of fiscal 2004, with the expected $125 million quarterly cost reduction already being realized. | ||
| 2003-10-31 | plant_closure | in_progress | U.S., Korea, Japan, U.K. and other countries | Production, support and sales facilities | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Cumulative across the 2001, 2002 and 2003 restructuring plans: more than 110 production, support and sales facilities exited or planned for exit, representing more than 4.3 million square feet (about 22 percent of worldwide property); approximately 90 percent vacated as of October 31, 2003, with lease payments continuing for up to five years. Facility-consolidation charges (e.g., $13 million in FY2003 under the 2003 Plan) are included in the plan-level charges reported above. Includes a U.K. production facility closed in fiscal Q3 2003, with a related $27 million impairment driven by the U.K. property market decline. | |||||
| 2003-10-31 | restructuring | completed | 8,400 | 2001 | Global | Primarily test and measurement and semiconductor products; all support functions | USD 15 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Cumulative program: 8,400 jobs reduced since inception; FY2003 charge of $15M is the current-year portion of $526M cumulative cost. All key actions executed; lease payments continue through 2008. | ||
| 2003-10-31 | restructuring | in_progress | 2,400 | 2002-08-19 | 2004-03-31 | Global | Manufacturing and field operations serving wireline markets (test and measurement); IT support services | USD 49 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | 2,500 announced; 2,400 reduced as of 2003-10-31 (cumulative since Aug 2002 announcement). FY2003 charge of $49M is current-year portion of $166M cumulative cost. Target: $1.6B quarterly operating cost structure. | |
| 2003-10-31 | restructuring | in_progress | 4,300 | 2003-02-21 | Primarily United States | All businesses, with significant reductions in test and measurement and semiconductor products; R&D and support functions | USD 308 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Approximately 4,000 announced; 4,300 reduced as of 2003-10-31. Charge comprises $238M workforce, $13M facilities, $57M asset impairment. Target: $1.45B quarterly operational costs; further charges expected in first half of 2004. | ||
| 2003-10-31 | plant_closure | in_progress | United States, Korea, Japan, United Kingdom and other countries | Production, support and sales facilities across all segments | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | More than 110 facilities exited or planned for exit, representing over 4.3 million square feet (~22% of worldwide property); approximately 90% vacated as of 2003-10-31, with lease payments continuing for up to five years. No separate employee count disclosed for closures. | |||||
| 2003-10-31 | other | completed | 7,000 | 2003-10-31 | Global | Company-wide | Item_1_Business f5-10k / MiMo-V2.6-Flash-fp8-HTML | Approximately 7,000 employees left the company during FY2003 (including ~1,000 in Q4), encompassing workforce reductions, attrition, divestitures and other departures; overlaps with the restructuring plans above. | |||
| 2003-10-31 | restructuring | completed | 8,400 | 2001-10-01 | Worldwide | All segments | USD 154 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2001 Plan: Announced in Q4 2001. Reduced workforce by approximately 8,400 jobs. Total cost through Oct 31, 2003 was $526 million, with $154 million charged in 2001. Key actions executed. | ||
| 2003-10-31 | restructuring | completed | 2,400 | 2002-08-19 | 2004-01-31 | Worldwide | Test and Measurement, Semiconductor Products, IT Support | USD 117 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2002 Plan: Announced Aug 19, 2002. Reduced workforce by approx 2,400 as of Oct 31, 2003. Total cost through Oct 31, 2003 was $166 million, with $117 million charged in 2002. Substantially complete. | |
| 2003-10-31 | restructuring | in_progress | 4,300 | 2003-02-21 | Worldwide | All segments | USD 308 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2003 Plan: Announced Feb 21, 2003. Reduced workforce by approx 4,300 as of Oct 31, 2003. Total cost through Oct 31, 2003 was $308 million. Still being implemented. | ||
| 2003-10-31 | restructuring | completed | 13,400 | 2001-10-01 | 2003-10-31 | Global | All segments | USD 372 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | Cumulative involuntary terminations of approx. 13,400 people across 2001, 2002, and 2003 plans. Total restructuring charges for FY2003 were $372 million. | |
| 2003-10-31 | restructuring | completed | 4,300 | 2003-02-21 | 2003-10-31 | Global | Test and Measurement, Semiconductor Products | USD 308 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | 2003 Plan announced Feb 21, 2003. Reduced workforce by approx. 4,300 as of Oct 31, 2003. Cost of plan was $308 million. | |
| 2003-10-31 | restructuring | completed | 2,400 | 2002-08-19 | 2003-10-31 | Global | Test and Measurement, Semiconductor Products | USD 166 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | 2002 Plan announced Aug 19, 2002. Reduced workforce by approx. 2,400 as of Oct 31, 2003. Cost of plan through Oct 31, 2003 was $166 million. | |
| 2003-10-31 | restructuring | completed | 8,400 | 2001-10-01 | 2003-10-31 | Global | Test and Measurement, Semiconductor Products | USD 526 (millions) | Item_1_Business f5-10k / Qwen3.6-27B-Q8_0 | 2001 Plan announced Q4 2001. Reduced workforce by approx. 8,400 jobs. Cost of plan through Oct 31, 2003 was $526 million. | |
| 2003-07-31 | restructuring | in_progress | 3,400 | 2003-02-21 | 2003-10-31 | Global (primarily United States) | All businesses; significant reductions in test and measurement and semiconductor products, including research and development | USD 255 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan announced a workforce reduction of approximately 4,000 jobs; approximately 3,400 reduced as of July 31, 2003. Total charge of $255 million through July 31, 2003 includes $196 million workforce reduction, $7 million excess-facility consolidation and $52 million asset impairments. Company expects to fully achieve the $125 million quarterly cost reduction by end of fiscal 2003. Approximately 2,400 people left the company during the third quarter of 2003. | |
| 2003-07-31 | restructuring | in_progress | 2,200 | 2002-08-19 | Global (all regions) | Manufacturing and field operations serving wireline markets within test and measurement; information technology support services | USD 160 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Plan announced a reduction of 2,500 jobs to reach a quarterly operating cost structure of approximately $1.6 billion; approximately 2,200 reduced as of July 31, 2003. Charge of $160 million total through July 31, 2003 ($117 million in fiscal 2002, $43 million in fiscal 2003). MD&A states significantly all savings have been achieved but the plan is not yet complete. | ||
| 2003-07-31 | plant_closure | in_progress | 300 | United Kingdom | Semiconductor Products (fabrication facility; production transferred to Singapore) | USD 33 (millions) | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Additional restructuring action announced during the third quarter of fiscal 2003: closure of a U.K. fabrication facility eliminating approximately 300 jobs, with production transferred to Singapore and the site in sale negotiations. Note 11 discloses a $33 million impairment on the U.K. property in the third quarter (an asset impairment within the 2003 Plan's $52 million impairment total). Exact announcement date not disclosed; incremental savings expected in fiscal Q4 2003 and fiscal Q1 2004. The 300 positions may be included within the 3,400 reductions reported under the 2003 Plan. | |||
| 2003-07-31 | restructuring | completed | 8,400 | 2001 | 2002-10-31 | Global (U.S., Korea, Japan, U.K. and other countries) | Primarily test and measurement and semiconductor products; manufacturing, selling, general and administrative functions | USD 527 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Workforce reduction of approximately 8,400 jobs substantially completed by the end of fiscal 2002; MD&A states the plan is complete and continues to deliver approximately $300 million per quarter in savings. Charge of $527 million total through July 31, 2003 ($154 million in 2001, $357 million in 2002, $16 million in fiscal 2003). Company continues facility consolidation, having exited or planned to exit more than 100 facilities (about 21 percent of worldwide property), with approximately 72 percent of that space vacated as of July 31, 2003; lease payments expected through at least the next 5 years. | |
| 2003-07-31 | restructuring | in_progress | 14,000 | 2001-10-01 | Global | All segments | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Cumulative reduction of approximately 14,000 people across 2001, 2002, and 2003 plans as of end of Q3 2003. Includes ~12,500 involuntary terminations and ~1,500 net attrition. | |||
| 2003-07-31 | restructuring | in_progress | 8,400 | 2001-10-01 | Global | Test and Measurement, Semiconductor Products | USD 527 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2001 Plan: Reduced workforce by approx. 8,400 jobs. Total cost through July 31, 2003 was $527 million. | ||
| 2003-07-31 | restructuring | in_progress | 2,200 | 2002-08-19 | Global | Test and Measurement, IT Support | USD 160 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2002 Plan: Reduced workforce by approx. 2,200 as of July 31, 2003. Total cost through July 31, 2003 was $160 million. | ||
| 2003-07-31 | restructuring | in_progress | 3,400 | 2003-02-21 | Primarily U.S. | Test and Measurement, Semiconductor Products, R&D | USD 255 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2003 Plan: Reduced workforce by approx. 3,400 as of July 31, 2003. Total cost through July 31, 2003 was $255 million. | ||
| 2003-07-31 | plant_closure | completed | 300 | 2003-07-31 | United Kingdom | Semiconductor Products | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Closure of fabrication facility in U.K., eliminating approx. 300 jobs. Production transferred to Singapore. | |||
| 2003-04-30 | restructuring | in_progress | 8,100 | 2001-10-31 | 2003-07-31 | Global (U.S., Korea, Japan and other countries) | Primarily Test and Measurement and Semiconductor Products; support functions across all segments | USD 8 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Cumulative program headcount reduction since fiscal 2001, not a current-quarter figure; $8M charge in fiscal 2003 to date ($519M cumulative). Includes exit of 100+ facilities (~4.0M sq ft, ~21% of worldwide property; ~70% vacated at 4/30/03). ~$13M severance for ~300 employees at one U.S. facility remains unpaid; announcement date approximate (initiated fiscal Q4 2001). | |
| 2003-04-30 | restructuring | in_progress | 2,100 | 2002-08-19 | 2003-10-31 | Global (all regions) | Manufacturing and field operations serving wireline markets within Test and Measurement; IT support services | USD 43 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Target was 2,500 job cuts to reach ~$1.6B quarterly operating cost structure; 2,100 reduced as of 4/30/03. Charge is fiscal 2003 to date ($160M cumulative). Company anticipates a further ~700-person reduction by end of fiscal Q4 2003. | |
| 2003-04-30 | restructuring | in_progress | 1,500 | 2003-02-21 | 2003-10-31 | Primarily United States; global | All businesses, with significant reductions in Test and Measurement and Semiconductor Products, including R&D and support functions | USD 122 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced ~4,000 job cuts to cut quarterly operational costs by $125M; 1,500 reduced as of 4/30/03. Charge covers plan inception (Jan 31, 2003) through 4/30/03. Across all plans, company anticipates an additional ~3,500-person reduction through the first half of fiscal 2004 (overlaps remaining 2002/2003 plan targets — do not sum). | |
| 2003-04-30 | plant_closure | completed | 2003-04-30 | 2003-04-30 | Newark, California, United States | Semiconductor Products | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Production ceased and facility closed at the end of the second quarter; expected operating cost reduction of ~$6M per quarter from fiscal 2003 second half onward. Employees affected not disclosed. | |||
| 2003-04-30 | restructuring | in_progress | 2001-10-01 | Global | Test and Measurement, Semiconductor Products, Support Services | USD 8 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiated Q4 2001. Total cost through Apr 30, 2003 was $519M. Q2 2003 charge of $8M related to facility consolidation and asset impairments. Workforce reduction of ~8,100 jobs substantially complete. | |||
| 2003-04-30 | restructuring | in_progress | 2002-08-19 | 2003-10-31 | Global | Test and Measurement, IT Support Services | USD 43 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiated Q4 2002. Targeted 2,500 job cuts; ~2,100 reduced as of Apr 30, 2003. Anticipate another 700-person reduction by end of Q4 2003. YTD 2003 charge of $43M. | ||
| 2003-04-30 | restructuring | in_progress | 1,500 | 2003-02-21 | Global (primarily U.S.) | Test and Measurement, Semiconductor Products, R&D, Support Services | USD 122 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Initiated Q1 2003. Announced 4,000 job cuts; ~1,500 reduced as of Apr 30, 2003. YTD 2003 charge of $122M. Includes facility consolidation and asset impairments. | ||
| 2003-01-31 | restructuring | in_progress | 8,000 | 2001-01-01 | 2003-07-31 | Global (U.S., Korea, Japan facility exits) | Primarily test and measurement and semiconductor products; support services across all segments | USD 511 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Cumulative cost through 2003-01-31 ($154M in 2001, $357M in 2002); no charge in Q1 2003. Workforce reduction of ~8,000 completed by end of Q4 2002; ~$17M severance for ~400 employees at two U.S. facilities remains unpaid, expected complete by Q3 FY2003. Facility exits cover >3.6M sq ft (~19% of worldwide property), ~60% vacated as of quarter end. | |
| 2003-01-31 | restructuring | in_progress | 2,500 | 2002-08-19 | 2003-07-31 | Global (all regions) | Manufacturing and field operations serving wireline markets within test and measurement; information technology support services | USD 42 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Q1 FY2003 charge of $42M ($37M workforce reduction, $5M asset impairment); cumulative cost $159M ($117M in 2002, $42M in 2003). Approximately 1,000 of the 2,500 positions reduced as of 2003-01-31; remaining savings expected by mid-2003. Target: $50M quarterly operational cost reduction at $1.6B revenue. | |
| 2003-01-31 | restructuring | announced | 4,000 | 2003-02-21 | 2003-10-31 | Global | All segments; test and measurement expected to account for approximately half of savings; semiconductor products slightly less than 20% | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced 2003-02-21, after quarter close; no charges taken in Q1 2003. Targets breakeven cost structure at $1.45B quarterly revenue and $125M quarterly cost reduction by end of Q4 FY2003. | ||
| 2003-01-31 | restructuring | in_progress | 2001-10-01 | Global | Test and Measurement, Semiconductor Products, Support Services | USD 0 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2001 Plan. No charges incurred in Q1 2003. Total cost through Jan 31, 2003 is $511 million. Workforce reduced by approx 8,000 jobs previously. | |||
| 2003-01-31 | restructuring | in_progress | 1,000 | 2002-08-19 | 2003-06-30 | Global | Test and Measurement, IT Support Services | USD 42 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | 2002 Plan. Reduced workforce by approx 1,000 as of Jan 31, 2003. Total charge in Q1 2003 was $42 million (includes $5M asset impairment). Plan to reduce workforce by 2,500 total. | |
| 2003-01-31 | restructuring | announced | 4,000 | 2003-02-21 | 2003-10-31 | Global | Global | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | 2003 Plan. Announced Feb 21, 2003. Intention to reduce workforce by 4,000 jobs in addition to previously-announced cuts. No charges taken in Q1 2003. | ||
| 2002-10-31 | restructuring | completed | 7,700 | 2001-08-20 | All regions; all expense categories and most segments | Primarily test and measurement and semiconductor products, plus support services (sales and marketing, finance, administration) across all segments | USD 175 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Substantially complete as of October 31, 2002. Reduction of ~7,700 comprises ~6,400 involuntary terminations and ~1,300 net attrition; announced target was 8,000 jobs (initial announcement of ~4,000 jobs, about 9% of workforce, on August 20, 2001, expanded November 15, 2001 by an additional ~4,000). $175M is the FY2002 workforce-reduction charge; ~$210M cash severance paid in FY2002; cumulative plan charges of $511M ($154M FY2001 plus $357M FY2002); savings of approximately $880M realized in FY2002. | ||
| 2002-10-31 | plant_closure | in_progress | 2001-08-20 | All regions, particularly the U.S. and Japan | All three segments; mostly sales and administrative office space, plus a small number of production facilities consolidated into fewer sites | USD 182 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Component of the 2001 Plan; workforce reductions tracked in the parent restructuring record. Exit (completed or planned) of more than 100 production, support and sales facilities or parts of facilities, over 3.6 million square feet (~19% of worldwide property); ~40% vacated as of October 31, 2002. FY2002 charges of $182M comprise $53M facility-consolidation costs (lease terminations and anticipated sublease losses) plus $129M property, plant and equipment impairment, of which one production facility in Kobe, Japan accounted for ~$60M (~80% of that facility's net book value). Lease payments on vacated properties continue for at least the next five years. | |||
| 2002-10-31 | restructuring | in_progress | 2,500 | 2002-08-19 | 2004-01-31 | Primarily test and measurement (manufacturing and field operations serving wireline markets); related equipment impairment primarily in semiconductor products group, Singapore | USD 117 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Targets reduction of ~2,500 jobs to cut operational costs by $50M per quarter and reach profitability at quarterly revenue of ~$1.6B; only ~300 reductions completed as of October 31, 2002 (implementation began late in Q4 FY2002), with the majority of quarterly savings expected by mid-2003. FY2002 charge of $117M comprises $83M workforce-reduction (severance) charges and $34M asset impairment on machinery and equipment (equipment to be sold, research consolidated to the U.S.). Completion expected no later than fiscal first quarter 2004 (quarter ending January 31, 2004). | ||
| 2002-10-31 | restructuring | completed | 7,700 | 2001-08-20 | 2002-10-31 | Worldwide | Test and measurement; Semiconductor products; corporate and shared support services | USD 357 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Two-step program: about 4,000 announced 2001-08-20 and a further 4,000 on 2001-11-15. Actual reduction of approximately 7,700 (about 6,400 involuntary, 1,300 net attrition) cumulative through 2002-10-31. Charge shown is FY2002 only; cumulative program cost was $511M ($154M in FY2001). Substantially complete at fiscal year-end, with lease payments on vacated properties continuing at least five more years. | |
| 2002-10-31 | restructuring | in_progress | 2,500 | 2002-08-19 | 2004-03-31 | Worldwide | Primarily test and measurement — wireline manufacturing and field operations | USD 117 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Target of $50M in quarterly operational cost reduction to reach profitability at $1.6B quarterly revenue. Approximately 300 employees reduced as of 2002-10-31; majority of the $50M quarterly saving expected by mid-2003. Charge shown is FY2002 activity only. | |
| 2002-10-31 | plant_closure | in_progress | 2001-08-20 | Worldwide, concentrated in the United States and Japan | All three segments — production, support and sales facilities | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Component of the 2001 Plan, not a separate program. More than 100 facilities or facility portions exited or planned for exit, over 3.6 million square feet (about 19% of worldwide property); approximately 40% vacated as of 2002-10-31. No separate employee count or charge disclosed — charges are included in the 2001 Plan record above. | ||||
| 2002-10-31 | restructuring | completed | 7,700 | 2001-08-20 | 2002-10-31 | Global | Test and Measurement, Semiconductor Products, Support Services | USD 511 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2001 Plan: Reduced workforce by approx. 7,700 (6,400 involuntary, 1,300 attrition). Substantially complete as of Oct 31, 2002. Total expenses incurred through Oct 31, 2002 were $511 million. | |
| 2002-10-31 | restructuring | in_progress | 300 | 2002-08-19 | 2004-03-31 | Global | Test and Measurement (Wireline) | USD 117 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 2002 Plan: Reduced workforce by approx. 300 as of Oct 31, 2002. Total expected reduction is 2,500. Plan expected to complete no later than Q1 2004. Charges through Oct 31, 2002 were $117 million. | |
| 2002-10-31 | restructuring | in_progress | 7,700 | 2001-08-20 | 2002-10-31 | Global | Test and Measurement; Semiconductor Products; Support Services | USD 511 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | The '2001 Plan' involved a workforce reduction of approximately 8,000 people. As of October 31, 2002, the company reduced its workforce by approximately 7,700 (6,400 involuntary terminations and 1,300 net attrition). The plan was substantially complete as of October 31, 2002. Total expenses incurred through Oct 31, 2002 were $511 million ($154 million in 2001 and $357 million in 2002). | |
| 2002-10-31 | restructuring | in_progress | 300 | 2002-08-19 | 2004-03-31 | Global | Test and Measurement (Wireline) | USD 117 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | The '2002 Plan' announced on August 19, 2002, intended to reduce operational costs by $50 million per quarter. As of October 31, 2002, the workforce was reduced by approximately 300. The company expects to reduce the workforce by 2,500 in total by completion. Expected completion is no later than the first quarter of 2004. Total charge recorded in 2002 was $117 million. | |
| 2002-07-31 | restructuring | in_progress | 4,000 | 2001-08-20 | 2002-12-31 | Global | All regions and most segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Original plan to eliminate approximately 4,000 jobs. Program-wide, approximately 7,100 positions had been eliminated as of July 31, 2002 against a total plan of 8,000, with completion expected by end of calendar 2002. Charges are disclosed at program level ($78M in Q3; $218M YTD), not by announcement. $42M of workforce-related payments accrued at July 31, 2002 to be paid to about 800 employees in Q4 2002. | ||
| 2002-07-31 | restructuring | in_progress | 4,000 | 2001-11-15 | 2002-12-31 | Global | All regions and most segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Enhancement of the August 2001 plan adding approximately 4,000 further job eliminations; components are workforce reduction, excess-facility consolidation, and asset impairment. | ||
| 2002-07-31 | restructuring | announced | 2002-08-19 | Global | Operations most impacted by weak telecommunications markets | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Post-quarter announcement of intent to cut operational costs by $50 million per quarter, entailing job cuts beyond the 8,000 previously announced; additional restructuring charges expected in Q4 2002 and first half of fiscal 2003, not yet estimable. Disclosed in MD&A restructuring discussion. | ||||
| 2002-07-31 | restructuring | in_progress | 7,100 | 2001-08-20 | 2002-12-31 | Global | All segments | USD 218 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Plan announced Aug 20, 2001 and expanded Nov 15, 2001 to reduce workforce by 8,000. As of July 31, 2002, reduced by approx 7,100. Total charges for nine months ended July 31, 2002 were $218 million. | |
| 2002-07-31 | restructuring | announced | 2002-08-19 | Global | All segments | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Announced intention to further reduce operational costs by $50 million per quarter. Additional job cuts expected beyond previous 8,000. Charges expected in Q4 2002 and first half of 2003. | ||||
| 2002-04-30 | restructuring | in_progress | 4,000 | 2001-08-20 | 2002-07-31 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | First of two 2001 workforce-reduction announcements totaling approximately 8,000 jobs; approximately 6,000 positions had been eliminated cumulatively as of April 30, 2002. Footnote expects substantial completion by end of fiscal Q3 2002, while MD&A states completion by the fourth quarter of 2002. Charges are disclosed only in aggregate across both announcements (approximately $35M in Q2 and $140M in the six months, including asset impairment), so no charge is attributed to this record. | ||
| 2002-04-30 | restructuring | in_progress | 4,000 | 2001-11-15 | 2002-07-31 | Global | Company-wide | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Second of two 2001 announcements, described as additional to the August 2001 plan. Workforce-reduction charges in the six months ended April 30, 2002 were $93M in Q1 and $32M in Q2, with a remaining severance liability of $33M at April 30, 2002; these are program-level amounts not split between the two announcements. | ||
| 2002-04-30 | other | in_progress | 1 | 2002-02-26 | 2002-05-31 | United States | Executive (Chief Operating Officer) | USD 2 (millions) | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Executive Vice President and COO resignation effective March 1, 2002 with employment ending on or before May 31, 2002; includes a $2 million gross severance bonus and full acceleration of unvested stock options. | |
| 2002-04-30 | restructuring | in_progress | 6,000 | 2001-08-20 | 2002-07-31 | Global | All segments | USD 140 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Consolidated count of workforce reduction from plans announced Aug 2001 and Nov 2001. Charges include severance and asset impairment. | |
| 2002-01-31 | restructuring | in_progress | 4,000 | 2001-08-20 | 2002-07-31 | Global | All segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | First of two announced plans to eliminate approximately 4,000 jobs each. Approximately $105 million of restructuring and asset impairment charges were recognized in the quarter across both plans; the filing does not allocate the charge between the two announcements. Cumulative workforce reduction of approximately 5,000 at 2002-01-31 spans both plans. | ||
| 2002-01-31 | restructuring | in_progress | 4,000 | 2001-11-15 | 2002-07-31 | Global | All segments | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Second announced plan, described as in addition to the August 20, 2001 plan. Company expects to substantially complete both plans by the end of fiscal Q3 2002. Quarterly restructuring charges of $105 million comprise $48M in cost of products and services, $12M in R&D, and $45M in SG&A, including $12M of asset impairment. | ||
| 2002-01-31 | restructuring | in_progress | 4,000 | 2001-08-20 | 2002-09-30 | Global | All segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Plan announced Aug 20, 2001 to eliminate approx. 4,000 jobs. Part of broader effort. | ||
| 2002-01-31 | restructuring | in_progress | 4,000 | 2001-11-15 | 2002-09-30 | Global | All segments | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Plan announced Nov 15, 2001 to eliminate approx. 4,000 jobs. Combined with prior plan, workforce reduced by approx. 5,000 as of Jan 31, 2002. | ||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | USD 175 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | Plan to cut discretionary costs, reduce the workforce about nine percent and reduce the number of occupied sites. Total plan cost estimated at $175 million; $154 million recognized in FY2001 ($79M in cost of products/services, $17M in R&D, $58M in SG&A). Approximately 3,000 employees separated in H2 FY2001; $65 million of severance paid by 2001-10-31 with the remaining liability expected to be utilized during 2002. Completion timing disclosed as 'by the middle of' fiscal 2002. | ||
| 2001-10-31 | restructuring | announced | 4,000 | 10% | 2001-11-15 | 2002-06-30 | subsequent_events f5-10k / GLM-5.3-flash-HTML | Additional 4,000 job eliminations (approximately 10 percent of the workforce) announced after fiscal year-end, targeted for completion by the middle of 2002. MD&A states the combined estimated cost of the August and November reduction plans is $350 million. The announcement also included reinstating the 10% pay reduction for approximately 2,000 senior managers starting Q1 FY2002 and an effective 5% salary reduction for other employees from February 2002. | |||
| 2001-10-31 | divestiture_reduction | completed | 2000-11-17 | 2001-08-01 | Healthcare Solutions (discontinued operations) | discontinued_operations_footnote f5-10k / GLM-5.3-flash-HTML | Healthcare solutions business sold to Koninklijke Philips Electronics N.V. under an Asset Purchase Agreement dated November 17, 2000; sale completed August 1, 2001 for a total purchase price of $1.7 billion (after-tax gain of $646 million). No employee headcount transferred or affected was disclosed in the filing. | ||||
| 2001-10-31 | other | completed | 2001-10-31 | Global (where legally permissible) | MD&A f5-10k / GLM-5.3-flash-HTML | 10% reduction in pay instituted from May 1 through October 31, 2001, applicable to all employees globally wherever legally permissible; implemented via a 10% reduction in hours for certain employees in accordance with local law. Subsequently reinstated for ~2,000 senior managers from Q1 FY2002 and extended at 5% for other employees effective February 2002 (see the November 15, 2001 announcement). | |||||
| 2001-10-31 | acquisition_addition | completed | 2001-01-05 | 2001-01-05 | Test and Measurement | business_combinations_footnote f5-10k / GLM-5.3-flash-HTML | Acquired Objective Systems Integrators, Inc. for approximately $716 million ($690 million cash plus fair value of options granted); OSI became part of the test and measurement business. Headcount acquired was not disclosed. | ||||
| 2001-10-31 | acquisition_addition | completed | 2001-07-20 | 2001-07-20 | Belgium | other f5-10k / GLM-5.3-flash-HTML | All shares of Sirius Communications N.V. acquired in exchange for 1,461,196 Agilent common shares issued in reliance on Regulation S. Headcount acquired was not disclosed. | ||||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Worldwide | Company-wide | USD 175 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Plan to cut about nine percent of workforce by mid-2002; $154M of the $175M total cost recognized in FY2001 ($79M cost of products and services, $17M R&D, $58M SG&A). Approximately 3,000 employees actually separated in the second half of FY2001; $65M severance paid by year-end, remainder payable during 2002. |
| 2001-10-31 | restructuring | announced | 4,000 | 10% | 2001-11-15 | 2002-06-30 | Worldwide | Company-wide | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Announced after fiscal year-end but before filing. MD&A states combined cost of both announced plans estimated at $350M, of which $154M recognized in FY2001. Paired with reinstatement of a 10 percent pay reduction for about 2,000 senior managers and a 5 percent salary reduction for other employees effective February 2002. | |
| 2001-10-31 | divestiture_reduction | completed | 2000-11-17 | 2001-08-01 | Worldwide | Healthcare solutions | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of healthcare solutions business to Koninklijke Philips Electronics for $1.7B completed 2001-08-01; headcount transferred not disclosed. Agilent restricted from competing in certain medical products for five years. | |||
| 2001-10-31 | acquisition_addition | completed | 2001-01-05 | United States | Test and measurement | USD 716 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Objective Systems Integrators, Inc. for approximately $716M ($690M cash); acquired headcount not disclosed. | |||
| 2001-10-31 | acquisition_addition | completed | 2001-01-31 | Japan | Company-wide | USD 99 (millions) | business_combinations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Completed purchase of Yokogawa's remaining 4.2 percent interest in Agilent Technologies Japan, Ltd. for approximately $99M, final step of a $521M three-step transaction; headcount impact not disclosed. | |||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Global | All segments | USD 154 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Plan announced August 20, 2001 to reduce workforce by approx 4,000 (9%) by mid-2002. $154 million recognized in 2001. Total estimated cost of plans is $350 million. |
| 2001-10-31 | restructuring | announced | 4,000 | 2001-11-15 | Global | All segments | subsequent_events f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | Announced November 15, 2001 intention to further reduce workforce by approx 4,000 people. Part of total $350 million restructuring cost estimate. | |||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Worldwide | All segments | USD 175 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Plan to reduce workforce by approximately 4,000, or about nine percent, by the middle of 2002. Total cost estimated at $175 million, of which $154 million recognized in 2001. |
| 2001-10-31 | restructuring | announced | 4,000 | 2001-11-15 | Worldwide | All segments | subsequent_events f5-10k / Qwen3.6-27B-Q8_0 | Announced intention to further reduce workforce by approximately 4,000 people. Combined with prior plan, total estimated cost is $350 million. | |||
| 2001-10-31 | acquisition_addition | completed | 2001-01-05 | 2001-01-05 | Worldwide | Test and Measurement | USD 716 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Acquired Objective Systems Integrators, Inc. for approximately $716 million. Headcount not explicitly disclosed. | ||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | USD 154 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Plan announced 2001-08-20 to cut about 4,000 jobs, roughly nine percent of workforce, by mid-2002; total estimated plan cost $175 million, of which $154 million was recognized in FY2001 ($79M in cost of products and services, $17M in R&D, $58M in SG&A); $65 million of severance paid by 2001-10-31 with the remainder expected to be paid during 2002. Filer also states approximately 3,000 employees were reduced in the second half of 2001 under its announced workforce measures — treated as execution of this program, not a separate action. Expected completion date approximated from 'by the middle of next year'. | ||
| 2001-10-31 | reduction_in_force | announced | 4,000 | 10% | 2001-11-15 | 2002-06-30 | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Post-fiscal-year-end announcement of an additional 4,000 job eliminations, about 10 percent of the workforce, targeted for mid-2002; no charge quantified in the filing. Expected completion date approximated from 'by the middle of 2002'. | |||
| 2001-10-31 | divestiture_reduction | completed | 2000-11-17 | 2001-08-01 | Global | Healthcare Solutions Group | discontinued_operations_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of the healthcare solutions business to Philips completed 2001-08-01 for a total purchase price of $1.7 billion; results presented as discontinued operations for all periods. Headcount transferred with the business is not disclosed in the filing. | |||
| 2001-10-31 | restructuring | in_progress | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Global | All segments | USD 175 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | Plan to reduce workforce by approximately 4,000, or about nine percent, by the middle of next year. Total cost estimated at $175 million, of which $154 million recognized in fiscal 2001. In the second half of 2001, Agilent reduced its workforce by approximately 3,000 employees. |
| 2001-10-31 | restructuring | announced | 4,000 | 10% | 2001-11-15 | 2002-06-30 | Global | All segments | subsequent_events f5-10k / Qwen3.6-27B-Q8_0 | Announced elimination of an additional 4,000 jobs, approximately 10 percent of workforce, by the middle of 2002. | |
| 2001-07-31 | restructuring | announced | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Global | Company-wide | subsequent_events f5-10q / MiMo-V2.6-Flash-fp8-HTML | Announced post-quarter; reduction of about nine percent of workforce by mid-2002. No severance charge disclosed in this filing. MD&A also cites hiring freeze, reduced temporary labor, discretionary spending cuts, and a temporary 10% global pay reduction effective 2001-05-01 through 2001-11-01. | |
| 2001-07-31 | divestiture_reduction | completed | 2000-11-17 | 2001-08-01 | Global | Healthcare Solutions | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Sale to Philips completed 2001-08-01 for $1.7 billion; operational facilities and associated assets and liabilities transferred. Headcount transferred not disclosed. Agilent will provide transitional support services to Philips for one year. | |||
| 2001-07-31 | restructuring | announced | 4,000 | 9% | 2001-08-20 | 2002-06-30 | Global | All segments | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Management announced workforce reduction of approximately 4,000 people, or about nine percent, by the middle of next year. | |
| 2001-04-30 | other | announced | 2001-04 | Global | All employees | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Temporary 10% pay reduction for all employees globally, effective May 1, 2001, implemented via reduced hours where required by local law. | ||||
| 2001-04-30 | other | in_progress | Global | All functions | MD&A f5-10q / MiMo-V2.6-Flash-fp8-HTML | Hiring freeze, significant reduction in temporary workers, reduced discretionary spending, and short-term manufacturing closures initiated in response to demand slowdown. | |||||
| 2001-04-30 | restructuring | in_progress | 2001-10-31 | Not specified | Healthcare Solutions (discontinued operations) | USD 9 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Remaining $9M of $21M restructuring liability from Q4 2000 for healthcare solutions business; expected to be utilized in second half of fiscal 2001. No employee count disclosed. | |||
| 2001-04-30 | acquisition_addition | completed | 2001-01-05 | 2001-01-05 | Not specified | Test and Measurement | business_combinations_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Objective Systems Integrators, Inc. for $716M total purchase price; no headcount added disclosed. | |||
| 2001-04-30 | divestiture_reduction | in_progress | 2000-11-17 | 2001-10-31 | Not specified | Healthcare Solutions | other f5-10q / MiMo-V2.6-Flash-fp8-HTML | Agreed to sell healthcare solutions business to Philips for approximately $1.7 billion; antitrust clearance received; no headcount removed disclosed. | |||
| 2001-04-30 | other | in_progress | 2001-04-01 | Global | All | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Announced temporary 10% reduction in pay effective May 1, 2001, applying to all employees globally wherever possible. Implemented via 10% reduction in hours for certain employees. | ||||
| 2001-04-30 | other | in_progress | 2001-04-30 | Global | All | MD&A f5-10q / Qwen3.6-27B-Q8_0 | Frozen hiring and cut back significantly on use of temporary workers to address recent slowdown in demand. | ||||
| 2001-01-31 | restructuring | in_progress | 2001-10-31 | Healthcare Solutions | USD 14 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Restructuring of healthcare solutions business originally charged in Q4 FY2000 ($21M total); $14M liability remaining, expected to be utilized in H2 FY2001. No employee count disclosed. | ||||
| 2001-01-31 | restructuring | in_progress | 2001-06-30 | Healthcare Solutions | USD 14 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Remaining liability from prior quarter restructuring; expected to be utilized in second half of 2001. | ||||
| 2001-01-31 | acquisition_addition | completed | 2001-01-05 | 2001-01-05 | Test and Measurement | USD 684 (millions) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of Objective Systems Integrators, Inc. (OSI). Headcount not disclosed. | |||
| 2001-01-31 | acquisition_addition | completed | 2001-01-01 | 2001-01-01 | Japan | USD 98 (millions) | business_combinations_footnote f5-10q / Qwen3.6-27B-Q8_0 | Acquisition of remaining 4.2% interest in Agilent Technologies Japan, Ltd. from Yokogawa Electric Corporation. Headcount not disclosed. | |||
| 2000-10-31 | restructuring | in_progress | 596 | 2000-08 | 2001 | United States, Asia Pacific, Europe | Healthcare solutions | USD 21 (millions) | restructuring_footnote f5-10k / GLM-5.3-flash-HTML | August 2000 restructuring of the healthcare solutions business combining workforce reductions via severance programs with consolidation of business operations. Affected population comprises 396 regular employees who accepted severance packages and 200 temporary employees terminated; the 596 count is the sum of these two disclosed populations. The $21M pre-tax charge comprises $13M estimated severance benefits and $8M non-cash asset writedowns. $2M of severance had been paid as of October 31, 2000, with the remaining liability expected to be utilized during 2001 (basis for expected completion year). Also described in Item 1/MD&A; extracted once from the footnote per deduplication rule. | |
| 2000-10-31 | divestiture_reduction | announced | 2000-11-17 | 2001-06-30 | Global | Healthcare solutions | subsequent_events f5-10k / GLM-5.3-flash-HTML | Agreement to sell the entire healthcare solutions business to Koninklijke Philips Electronics, N.V. for approximately $1.7 billion. Virtually all business employees, including 100% of business-dedicated infrastructure employees, will be offered employment by or transferred to Philips; estimated net assets to transfer are $400 million. Agilent restricted from competing in development, manufacturing, selling or servicing of certain medical products for five years. Sale price is consideration, not a charge. Segment headcount was approximately 5,000 at October 31, 2000, but the filer does not state a specific affected-employee figure for this transaction. Expected completion by mid-calendar year 2001, subject to regulatory approvals and closing conditions. | |||
| 2000-10-31 | restructuring | in_progress | 596 | 2000-08 | 2001 | United States, Asia Pacific and Europe | Healthcare solutions | USD 21 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | Comprises 396 regular employees accepting severance packages plus 200 temporary employees terminated; charge of $21M pre-tax ($13M severance, $8M non-cash asset writedowns); $2M severance paid at year-end, remainder expected to be utilized during 2001 | |
| 2000-10-31 | divestiture_reduction | announced | 2000-11-17 | 2001-06-30 | Global | Healthcare solutions | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Sale of healthcare solutions business to Philips for approximately $1.7 billion; virtually all business employees, including dedicated infrastructure staff, to be offered employment by or transferred to Philips; no headcount quantified; net assets to transfer estimated at $400 million | |||
| 2000-10-31 | acquisition_addition | announced | 2001-01-05 | 2001-01-05 | Not disclosed | Test and measurement | USD 684 (millions) | subsequent_events f5-10k / MiMo-V2.6-Flash-fp8-HTML | Acquisition of Objective Systems Integrators, Inc. completed for approximately $684 million in cash; acquired headcount not disclosed | ||
| 2000-10-31 | restructuring | in_progress | 596 | 2000-08 | 2001-10-31 | United States, Asia Pacific, Europe | Healthcare Solutions | USD 21 (millions) | MD&A f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML | 396 regular employees accepted severance packages and 200 temporary employees terminated. $21 million pre-tax charge ($13 million severance, $8 million asset writedowns). $2 million paid as of Oct 31, 2000; remainder expected utilized in 2001. | |
| 2000-10-31 | restructuring | in_progress | 596 | 2000-08 | 2001-12-31 | United States, Asia Pacific, Europe | Healthcare Solutions | USD 21 (millions) | restructuring_footnote f5-10k / Qwen3.6-27B-Q8_0 | 396 regular employees accepted severance; 200 temporary employees terminated. $13M severance, $8M asset writedowns. Liability expected utilized during 2001. | |
| 2000-07-31 | restructuring | announced | 650 | 2000-07-31 | 2000-10-31 | United States, Asia Pacific, Europe | Healthcare Solutions | USD 25 (millions) | restructuring_footnote f5-10q / MiMo-V2.6-Flash-fp8-HTML | Subsequent-event announcement; exact announcement date not specified beyond 'subsequent to July 31, 2000'. Approximately 450 regular and 200 temporary employees. Expected annual savings of ~$80M starting 2001. Charge expected in fiscal Q4 2000 (quarter ending Oct 31, 2000). | |
| 2000-07-31 | restructuring | announced | 650 | 2000-07-31 | United States, Asia Pacific, Europe | Healthcare Solutions | USD 25 (millions) | subsequent_events f5-10q / Qwen3.6-27B-Q8_0 | Announced subsequent to July 31, 2000. Includes approx. 450 regular and 200 temporary employees. One-time charge of approx. $25 million expected in Q4 2000. | ||
| 2000-01-31 | voluntary_separation | completed | 1,650 | 1998-10-31 | 2000-01-31 | Global | Manufacturing and other positions included in cost of products and services | USD 78 (millions) | restructuring_footnote f5-10q / Qwen3.6-27B-Q8_0 | Approximately 1,650 employees accepted voluntary severance incentive packages by the October 31, 1998 deadline. Approximately 80% were in manufacturing or other positions included in cost of products and services. The entire $78 million severance charge has been paid as of January 31, 2000. | |
| 1999-10-31 | voluntary_separation | completed | 1,650 | 1998-01-01 | 1998-10-31 | Global | All four business segments; primarily manufacturing | USD 78 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY1998 program; approximately 1,650 employees accepted voluntary severance packages by the October 31, 1998 deadline. Approximately 80% were in manufacturing or cost-of-products positions. Severance portion of the $163M total pre-tax restructuring charge. $69M paid as of October 31, 1999. | |
| 1999-10-31 | restructuring | completed | 1998-10-01 | 1999-10-31 | Global | Semiconductor products | USD 51 (millions) | restructuring_footnote f5-10k / MiMo-V2.6-Flash-fp8-HTML | FY1999 charge for write-down of a building under construction for eight-inch semiconductor wafer manufacturing. Construction stopped after October 1998 decision to outsource wafer production. No associated headcount reduction disclosed for this charge. | ||
| 1999-10-31 | divestiture_reduction | completed | 1999-01-01 | 1999-10-31 | Global | Multiple — portions of businesses sold to third parties | other f5-10k / MiMo-V2.6-Flash-fp8-HTML | Gross proceeds from divestitures were $121 million in FY1999; gains of $54 million recognized in other income. No headcount associated with divestitures disclosed. | |||
| 1999-10-31 | voluntary_separation | completed | 1,650 | 1998-10-31 | 1998-10-31 | Worldwide | All segments | USD 78 (millions) | MD&A f5-10k / Qwen3.6-27B-Q8_0 | Approximately 1,650 employees accepted voluntary severance incentive packages by the October 31, 1998 deadline. $78 million in severance charges recorded in FY1998. Approximately 80% were in manufacturing or other positions included in cost of products and services. |